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Rett syndrome (RTT) is a severe neurological disorder that affects approximately 1:10000 
girls. Classical RTT is defined by a developmental regression phase and subsequent 
stabilisation of diagnostic criteria, which include partial or complete loss of spoken 
language, dyspraxic gait and stereotypic hand movements such as hand mouthing. RTT is a 
monogenic disorder, with the majority of cases being due to loss-of-function mutations in 
MeCP2 (methyl-CpG binding protein 2). Due to this clear genotype-phenotype link multiple 
RTT mouse models have been used to elucidate the molecular details, and consequent 
neuropathogenesis, of this complex neurological disease, as well as for the development of 
potential therapeutics for RTT. However, as the molecular details become clearer, the need 
for a simpler model system becomes evident. Human induced pluripotent stem cells 
(hiPSCs) generated from RTT patient fibroblasts are an option; however the handling of 
these cells is laborious, time-consuming and expensive and they often differentiate into a 
heterogeneous population of cells. To explore an alternative human model system I have 
been genetically engineering and experimenting with the human dopaminergic LUHMES 
cell line. LUHMES cells are an immortalised pre-neuronal cell line derived from an 8-week 
old, female foetus and can readily be differentiated into a homogeneous population of 
mature, electrically active neurons in just one week. In this thesis I have assessed the 
phenotypic properties of the wild-type cell line, demonstrated the ease of genetic 
manipulation of LUHMES cells by CRISPR/Cas9 approaches, generated seven mutant 
MECP2 LUHMES cell lines and explored the potential of protein therapy as a therapeutic 
approach for RTT. The LUHMES cell line proves to be extremely easy to handle and robust 
and has yielded novel molecular insights into the function of MeCP2 in human neurons. In 
particular, MeCP2-null cells show a striking relationship between the level of gene body 
methylation and the extent of transcriptional upregulation when compared to wild-type 




recruit a transcriptional corepressor complex (the R306C mutant) do not exhibit substantial 
gene expression alterations, yet do display a consistent decrease in total RNA amount. This 
decrease in total RNA is recapitulated in MeCP2-null LUHMES-derived neurons and in 
brain regions from MeCP2-R306C mice. The requirement for functional DNA binding for 
normal gene-body methylation dependent gene repression is demonstrated by assessing 
LUHMES cells that overexpress MeCP2-R111G, a protein that cannot bind to DNA. 
Furthermore, overexpression of the MeCP2-R306C protein highlights the importance of 
NCoR binding for normal gene repression, but also demonstrates that MeCP2-R306C protein 
retains some gene repression activity. Thinking more broadly, this cell line also has 
applications as a model system for a variety of other neurological disorders; as a simplified 
model system to elucidate molecular and neurological phenotypes, and as a relevant human 











Rett syndrome is a rare neurological disorder that has a frequency of 1 in 10000 live female 
births. It is a severe disorder characterised by apparent normal development for the first 12-
18 months of life, followed by a loss of motor skills, loss of acquired speech, stereotypical 
hand movements, seizures, cardiac problems and hyperventilation. Unlike other autism-
associated disorders, Rett syndrome is predominantly caused by mutations in a single gene, 
MECP2. Rett syndrome is also exceptional due to the discovery that in mice, the majority of 
phenotypes can be reversed if a functional copy of MeCP2 is restored. With the knowledge 
that Rett syndrome is potentially curable, the field is now working towards developing 
therapeutics to treat, and hopefully cure the disorder. One avenue towards achieving such a 
goal is to understand the function of the MeCP2 protein in cells. 
 
MeCP2, or methyl-CpG binding protein 2, is a DNA-binding protein that is highly expressed 
in the brain, particularly in neurons. MeCP2 recognises a DNA modification called a 
methylated-CpG dinucleotide, or mCpG. The mCpG mark is associated with the repression 
of gene expression and thus it is assumed that MeCP2 binds to this modification and 
contributes to gene repression in neurons. This suggests that upon mutation of MeCP2, this 
repressive activity is lost, and the resulting perturbation of gene expression leads to the Rett 
syndrome phenotype. As such, one would expect that upon deletion or mutation of MeCP2, 
the expression level of a number of genes would be increased. In contrast, gene expression 
both increases and decreases thus complicating the interpretation of the function of MeCP2. 
 
Most studies have used mouse models of Rett syndrome, which though valuable, have 
limitations. The rodent brain contains multiple different cell types that may or may not 
accurately reflect the function of MeCP2 in humans. This thesis, therefore, will assess the 




studying MeCP2 and Rett syndrome. Firstly, I establish that LUHMES cells are a robust, 
easy to handle cell line that can be rapidly differentiated into mature, electrically active 
neurons and can be genetically manipulated to create novel MeCP2 mutant cell lines. 
Secondly, I demonstrate that MeCP2 mutant LUHMES cells can differentiate into a 
population of mature neurons, thus expelling the hypothesis that MeCP2 mutations 
inevitably cause neurodevelopmental defects. Thirdly, assessment of RNA levels (the 
product of gene expression) in MeCP2 mutant neurons reveals potential mechanisms for how 
MeCP2 regulates gene expression, as well as revealing novel defects in total levels of RNA. 
Finally, this thesis also assesses the use of LUHMES cells as a tool for developing 
therapeutic strategies by demonstrating that MeCP2 protein itself can enter mature, human 
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Every cell in our body contains the same complement of genes and DNA sequences, so the 
question of how, for example, a skin cell is distinguished from a liver cell is an important 
question. One answer lies with the regulation of gene expression. While every cell in our 
body contains the same set of genes, only certain subsets of these are expressed in each 
tissue and cell type. There are a number of mechanisms that contribute to tissue-specific 
gene regulation including the modification of histone tails, organisation in 3-dimensional 
space, tissue-specific and DNA-sequence specific transcription factors, and DNA 
methylation. DNA methylation is a true epigenetic mechanism as its properties can be passed 
from mother to daughter cell. It is found in a variety of species including bacteria, 
invertebrates, plants, mammals and fish, although the distribution of DNA methylation 
varies from organism to organism (Hendrich & Tweedie, 2003). The importance of this 
epigenetic modification is underscored by its requirement for proper embryonic development 
(Li et al., 1992), its disruption as a hallmark for many diseases including cancer (Schubeler, 
2015), and the presence of mutations in proteins that recognise the methylation mark being 
associated with neurological disorders (Amir et al., 1999). 
 
DNA methylation was first discovered in 1948 by paper chromatography experiments that 
separated individual nucleoside molecules from calf thymus samples. The separation of 
deoxyribonucleic acid samples revealed a peak that corresponded to an unknown substance 




cytosine was similar to the relationship of thymine (5-methyluracil) to uracil. Thus it was 
hypothesised that this so-called “epicytosine” mark was in fact 5-methylcytosine (Hotchkiss, 
1948). Since then, the 5-methylcytosine (m5C) mark has been found in multiple organisms in 
the context of a symmetrical CpG dinucleotide, allowing for the preservation of the DNA 
modification during cell division via semi-conservative DNA replication (Bird, 1978; Bird & 
Taggert, 1980; Holliday & Pugh, 1975; Riggs, 1975). 
 
Vertebrate genomes are globally methylated at a level of 60-90%, with the exception of so-
called CpG islands (CGIs). CGIs are ~ 1kb-long stretches of GC-rich, CpG-rich DNA that 
are unmethylated and often found associated with gene promoters. Developmentally 
regulated methylation of CGIs, though relatively rare, is associated with silencing of the 
associated gene (Bird, 1986; Illingworth et al., 2010; Tweedie et al., 1997). The remaining 
unmethylated CGIs that are not associated with a known gene promoter (e.g. intragenic 
CGIs) are often associated with active transcription and H3K4me3, suggesting a potential 
role for intragenic CGIs in regulating alternative promoters that are situated within gene 
bodies (Maunakea et al., 2010). In the vertebrate genome, the CpG dinucleotide, while being 
frequently methylated, is found at frequency lower than expected (~ 1/5) (Bird et al., 1985; 
Bird, 1986). The reason for this unusual abundance of mCpG is due to the mutability of the 
mC mark. This base has a tendency to be mutated to thymine, thus over evolutionary time 
mC can be converted to T resulting in a lower than expected CpG frequency in the bulk 
genome. CGIs, however, remain unmethylated and therefore are not subjected to mCp 
mutation pressures and thus retain the expected frequency of CpGs for their CG densities. It 
is thought that the active binding of transcription factors at these promoter-proximal sites 
prevents the methylation-depositing machinery from gaining access and thus contributes to 
the methylation-free, CpG-high status of CGIs (Bird, 1986). 
 
The methyl modification is placed on position 5 in the cytosine ring by DNA 
methyltransferase enzymes, or DNMTs, using S-adenosyl-L-methionine (SAM) as a methyl 
donor group. DNMT3a and DNMT3b are known as the de novo methyltransferases as these 
two enzymes have the ability to place a methyl group on a cytosine ring, in the absence of 
any pre-existing methylation (Okano et al., 1999). DNMT1 is known as the maintenance 
DNMT due to its ability to recognise hemi-methylated DNA (for example, immediately after 
DNA replication) and place a methyl group on the un-modified cytosine (Jones & Liang, 
2009). The importance of DNMTs is underscored in mouse models where knock-outs (KOs) 




patients where mutations within them are frequently associated with diseases such as cancer 
(Jones & Liang, 2009). 
 
The discovery of proteins that can read and write the mCpG DNA modification was crucial 
to establishing the importance of this mark. The first protein that was discovered to bind to 
methylated DNA was eukaryotic MDBP (methylated DNA-binding protein) (Huang et al., 
1984). Further analysis of the binding specificities of this protein in vivo in human placenta 
discovered that in fact MDBP could bind to non-methylated sites, due to the replacement of 
methyl-cytosine with thymine (which contains a methyl group, also on the carbon-5 position 
of the pyrimidine ring) (Zhang et al., 1989). MeCP1 (methyl-CpG binding protein 1) was 
therefore the first identified protein that could bind specifically to DNA only when it was 
methylated (Meehan et al., 1989). MeCP1 requires at least 12 mCpG dinucleotides for 
binding and can bring about gene repression in both in vitro and in vivo studies (Boyes & 
Bird, 1991; Meehan et al., 1989). A 2nd protein with methylation-specific DNA binding 
properties was reported three years after the discovery of MeCP1, and was termed MeCP2 
(Lewis et al., 1992). Like MeCP1, MeCP2 could repress transcription both in vitro and in 
vivo, but unlike MeCP1, MeCP2 required only a single mCpG dinucleotide for binding and 
repression (Lewis et al., 1992; Meehan et al., 1992). A 3rd methylated DNA binding domain 
(MBD)-containing protein was later identified called MBD1 (originally called PCM1 for 
protein containing MBD 1) that, despite having its own transcriptional repression domain 
(TRD), may be part of a complex with MeCP1 and also contains CXXC domains which can 
bind to non-methylated DNA (Cross et al., 1997; Ng et al., 2000). The CXXC and MBD 
domains of MBD1 mean that MBD1 can be recruited by both methylated and non-
methylated CpG dinucleotides, a unique property that means MBD1 can exert a repressive 
effect upon transcription regardless of the methylation status of the DNA (Fujita et al., 1999; 
Jorgensen et al., 2004; Ng et al., 2000). 
 
With the sequence of the methylated-DNA binding domain (MBD) of MeCP2 to hand 
(Lewis et al., 1992), database searches identified a whole family of proteins that also contain 
an MBD-like domain; MBD1, MBD2a, MBD2b, MBD3, MBD4, MeCP1 and MeCP2 
(Hendrich & Bird, 1998). MBD2 and MBD3 have 71.1% amino acid sequence similarity, but 
apart from that the only sequence homology between the members of the family is the MBD 
itself. All proteins are expressed in a variety of somatic tissues, are absent or expressed at 




although the DNA binding property of MBD3 is not specific to methylated DNA. Consistent 
with this, MBD-1, -2 and -4 all localise to mCpG-rich heterochromatic foci in mouse cells, 
whereas MBD3 demonstrates diffuse nuclear staining or occasional foci that do not co-
localise with heterochromatic foci (Hendrich & Bird, 1998). 
 
Two other MBD-containing proteins (MBD5 and MBD6) were identified using less stringent 
bioinformatics approaches concerning homology within the MBD domain (Laget et al., 
2010; Roloff et al., 2003). Despite localising to heterochromatic foci in cells, MBD5 and 
MBD6 cannot bind to methylated DNA in vitro and do not lose cellular localisation upon 
DNA methylation depletion, thus casting doubts over their roles as methylation-specific 
DNA binders (Laget et al., 2010). Finally, a family of proteins (the Kaiso family) that do not 
contain a canonical MBD but can bind to methylated DNA have also been identified (Filion 
et al., 2006; Prokhortchouk et al., 2002). Kaiso in particular is known to interact with NCoR 
(a component of the NCoR/SMRT transcriptional repressor complex) and lead to decreased 
transcription in vivo (Yoon et al., 2003b). 
 
In terms of expression profile, all of the methylated DNA binding proteins studied have a 
broad expression pattern throughout the body, but in contrast to the mark that they bind, are 
not required for embryogenesis suggesting potential redundancy between certain MBD 
proteins. In order to identify if there was functional redundancy, MeCP2 null mice were 
crossed with MBD2 null mice to create double KO mice. The phenotypes of these mice were 
no different to that of MeCP2 null mice and thus there appears to be no functional 
redundancy of these two proteins for development (Guy et al., 2001). Triple KO of MeCP2, 
MBD2 and Kaiso also demonstrated no altered phenotype compared to MeCP2 null mice 
(Caballero et al., 2009). This study also showed that the triple KO neural stem cells retained 
the full potential to differentiate into astrocytes and neurons, but differentiation into neurons 
was somewhat delayed as determined by expression of βIII-tubulin. This reduced expression 
level, however, was not found in either of the single KO cells thus suggesting some 
redundancy between at least 2 of these 3 proteins (Caballero et al., 2009). 
 
Thus to conclude, the MBD-containing MeCPs include MBD1, MBD2, MBD4 and MeCP2, 
while Kaiso and its family of proteins bind to methylated DNA using zinc-finger domains. 
None of these proteins are essential for embryonic development and MeCP2 null mice 




proteins can all bind to and repress the same reporter gene, there appears to be no functional 
redundancy between these proteins in vivo. 
 
DNA methylation is thought to be involved in gene repression and there is much evidence in 
support of this. Cells that express the chicken β-actin gene contain unmethylated sites at the 
end of the gene, whereas cells that do not express this gene are generally methylated at this 
site (McGhee & Ginder, 1979). Cytidine analogues such as 5-aza-cytidine that inhibit DNA 
methylation result in differentiation phenotypes (Jones & Taylor, 1980; Taylor & Jones, 
1979) and cause the upregulation of genes on the inactive X chromosome (Mohandas et al., 
1981). Furthermore, methylation of reporter genes prior to transfecting them into cells results 
in the absence of gene expression of that reporter gene (Boyes & Bird, 1991; Buschhausen et 
al., 1985; Busslinger et al., 1983). More recent genome-wide studies looking at the 
correlations between DNA methylation and endogenous transcription levels also confirm the 
association of DNA methylation with a repressive environment, at least at CGI promoters 
(Illingworth et al., 2008; Weber et al., 2007). 
 
Potential mechanisms for how DNA methylation may regulate transcription include the 
direct inhibition of transcription factor binding and indirect mechanisms involving 
recruitment of MBD-containing proteins. Evidence of the former includes the inability of the 
transcription factor AP-2 to bind to the proenkephalin gene upon CpG methylation (Comb & 
M.Goodman, 1990) and a loss of transcriptional activity upon methylation of the cAMP-
responsive element in PC12 and HeLa cells (Iguchi-Ariga & Schaffner, 1989). Nevertheless 
the observation that methylation of the Herpes simplex virus thymidine kinase promoter 
reduces transcriptional output from the promoter, but does not affect that ability of CTCF 
and Sp1 transcription factors from binding to their target sites within the promoter suggests 
that alternative mechanisms are possible (Ben-Hattar et al., 1989). Furthermore, it can take 
48 hours to repress methylated reporter constructs suggesting that inhibition of transcription 
might be mediated by indirect mechanisms that take time to be established in the cell 
(Buschhausen et al., 1985). In line with this, the establishment of chromatin is required for 
DNA methylation-dependent inhibition (Buschhausen et al., 1987), this chromatin may 
spread along a plasmid to cover unmethylated sites (Kass et al., 1993), and repression of 
transcription can occur when the DNA methylation is placed distally from the gene of 
interest (Nan et al., 1997). This data suggests that repression can be achieved after MBD-




repressive environment. These proteins may then function in a variety of manners; inhibition 
of the binding of transcription factors, interference with the binding and/or progression of 
RNA polymerase or alterations of the chromatin architecture to create a general inactive 
chromatin environment by recruitment of histone modifying enzymes. In line with this, 
histone modifications that are generally associated with gene repression are often found co-
localised with sites of methylated CpGs, such as H3K9me3, whereas unmethylated CGIs are 
associated with active histone modification marks such as H3K4me3 (Illingworth et al., 
2010; Maunakea et al., 2010; Weber et al., 2007). 
 
While DNA methylation and gene repression are certainly linked, most studies described so 
far demonstrate this relationship by looking at promoters, which in vivo are predominantly 
unmethylated. How the bulk of the vertebrate genome methylation (which is situated in gene 
bodies and intergenic regions) affects transcription is unknown. Gene-body methylation of 
an integrated reporter construct in mouse cells has been shown to reduce transcription 
compared to an unmethylated construct, despite the promoter remaining methylation-free, 
thus demonstrating that gene-body methylation has an ability to repress transcription, 
independent of the promoter (Appanah et al., 2005). A hypothesis for the function of 
endogenous gene-body methylation is that it works to repress transcription in such a manner 
as to reduce transcriptional noise (Bird et al., 1995). This hypothesis stems from the fact that 
invertebrate genomes lack DNA methylation, whereas vertebrate genomes maintain very 
high levels of it, despite its propensity to induce sequence mutations (Tweedie et al., 1997). 
Vertebrate genomes have larger numbers of genes and highly complex developmental 
patterns which perhaps require an extra constraint on transcription to prevent inappropriate 
expression at the wrong time or place during development. Evidence to support such a 
mechanism includes the fact that intragenic DNA methylation has a role in the regulation of 
alternative promoters in different cell types (Maunakea et al., 2010), and that upon depletion 
of DNA methylation, transcription does not dramatically increase, as might be expected, but 
minor changes occur (Feng et al., 2010). A mechanism for how gene-body methylation 
might interfere with spurious transcription and enforce a tight control on inappropriate 
transcription is unknown. While the results of Appanah et al indicated that RNAP II 
recruitment to the promoter of a gene-body methylated transgene in mouse cells was reduced 
compared to an unmethylated transgene (Appanah et al., 2005), nuclear run-on experiments 
in the fungus Neurospora crassa found that methylation reduces the rate of transcription by 
5-fold by inhibiting RNAP elongation rather than RNAP initiation (Rountree & Selker, 




increased gene expression could be explained by gene body methylation functioning to 
prevent inappropriate transcription throughout the gene by interfering with RNAP initiation 
and/or elongation (Ball et al., 2009; Flanagan & Wild, 2007; Rauch et al., 2009). Perhaps the 
function of DNA methylation, and of the proteins that bind to this modification, is to dampen 
gene expression and provide an extra constraint on inappropriate RNAP function, thus 
providing an environment where expression of appropriate full-length transcripts can be 
achieved. 
  
Thus the question still remains, how do proteins that bind to mCpG bring about gene 
repression or transcriptional restraint in a cell- and locus-specific manner? Is the action of 
occupying sites of methylation enough to inhibit RNA polymerase initiation and/or 
elongation, or are downstream events also required. If so, what are these downstream events? 
 
DNA methylation is known to be dynamically regulated during mammalian development, 
and in particular in the brain DNA methylation dynamics are associated with neuronal 
function, such as long-term potentiation (LTP) [for reviews see: (Graff et al., 2011; Telese et 
al., 2013)]. In line with the importance of DNA methylation for proper neuronal function, 
post-natal deletion of DNMT1 and DNMT3A in forebrain excitatory neurons results in 
learning, memory, and synaptic plasticity defects (Feng et al., 2010), while CNS deletion of 
DNMT3A results in sever motor defects and mice die prematurely (Nguyen et al., 2007). 
 
While methylation of the CpG dinucleotide has been the predominant focus of the field, 
recent analysis of non CpG methylation (i.e. mCpH) has discovered widespread deposition 
of this mark in vivo, with evidence for a role in gene regulation. Initial in vitro studies found 
that all three DNMT enzymes can methylate CpH sites (Hubrich-Kuhner et al., 1989; 
Yokochi & Robertson, 2002), which led to subsequent analysis of mCpH in vivo. This mark, 
in particular mCpA, is found in the male and female mouse germ line (Ichiyanagi et al., 
2013; Smith et al., 2012; Tomizawa et al., 2011), mouse and human ESCs (Laurent et al., 
2010; Ramsahoye et al., 2000; Ziller et al., 2011) and human iPSCs (Ziller et al., 2011), 
however was not believed to be present in differentiated cell types due to its absence from 
human fibroblasts, embryoid bodies, neural precursor cells, pancreatic islets, rectal mucosa, 
rectal smooth muscle, skeletal muscle, stomach muscle and blood samples (Laurent et al., 
2010; Ziller et al., 2011), as well as being absent from mouse liver, kidney, spleen and lung 




revealed that a significant proportion of cytosine methylation in the adult brain is composed 
of the CpH dinucleotide (Guo et al., 2013; Lister et al., 2013; Varley et al., 2013; Xie et al., 
2012). As a proportion of all cytosine methylation, mCpH makes up 25% in the dentate 
gyrus (Guo et al., 2013), and 53% in neurons of the frontal cortex (Lister et al., 2013). The 
levels of CpH methylation increase during development, reaching a peak of 1.5% and 1.3% 
mCpH/CpH in human and mouse adults respectively (Lister et al., 2013). In particular the 
most rapid increase is during the first two years of post-natal human development, a time 
period that coincides with rapid levels of synaptogenesis and increases in synaptic density 
(Lister et al., 2013). These high levels of non-CpG methylation in the adult central nervous 
system, and the absence of it from most other differentiated cell types suggests a unique role 
for CpH methylation in the function of neurons. 
 
The function of CpH methylation in neurons appears to be linked to gene repression. Gene 
expression is inversely correlated with mCpH in the gene body and the surrounding ±5 kb 
environment and in particular, lowly expressed genes tend to have higher gene body mCpH 
levels than their surrounding regions suggesting a role for gene body methylation in gene 
repression (Guo et al., 2013). Furthermore, genes that lose mCpG and mCpH during 
neuronal development tend to be highly expressed, constitutive genes that are enriched for 
neuronal functions and depleted of astrocytic functions. These genes concomitantly gain 
H3K4me1 and H3K27ac marks as well as exhibit increased DNaseI hypersensitivity, 
whereas genes that gain mCpH during development tend to have lower levels of H3K4me1, 
H3K27ac and DNaseI hypersensitivity (Lister et al., 2013). This indicates that the loss of 
CpH methylation during development occurs concomitantly with the gain of active 
chromatin marks indicative of active transcription. While there is a tendency for binding 
sites of neuron-specific transcription factors to be depleted of mCpH (Guo et al., 2013), it 
remains to be determined whether active transcription prevents mCpH deposition, or 
encourages active mCpH removal. Nevertheless, transfection of mCpH-methylated reporter 
gene constructs into mouse hippocampal neurons is sufficient to significantly repress 
transcription to similar levels as mCpG does (Guo et al., 2013). 
 
Efforts have also been made to establish the proteins that deposit or bind to this 
modification. While DNMT3B has been suggested to be responsible for mCpH in ESCs due 
to its high expression levels (Laurent et al., 2010), DNMT3A is the more likely candidate for 
mCpH deposition in neurons. The first evidence came from bioinformatics analysis that 




methylation compared to a random genomic sampling (Guo et al., 2013; Lister et al., 2013). 
Using adeno-associated viruses (AAVs) to deliver shRNAs against DNMT3A into the adult 
mouse dentate gyrus demonstrated a significant decrease in the level of CpH methylation, 
with no effect on mCpG levels, and this resulted in a loss of repression at the loci that lost 
gene body mCpH, providing strong evidence for the role of DNMT3A as the depositor of 
mCpH in neurons, and for the role of mCpH in transcriptional repression (Guo et al., 2013). 
This study also identified MeCP2 as a specific binder of mCpH. In vitro EMSA assays found 
that MeCP2, but not MBD2, could bind to mCpH, albeit at a slightly reduced capacity than 
for mCpG. This was supported with in vivo ChIP analysis which showed that MeCP2-
immunoprecipatated DNA fragments contained mCpH as determined by bisulphite analysis 
(Guo et al., 2013). As MeCP2 is the major focus of this study, further information about the 
binding specificities of MeCP2 will be described in Chapter 1.2.4. 
 
The discovery that mCpH is highly enriched in the neuronal genome and the fact that the 
levels of this mark are less binomial than mCpG strongly suggests a role for mCpH in the 
regulation of transcriptional networks during mammalian brain development. Furthermore, 
the strong conservation of methylation patterns between human and mouse suggests a 
functional role (Maunakea et al., 2010). In line with this, post-natal deletion of all three 
DNMT enzymes in the postnatal hippocampus led to a decrease in the level of mCpH with 
little effect on mCpG, suggesting that mCpH has the potential for dynamic regulation even 
within a differentiated cell type (Guo et al., 2013). 
 
MeCP2 (methyl-CpG binding protein 2) was discovered in 1992 by Southwestern assays 
using rat brain extracts that were designed to identify methyl-CpG binding proteins (MeCPs) 
that could specifically bind to methylated DNA (Lewis et al., 1992). It was identified with an 
apparent molecular weight of 84 kDa (Lewis et al., 1992), showed highest expression (as 
judged by Southwestern assays) in rat and mouse brain tissue compared to other tissues 
(Meehan et al., 1992), and is tightly bound to chromatin, requiring high salt to remove it 
from DNA (Meehan et al., 1992). Deletion analysis of full-length rat MeCP2 protein 
identified the minimal region required for binding to methylated DNA, termed the 
methylated DNA binding domain (MBD) which consists of amino acids 78-162 and has a 




identified a nuclear localisation signal (NLS) that corresponds to amino acids 255-271 (Nan 
et al., 1996). The observation that MeCP2 binds specifically to methylated DNA suggested 
that it may play a role transcriptional repression. In line with this, a transcription repression 
domain (TRD), defined as the minimal region required to repress transcription from a 
reporter gene when transfected into cells, was discovered that consists of amino acids 207-
310 (Nan et al., 1997) A small region within the TRD was later identified to be responsible 
for an interaction with the NCoR/SMRT corepressor complex, and was termed the NCoR 
Interaction Domain (NID) (Lyst et al., 2013). The importance of this small domain and the 
MBD are exemplified by the fact that missense mutations within these domains cause a 
neurological disorder called Rett syndrome (RTT), whereas most missense mutations 
outwith these two domains are tolerated in the general population as judged by the ExAC 
database (Figure 1B) (Amir et al., 1999; Lyst et al., 2013). This has led to the “bridge” 
hypothesis whereby the function of MeCP2 is to recruit the NCoR/SMRT complex to sites of 
methylated DNA in order to maintain gene repression. Evidence for and against this 
hypothesis will be discussed in the rest of Chapter 1.2. 
 
When MeCP2 was first purified from rat brains in 1992, digestion followed by partial 
sequencing of the amino acid sequence allowed for primers to be designed that ultimately led 
to the sequencing and cloning of full-length, rat Mecp2 cDNA (Lewis et al., 1992). Two 
years later the mouse Mecp2 gene was mapped to the X-chromosome (Quaderi et al., 1994), 
and two years after that the precise location was determined in human cells and was shown 









females and identifying a possible role for MeCP2 in disorders involving the X-chromosome 
(D'Esposito et al., 1996). Detailed sequence analysis of both the human and mouse 
transcripts revealed four alternative polyadenylation (polyA) signals within a large 3’ 
untranslated region (UTR), suggesting the potential for tissue- and developmental-specific 
regulation of MeCP2 expression levels (Figure 1A) (Coy et al., 1999; Reichwald et al., 
2000). In line with this, recent studies have found that the levels of the two main alternative 
transcripts (the 10.2 kb and 1.8 kb transcripts) are tightly regulated during development as 
well as between the central nervous system and peripheral tissues, leading to high expression 
levels in post-mitotic neurons that increases during development (McGowan & Pang, 2015; 
Pelka et al., 2005; Rodrigues et al., 2016). 
 
For many years MECP2 was thought to contain only three exons, all of which contributed to 
the coding sequence. In 2000, sequence analysis of the human and mouse loci revealed a 
novel upstream exon (Reichwald et al., 2000), which was later shown to be a coding exon, 
thus identifying a novel protein isoform of MeCP2 which has an alternative N-terminus 
(Kriaucionis & Bird, 2004; Mnatzakanian et al., 2004). The MeCP2_e1 isoform (previously 
MeCP2B or MeCP2ɑ) begins transcription in exon 1, creating a unique 32 amino acid N-
terminus, and splices out exon 2 from the mature mRNA transcript, while the MeCP2_e2 
isoform (previously MeCP2A or MeCP2β) is encoded from exon 2 creating a shorter, 20 
amino acid N-terminus (Figure 1) (Kriaucionis & Bird, 2004). Both isoforms contain the 
coding sequence from exons 3 and 4 which contain the MBD and TRD, and thus it is not 
surprising that both isoforms localise to methylation-dense heterochromatic foci in mouse 
cells (Kriaucionis & Bird, 2004). The fact that human MeCP2_e1 alone is able to rescue 
phenotypes in Xenopus laevis embryo’s (whose endogenous MeCP2 is more similar to 
MeCP2_e2) suggests that both isoforms have the same function (Stancheva et al., 2003). 
Furthermore, the phenotype in Mecp2-/y mice can be rescued by either isoform (Kerr et al., 
2012). Yet the observation that a RTT-causing mutant (A2V) is found in exon 1 of MECP2 
and is therefore only specific to the MeCP2_e1 isoform (Fichou et al., 2009), suggests 
differential importance of the two isoforms. Indeed in vivo studies have found the 
MeCP2_e1 isoform to be the more highly expressed isoform in a range of mouse tissues, in 
the human brain, and during mouse development (Dragich et al., 2007; Kriaucionis & Bird, 
2004) thus explaining the debilitating effect of the e1-specific A2V RTT mutation. While 
MeCP2_e1 is now known to be the major isoform expressed in vivo, all RTT mutation 
nomenclatures were designated according to the MeCP2_e2 isoform. Thus, for example, the 




threonine 170 in the expressed MeCP2_e1 isoform. Throughout this thesis, all RTT 
mutations will be referred to using the standard MeCP2_e2 nomenclature. 
 
When MeCP2 protein was first identified, analysis of the 492 amino acid (aa) long rat 
protein revealed some interesting features that have implications for the DNA binding 
properties of MeCP2 (Lewis et al., 1992). Firstly, MeCP2 is a very basic protein with lysine 
and arginine residues comprising 22.5% of the entire MeCP2 protein sequence. Secondly, 
MeCP2 contains two (R)GRP(K) motifs which in other proteins are known to be responsible 
for binding to AT-rich DNA sequences (AT hooks, see Figure 1)), and eight SPKK motifs 
that are implicated in binding to the minor groove of AT-rich DNA. Finally, the methylated-
DNA binding domain also contributes to DNA binding specificities (Lewis et al., 1992; Nan 
et al., 1993). A highly basic protein that contains multiple motifs for binding to AT-rich or 
methylated DNA suggests that binding to DNA is a major function of MeCP2. 
 
Efforts towards solving the structural conformation of MeCP2 protein have been hampered 
by some unusual protein characteristics. Despite the amino acid sequence predicting a 
protein of roughly 53 kDa in size, MeCP2 migrates in an SDS-PAGE gel at ~75-80 kDa, and 
size exclusion chromatography finds MeCP2 eluting at 400-500 kDa (Klose & Bird, 2004). 
This unexpected pattern is not due to multimers because band shifts using tagged and 
untagged MeCP2 and analytical centrifugation suggests that MeCP2 is a monomer (Adams 
et al., 2007; Nan et al., 1993). The precise reason for the unexpected migration pattern was 
assumed to be caused by the rigid, rod-like structure (Adams et al., 2007) and the elongated 
shape that MeCP2 exhibits (Klose & Bird, 2004), and this was later confirmed by small 
angle X-ray scattering (Yang et al., 2011).  
 
Circular dichroism (CD) spectroscopy has demonstrated that approximately 59% of the 
protein is unstructured (40% of the MBD and 85% of the TRD are also unstructured), 
highlighting that in-depth structural analysis of full-length MeCP2 will be a challenging 
process (Adams et al., 2007). Trypsin digestion studies to identify “weak points” in the 
MeCP2 structure revealed that the MBD, the TRD and the C-terminal domain of MeCP2 do 
retain some tertiary structure that protects them from proteolytic cleavage (Adams et al., 
2007), and in line with this the MBD and the NID are the only two structures that have been 
solved to date. The first structure was the solution structure of the MBD (amino acids 77-
164) which was solved using NMR spectroscopy and revealed for the first time, the DNA-




structure was described as a non-symmetrical, wedge-shape that positions multiple lysine 
and arginine residues at the surface thus creating a large non-specific DNA recognition 
interaction surface. Later came the crystal structure of the MBD (amino acids 77-167) 
complexed to a 20bp DNA probe (Ho et al., 2008). This highlighted the importance of water 
molecules for recognition of the mCpG dinucleotide and uncovered an Asx-ST turn that is 
critical for structural integrity of the MBD. Interestingly, individual residues that were 
highlighted as being important for mCpG recognition and/or MBD structure were found to 
be frequently mutated in RTT (Ho et al., 2008). More recently a co-crystal structure of a 
short NID peptide was solved in complex with the C-terminus of the TBL1R1 protein, an 
NCoR complex subunit (Kruusvee et al., 2017). Importantly, the four individual residues in 
the NID that make contact with TBL1R1 are all mutated in RTT cases and, looking at the 
interface from the reverse angle, two important residues in TBL1R1 for MeCP2 recognition 
are frequently found mutated in developmental delay and intellectual disorders (Kruusvee et 
al., 2017).  Interestingly, a TBL1R1 residue (Y446) that when mutated causes the intellectual 
disability disorder Pierpoint syndrome (Y446C) (Heinen et al., 2016), was found at the NID-
interaction interface. Mutation of Y446 to phenylalanine, however, did not disrupt the 
interaction with MeCP2 (Kruusvee et al., 2017). Perhaps analysis of the exact Pierpoint 
Y446C mutation might reveal a deficit in the interaction with MeCP2 or alternatively 
Pierpoint syndrome might be caused by the disruption of TBL1R1 with other interaction 
partners. 
When MeCP2 was discovered, analysis of protein expression in different mouse tissues was 
assessed by Southwestern assay which found it to be highly expressed in mouse and rat 
brain, with lower levels in mouse spleen, liver and kidney, and the lowest levels in rat testes 
(Meehan et al., 1992). Assessment of  transcript levels found MECP2 ubiquitously in a range 
of human tissues (Coy et al., 1999; D'Esposito et al., 1996; Reichwald et al., 2000), but 
analysis of protein levels by immunofluorescence and quantitative laser scanning cytometry 
determined protein expression to be highest in central nervous system (CNS) tissues in both 
mouse and human post-mortem samples (Balmer et al., 2003; LaSalle et al., 2001). A broad 
distribution of MeCP2 expression was observed in the CNS tissues, and when cells were 
distinguished according to neuron vs glial status, glial cells uniformly contained lower 
amounts of MeCP2, while neuronal cells still displayed a broad distribution of MeCP2 
abundance (Balmer et al., 2003; LaSalle et al., 2001). This result was confirmed by Western 
blot analysis of mouse tissues and immunofluorescence analysis of mouse and human brain 




oligodendrocytes (Kishi & Macklis, 2004; Shahbazian et al., 2002a). More recently, semi-
quantitative analysis of MeCP2 levels in adult mouse tissues has further established that 
MeCP2 expression is highest in the brain (although within the brain, expression is low within 
the cerebellum), and is much lower in other tissues (Ross et al., 2016). 
 
Analysis of MeCP2 expression during mouse development demonstrated an increase in 
levels and strong punctate staining, corresponding to the localisation of MeCP2 at 
heterochromatic foci in mouse nuclei, which is where the majority of mC in the mouse 
genome is localised (Kishi & Macklis, 2004; Shahbazian et al., 2002a). 
Immunohistochemistry in rat brain slices also found high levels of expression in neurons, an 
increase of expression during development, and low levels in astrocytes (Jung et al., 2003). 
These results have also been confirmed by tissue culture neuronal differentiation protocols 
using rat, mouse and human cells (Jung et al., 2003; Kishi & Macklis, 2004). More recently, 
quantitative approaches have determined the number of MeCP2 molecules in the adult 
mouse NeuN+ nucleus to be 16 x 106, while NeuN- cells only have approximately 2 x 106 
molecules/nucleus. This high level of expression in mature neurons of the CNS puts MeCP2 
expression at near histone octamer levels (Skene et al., 2010). 
 
Thus, MeCP2 is ubiquitously expressed, particularly at the transcript level, but post-
transcriptional regulatory mechanisms act to increase the expression level significantly in 
neurons of the central nervous system. The expression level of MeCP2 in neurons increases 
as development progresses, and MeCP2 staining becomes more punctate, indicative of strong 
hetereochromatic binding. 
 
There is extensive evidence for the ability of MeCP2 to bind to methylated DNA. These 
include Southwestern and band shift assays that established that symmetrically modified 
mCpG is a binder of MeCP2, hemi-methylated DNA cannot bind MeCP2 and binding to 
non-CpG methylation (mCpH) is observed but is extremely weak (Jones et al., 1998; Lewis 
et al., 1992; Meehan et al., 1992). Furthermore methylation of the guanine residue in the 
mCpG dinucleotide has no effect on MeCP2 binding (Nan et al., 1993). 
 
This in vitro data is supported by immunofluorescence analysis, where in mouse cells 
MeCP2 co-localises with heterochromatic foci in interphase cells and with pericentromeric 




(Lewis et al., 1992). Furthermore, MeCP2 localisation to heterochromatic foci is lost in 
mouse cells that have ~5% the level of m5C due to a disrupted DNMT1 gene (Nan et al., 
1996). Immunofluorescence analysis of MeCP2 localisation in other organisms suggested 
early on that MeCP2 might bind globally throughout the genome as human HeLa, monkey 
COS7 and rat cells all show broad distribution throughout chromosome arms which, in 
comparison to mouse cells, do not have mCpG-rich pericentromeric heterochromatin (Nan et 
al., 1997). 
 
ChIP experiments have further confirmed the mCpG-binding preferences of MeCP2 in vivo. 
MeCP2 associates with integrated proviral DNA in a methylation-specific manner in mouse 
cells (Lorincz et al., 2001), binds to a hypermethylated viral promoter in a 5-aza-cytidine 
dependent manner in chicken cells (Rietveld et al., 2002), and 5-aza-cytidine treatment in 
neural stem cells dramatically reduces the association of MeCP2 with a methylated reporter 
construct (Muotri et al., 2010). While these experiments use reporter transgenes and 
integrated viral DNA, there is also evidence at endogenous loci that MeCP2 associates with 
DNA in a methylation-dependent manner. For example ChIP in mouse neurons reveals that 
in female samples, MeCP2 specifically associates with the XIST allele that is methylated, 
rather than the unmethylated allele, (Skene et al., 2010), and the endogenous MDR1 CGI in 
human T cells loses MeCP2 association upon 5-aza-cytidine treatment (El-Osta et al., 2002). 
Similarly, MeCP2 ChIP-on-ChIP signal is lost when human MRC5 cells are treated with 5-
aza-cytidine (Klose et al., 2005). 
 
Genome-wide ChIP-sequencing studies have recently assessed the profile of MeCP2 binding 
throughout the genome. As might be expected from a protein whose binding site is abundant 
in the genome, and based on initial immunofluorescence analysis (Nan et al., 1997), MeCP2 
binding was found throughout the entire genome, with the most prominent feature being a 
lack of binding at unmethylated CGIs in mouse whole brain (Skene et al., 2010), cortex and 
cerebellum (Gabel et al., 2015), hypothalamus (Chen et al., 2015) and cultured mouse 
neurons (Cohen et al., 2011). Surprisingly, such genome-wide analysis uncovered an 
enrichment of MeCP2 binding in areas of low mCpG density. These areas, however, have a 
high mCpH density and further analysis found that genes containing high levels of gene-bosy 
mCpH have high levels of MeCP2 occupancy (Chen et al., 2015). As detailed in Chapter 
1.1.4, mCpH levels increase during mammalian brain development and this increase 
coincides with the increase in MeCP2 expression during development (Chapter 1.2.3). The 




(Gabel et al., 2015), agreeing with earlier band shift experiments that also identified non-
mCpG binding capabilities of MeCP2 (albeit with a very weak affinity in the earlier study) 
(Guo et al., 2013; Meehan et al., 1992). The most recent analysis of MeCP2 binding by 
EMSA and ChIP-seq analysis has refined the mCpH preference to mCAC and modelled the 
potential binding interface of the MBD with a mCAC motif by in silico analysis of the 
crystal structure of the MBD (Lagger et al., 2017). 
 
Attempts to identify binding preferences outwith the methylated residue include methyl-
SELEX studies which found a preference for an [A/T] run of 4 or more bases adjacent to the 
mCpG dinucleotide (Klose et al., 2005), a result that was strengthened by the X-ray crystal 
structure of the MBD which showed a run of [A/T] residues induced a DNA bend that could 
accommodate DNA binding by the Asx-ST motif in MeCP2 (Ho et al., 2008). 
 
The evidence finds that MeCP2 binds to mCpG and mCAC in vitro and in vivo, and 
demonstrates how genes that have high levels of these two modifications (and therefore high 
levels of MeCP2 occupancy) in WT cells are the most misregulated in MeCP2 KO cells 
(Chen et al., 2015; Gabel et al., 2015; Lagger et al., 2017). The extremely high incidence of 
these two modifications throughout the genome (~1 every 100bp) has implications for the 
mechanism of gene repression by MeCP2. It implies that MeCP2 will affect the expression 
of thousands of genes to act as a global repressor. Quite how MeCP2 might bring about 
global transcriptional repression or exert a restraint on gene expression is unknown. Even 
though MeCP2 has the capacity to bind to a large number of genes, likely the local 
transcriptional and chromatin environment of each individual gene will impact upon the 
ability of MeCP2 to bind to and regulate that gene. 
 
When MeCP2 was first identified a methylation-specific gene repression role could not be 
found. In vitro experiments using purified rat MeCP2, the human ɑ-globin locus and rat liver 
nuclear extracts failed to determine any mCpG-dependent transcriptional repression. In fact, 
transcription was inhibited regardless of the methylation status of the ɑ-globin locus. Thus, it 
was assumed that MeCP2 regulates gene expression by simply binding to DNA in a non-
discriminate manner (Meehan et al., 1992). A later study using a purer MeCP2 protein 
preparation managed to demonstrate methylation-specific repression activities of MeCP2 in 
vitro (Nan et al., 1997). This study also mapped the minimal region required to mediate 




and demonstrated that an N-terminal peptide of amino acids 1-162 could weakly repress 
transcription in vitro, suggesting that binding of MeCP2 to promoters was not enough for full 
repression and that the activity of the so-called transcriptional repression domain (TRD) was 
required for complete repression. Methylation-dependent repression by MeCP2 in vitro was 
confirmed using MeCP2 purified from Xenopus (Kaludov & P.Wolffe, 2000), and both 
studies found that MeCP2 could repress transcription from a distance, either 1.3kb and 2.1kb 
upstream of the promoter (Nan et al., 1997) or 250bp and 500bp upstream (Kaludov & 
P.Wolffe, 2000). These experiments are also supported by luciferase reporter assays in 
mouse tail fibroblasts that demonstrate MeCP2 can preferentially repress a methylated 
luciferase gene (Guy et al., 2001), and in human HeLa cells where MeCP2 can repress 
transcription in a methylation-dependent manner and this repression is abolished upon 
deletion of the TRD (but surprisingly not with the R306C mutation, see discussion below) 
(Drewell et al., 2002). 
 
The observation that the binding of a TRD-less MeCP2 could not fully repress a reporter 
construct (Nan et al., 1997) led to the hypothesis that the function of the TRD was to recruit 
a corepressor complex to DNA to mediate full repression. Many such protein interactions 
have been identified over the years including Sin3a (Nan et al., 1998), Ski (Kokura et al., 
2001), NCoR (Kokura et al., 2001), SMRT (Stancheva et al., 2003), CoREST (Lunyak et al., 
2002), SUV39H1 (Lunyak et al., 2002), YY1 (Forlani et al., 2010) and TBLR1 (Kruusvee et 
al., 2017). The majority of these interactions have not been assessed in multiple organisms or 
by different laboratories and the in vivo relevance of many of these findings remains to be 
determined (Lyst & Bird, 2015). For many years Sin3a was to be considered the major 
interactor of MeCP2 and interactions were demonstrated in HeLa cells (Nan et al., 1998), rat 
brain extracts (Nan et al., 1998) and Xenopus oocyte extracts (Jones et al., 1998). The 
observation that MeCP2-mediated repression was reduced upon treatment with an HDAC 
inhibitor (TSA) was consistent with Sin3a being the transcriptional mediator as Sin3a is 
known to interact with HDAC1 and HDAC2 (Jones et al., 1998; Nan et al., 1998). The 
importance of Sin3a interactions for in vivo function, however, was questioned as the 
interaction domain was found to not overlap with the TRD (Nan et al., 1998), and more 
importantly the interaction was found to be rather unstable (Klose & Bird, 2004) and in fact 
quite weak (Lyst et al., 2013). 
 
Since then the focus has shifted to the NCoR/SMRT corepressor complex which was first 




and 2003 (Stancheva et al., 2003), but the importance of this interaction was not confirmed 
until 2013 (Lyst et al., 2013). The NCoR/SMRT corepressor complex is a large, multi-
subunit complex predicted to contain around 10-12 different protein components, including 
the histone deacetylase HDAC3. It functions to repress transcription through its association 
with nuclear receptors such as thyroid hormone receptors and retinoic acid receptors, with 
the repression being dependent on NCoR, SMRT, HDAC3, TBL and TBLR1 activities 
(although due to significant homology between TBL1 and TBLR1 it is perhaps not 
surprising that repression is alleviated only when both components are removed from the 
system, suggesting redundancy) (Yoon et al., 2003a). Homozygous deletion of NCoR from 
mice found the protein to be necessary for embryonic development (with embryos dying by 
E15.5) while T cell development, erythropoiesis and CNS development (specifically neural 
precursor self-renewal) were all impaired (Hermanson et al., 2002; Jepsen et al., 2000). This 
study also found the NCoR complex to have varying functions in repression and activation 
depending on the co-receptors, ligands and loci in question (Jepsen et al., 2000). Of note, 
NCoR has been implicated in binding to another mCpG-binding protein Kaiso both in vitro 
and in vivo and is required for Kaiso-mediated repression of the MTA2 locus in vivo in HeLa 
cells (Yoon et al., 2003b). Thus the NCoR/SMRT corepressor complex has been identified 
in a number of in vivo complex interactions suggesting it may play roles in the regulation of 
a number of different loci under a variety of different conditions. 
 
The interaction of MeCP2 with the NCoR/SMRT complex has been mapped to a C-terminal 
portion of the MeCP2 TRD domain, termed the NID (NCoR-interaction domain, Figure 1) 
(Lyst et al., 2013). This interaction is abolished when a NID-containing RTT mutation 
R306C is introduced and furthermore mice containing this mutation exhibit significant RTT-
like phenotypes, similar to MeCP2 null mice, and have a decreased lifespan (Lyst et al., 
2013). Furthermore, all four RTT mutations that localise to the NID domain are able to 
abolish the interaction of MeCP2 with NCoR and result in reduced repression of a luciferase 
construct in mouse NIH-3T3 assays highlighting the functional significance of this MeCP2-
NCoR interaction for MeCP2 function in vivo (Lyst et al., 2013). The specific MeCP2 
interaction site on the NCoR/SMRT complex has recently been mapped to the WD40 
domain of the TBL1/TBLR1 proteins with a co-crystal structure identifying the direct 
interactions the NID residues have with TBLR1. Interestingly, TBLR1/TBL1 mutations that 
cause intellectual disability and autism spectrum disorders map to the MeCP2-TBL interface 





While for many years repression assays confirmed the hypothesis that MeCP2 functions as a 
transcriptional repressor, global transcriptome analysis did not find an overall upregulation 
of gene expression upon MeCP2 deletion. There have been numerous microarray studies of 
MeCP2 null mouse brain regions at different ages of phenotype progression, all of which 
found small numbers of significantly changing genes that both increase and decrease in their 
expression level (Ben-Shachar et al., 2009; Chahrour et al., 2008; Jordan et al., 2007; 
Kriaucionis et al., 2006; Nuber et al., 2005; Tudor et al., 2002; Urdinguio et al., 2008). The 
largest changes were observed in the study by Chahrour and colleagues who looked at the 
hypothalamus and found 2582 genes that were misexpressed in both MeCP2 null and 
transgenic (overexpression) animals (Chahrour et al., 2008). Indeed, microarray analysis of 
patient samples have revealed the same patterns of low numbers of genes that increase or 
decrease their expression level less than 2-fold in the cerebral cortex, superior frontal cortex, 
T lymphocytes, B lymphoblastoid cells and fibroblasts (Ballestar et al., 2005; Colantuoni et 
al., 2001; Delgado et al., 2006; Deng et al., 2007; Nectoux et al., 2010; Traynor et al., 
2002). As well as low numbers of changing genes, there is no clear functional group of genes 
that are misregulated in every sample and each study seemed to find its own group of 
“MeCP2 target genes”, for example glucocorticoid-related genes (Nuber et al., 2005), G-
protein coupled receptors (Chahrour et al., 2008), mitochondrial genes (Kriaucionis et al., 
2006) and an extracellular proteoglycan (Delgado et al., 2006). Thus it is not surprising that 
for many years the field has been divided as to whether MeCP2 acts as a repressor or an 
activator (Ben-Shachar et al., 2009; Chahrour et al., 2008). 
 
Recently the relationship between MeCP2 binding, DNA methylation and gene expression 
changes by RNA-sequencing analysis has been analysed in order to reveal trends in 
individual datasets rather than looking for groups of commonly misregulated genes between 
datasets. Such analyses in mouse hypothalamus (Chen et al., 2015), cortex and cerebellum 
(Gabel et al., 2015; Kinde et al., 2016) demonstrates that genes that are up-regulated in 
MeCP2 KO brains tend to have high levels of gene-body mCpA (mCpH in Chen study). As 
discussed in Chapter 1.2.4, MeCP2 ChIP-sequencing in these brain regions shows 
enrichment for genes that have high levels of gene-body mCpA, and that EMSA analysis and 
ChIP-seq normalised reads determines mCpG to be the strongest predictor of MeCP2 
binding, followed by mCpH and then unmethylated DNA (Chen et al., 2015). In line with 
this, genes that are repressed in MeCP2 transgenic mice tend to have higher levels of gene-
body mCpH compared to the rest of the genome, suggesting mCpH is directing MeCP2 




will be up-regulated in MeCP2 KO samples was observed in 3 KO brain regions, in R306C 
mice and in RTT patient brain samples (Gabel et al., 2015) and was narrowed to mCAC 
recently (Lagger et al., 2017). Furthermore Dnmt3A conditional KO mice (nestin-cre) 
demonstrate a loss of mCpH levels but no change in mCpG levels and microarray analysis in 
the cerebellum reveals a mCpA-dependent increase in gene expression levels in these mice 
(Gabel et al., 2015). But, MeCP2 binding is not abolished in these mice, demonstrating that 
mCpG dinucleotides are still important for MeCP2 occupancy (Kinde et al., 2016). A direct 
comparison of gene expression changes in the MeCP2 null and dnmt3a null mice would be 
useful for distinguishing the contributions of mCpG and mCpA binding for MeCP2-
mediated gene repression. While the Chen study found genes that were down-regulated in 
the absence of MeCP2 (MeCP2-activated genes) were also enriched for gene-body mCpA in 
the hypothalamus, this finding was not recapitulated in analysis of the same dataset as well 
as those from cortex and cerebellum (Kinde et al., 2016; Lagger et al., 2017). In fact, genes 
that are repressed in the absence of MeCP2 do not seem to share any distinguishable features 
with regards to mCpG, mCpA, gene length or histone acetylation status suggesting that these 
genes are not direct targets for MeCP2-dependent regulation, but are instead secondary 
transcriptional effects (Kinde et al., 2016; Lagger et al., 2017). 
 
To conclude, the current evidence suggests that MeCP2 acts as a transcriptional repressor, 
via the action of binding to sites of mCpG and mCAC in order to temper gene expression. As 
opposed to functioning like a flicker switch and turning gene expression off by direct 
binding, MeCP2 seems to act like a dimmer switch to dampen gene expression and provide 
an extra level of transcriptional constraint. Gene expression changes are not large upon the 
loss of MeCP2, but they are numerous and they consistently correlate with genes that have 
high levels of gene-body methylation. This suggests that MeCP2 functions to restrain gene 
expression via binding within the body of genes. How MeCP2 achieves this repression 
mechanistically is still unknown. 
 
While there is strong evidence for the role of MeCP2 in transcriptional repression, multiple 
other models have been proposed, reviewed in (Lyst & Bird, 2015) (Figure 1C). The 
relevance of some of these functions for RTT pathology are yet to be established, but it is 







In the hypothalamus of MeCP2 null mice, more genes are downregulated then upregulated 
and the reverse is true for mice that overexpress MeCP2 (Chahrour et al., 2008). A subset of 
genes showed this reciprocal effect suggesting that MeCP2 could be activating gene 
transcription in the hypothalamus. Similar results have also been found in the cerebellum 
(Ben-Shachar et al., 2009) and a mechanism for how these transcriptional changes take place 
has been put forward. Specifically, an interaction between MeCP2 and CREB (cAMP-
responsive element binding protein 1) which is a known transcriptional activator has been 
suggested (Chahrour et al., 2008). In line with an activation hypothesis, MeCP2 has been 
observed to bind to unmethylated promoters in SH-SY5Y cells (Yasui et al., 2007) and in 
olfactory neurons in vivo (Rube et al., 2016). Furthermore, there is evidence in mouse and 
human ESC-derived neurons that total transcription is reduced in MeCP2 KO samples (Li et 
al., 2013c; Yazdani et al., 2012). MeCP2 has also been claimed to interact with the 
euchromatin-associated transcriptional activator Brahma (Harikrishnan et al., 2005), 
however this interaction was later questioned and thus the only current hypothesis for how 




MeCP2 has also been implicated in the regulation of miRNA processing by a number of 
studies (Cheng et al., 2014; Szulwach et al., 2010; Tsujimura et al., 2015; Urdinguio et al., 
2010; Wu et al., 2010). The relevance of these studies is uncertain, however, as Cheng and 
colleagues claim MeCP2 inhibits miRNA processing by interfering with the Drosha complex 
whereas Tsujimura and colleagues claim MeCP2 acts as part of the Drosha complex to 
facilitate miRNA processing. Furthermore, the region of MeCP2 that has been mapped as the 
Drosha interacting domain (the C-terminus of MeCP2) is indispensable for MeCP2 function 
because mice that are truncated at residue 312 are phenotypically WT (Sabine Lagger et al, 
unpublished results). 
 
Regulation of splicing 
MeCP2 has been implicated in the regulation of splicing via an RNA-dependent interaction 
with YB-1 (Young et al., 2005). A YB1-interaction domain has been mapped to residues 
195-310 and alternative splicing was found misregulated in mice that express a truncated 
form of MeCP2 (Shahbazian et al., 2002b). Furthermore, two papers have been published 




MeCP2 affects the use of alternative exons by binding to the 5hmC DNA modification 
(Cheng et al., 2017) and while MeCP2 has been shown to be able to bind to this modification 
by other laboratories (Gabel et al., 2015; Lagger et al., 2017; Mellen et al., 2012; Valinluck 
et al., 2004), it exists at such a low level in the adult mouse and human brain that its 
biological relevance is questionable (Lister et al., 2013). The second paper proposed a 
mechanism whereby reduced DNA methylation results in reduced MeCP2 binding 
throughout gene bodies leading to reduced splicing and increased intron retention in primary 
mouse granulocytes (Wong et al., 2017). A similar observation has been seen in human lung 
and colon carcinoma cell lines (Maunakea et al., 2013), however the relevance of these 




Several studies have demonstrated a role for MeCP2 in chromatin remodelling and 
chromatin interactions. Early in vitro experiments demonstrated the ability of MeCP2 to bind 
to nucleosomal plasmid DNA and compete with H1 (Nan et al., 1997). MeCP2 was also 
shown to bind to nucleosomal linker DNA both in vitro and in vivo (Ishibashi et al., 2008; 
Nikitina et al., 2007a) and is able to compete for binding with H1 in mouse fibroblasts, being 
more effective at displacing H1 than vice versa (Ghosh et al., 2010). In support of a 
mechanism whereby MeCP2 preferentially binds to methylated cytosines in linker DNA, 
thus displacing H1, H1 levels are surprisingly low in neurons (Pearson et al., 1984), and 
were found to be increased 2-fold in MeCP2 KO neuronal nuclei (Skene et al., 2010). In 
addition, a number of studies have shown that MeCP2 can induce chromatin compaction. 
Electron microscopy using nucleosomal arrays demonstrated how MeCP2 is able to bind 
arrays and cause compaction (Georgel et al., 2003; Nikitina et al., 2007b). In addition, 
looping of DNA has been observed both in vitro (Ghosh et al., 2010) and in vivo (Horike et 
al., 2005). Specifically, atomic force microscopy observed a single MeCP2 molecule making 
numerous contacts with a single strand of DNA thus creating observable DNA loops (Ghosh 
et al., 2010), while a specific loop at the Dlx5-Dlx6 imprinted locus in mouse brain is lost 
upon MeCP2 KO (Horike et al., 2005). The biological significance of this is questionable as 
a second group could not replicate the MeCP2-loop-dependent silencing of this locus 
(Schule et al., 2007). More recently array tomography microscopy has revealed alterations in 
the chromatin landscape in MeCP2 KO cells in brain slices from a Mecp2+/- female mouse 
(Linhoff et al., 2015). If MeCP2 was involved in chromatin compaction one would expect an 




was found. Heterochromatic foci volumes were increased in nuclei that lacked MeCP2 but a 
larger quantity of DAPI staining was present within these foci, indicating a redistribution of 
DNA into larger heterochromatic foci. Interestingly, Linhoff and colleagues observed 
increased chromatin compaction in hippocampal CA1 pyramidal neurons and dentate 
granule neurons, but not in cerebellar granule neurons, which corresponds with the lower 
expression level of MeCP2 in the cerebellum (Ross et al., 2016). 
 
Inhibitor of retrotransposon 
Retrotransposons are interspersed, repetitive elements within the mammalian genome, which 
can be transcribed and often retain the ability to transpose into new locations within the 
genome. The highly methylated state of their integrated form suggests that MeCP2 could 
play a role in the regulation of transcription and transposition of these elements. In line with 
this hypothesis, exogenous expression of MeCP2 (but not MBD1 or MBD2) in HeLa cells 
reduces the frequency of L1 retrotransposition, thus suggesting that MeCP2 inhibits the 
transposition of repetitive elements (Yu et al., 2001). Furthermore, increased transposition of 
the L1 retrotransposon has been observed in the brains of Mecp2-/y KO mice and neural 
precursors derived from RTT patient iPSCs (Muotri et al., 2010) and transcripts derived 
from repetitive elements are somewhat increased in NeuN+ nuclei from Mecp2-/y brain 
(Skene et al., 2010) and in the brains of Mecp2-/y KO mice (Muotri et al., 2010). The 
relevance of this phenotype remains to be determined, but the fact that RTT-like phenotypes 
in mice can be reversed upon re-expression of MeCP2 suggests that the irreversible 
insertional mutagenesis imposed by retrotransposition is not a major contributor (Guy et al., 
2007). MeCP2-induced repression of retrotransposon expression, however, could still be 
relevant for RTT pathologies. 
 
Non-methylated DNA binding 
While MeCP2 can specifically recognise and bind to sites of methylation in the genome 
there is evidence that this methylation-specific binding is assisted by non-methylated DNA 
recognition. In particular, the observation that depletion of DNA methylation does not result 
in the complete dissociation of MeCP2 from DNA but rather its redistribution suggests that 
MeCP2 has the ability to bind to non-methylated sites in vivo (Baubec et al., 2013). In vitro 
data has shown that MeCP2 can bind to nucleosomal arrays regardless of the methylation 
status of the underlying DNA, and that this non-specific binding may be modulated by the C-
terminus of MeCP2 (Georgel et al., 2003; Ghosh et al., 2010; Nikitina et al., 2007b). This in 




2007), mouse cortical neuronal cultures (Harikrishnan et al., 2010) and mouse olfactory 
neurons (Rube et al., 2016) showing binding of MeCP2 to non-methylated loci. 
 
Three outstanding questions remain though; what domains within MeCP2 specifically 
mediate this non-methylated DNA binding, to what extent does this binding occur genome-
wide, and how critical is this mode of DNA binding for Rett syndrome? To address the 
former question, there has been some focus on the three potential AT-hook motifs within 
MeCP2 that, if functional, would mediate AT-rich sequence binding of MeCP2 (Figure 1). 
The most C-terminal AT-hook (AT-hook 3) is not recognised as an AT-hook motif by in 
silico analysis and in fact has sequence disruptions in the core motif suggesting that it cannot 
function as an AT-hook. The other two AT-hooks have recently been assessed in vitro and in 
vivo for AT-hook character, and while AT-hook 1 can mediate AT-rich DNA binding in the 
absence of a functional MBD, AT-hook 2 is less robust (Lyst et al., 2016). Truncation of 
MeCP2 at arginine 168 results in decreased binding of MeCP2 to non-methylated 
nucleosomal arrays in vitro, although does not abolish it (Georgel et al., 2003). Alternative 
truncations to R274X and H370X also dramatically reduce DNA binding and abolish it when 
R274X is combined with the MBD-containing point mutation R106W, thus suggesting that 
the C-terminal domain is critical for non-methylated DNA binding (Nikitina et al., 2007b). 
In addition, the MBD, the intervening domain and the TRD have all been implicated in non-
methylated DNA binding as well [reviewed in (Hansen et al., 2010)]. 
 
Perhaps all of these domains contribute to non-methylated DNA binding of MeCP2, 
implicating multi-modal DNA binding properties. MeCP2 may bind non-discriminately 
throughout the genome, but have higher affinities (and perhaps longer residence times) in the 
presence of methylated cytosines. In vivo ChIP analysis of the MeCP2 truncations and point 
mutations used in these in vitro experiments will help to determine the ability of these 
proteins to bind to non-methylated DNA in an endogenous context. In addition, downstream 
mouse phenotyping or neuronal transcriptome analysis will help to determine the 
significance of this mode of binding for proper MeCP2 function. 
 
 
In 1999 mutations in MeCP2 were discovered as the leading cause of Rett syndrome (RTT: 
Online Mendelian Inheritance in Man #312750), a severe neurological disorder and one of 




described in 1966 by Andreas Rett, an Austrian clinician who reported his observations on 
22 girls who had similar clinical features (Rett, 2016). It was not until 1983, however, when 
Bengt Hagberg published his own observations of this disease that the term Rett syndrome 
was coined (Hagberg et al., 1983). RTT has a prevalence of 1 in every 10000 live female 
births and due to the X-linked nature of its genetics, primarily affects females. Despite early 
predictions that RTT was a disorder of the X chromosome, it took many years for the genetic 
cause to be identified due to the sporadic nature of the disorder (Hagberg et al., 1983). With 
about 12 familial cases of RTT having been identified worldwide (i.e. multiple cases of RTT 
occurring within the same family tree), exclusion mapping using microsatellite markers on 
the X chromosome led to the localisation of the genetic cause to the Xq28 region on the X 
chromosome (Curtis et al., 1993; Schanen et al., 1997; Sirianni et al., 1998). Genetic 
screening of genes located within this region eventually led to the identification of MECP2 
as the causative agent (Amir et al., 1999). Women and girls with the disorder are 
heterozygous for the MeCP2 mutation and exhibit mosaicism whereby ~50% of their cells 
express a wild-type (WT) copy of MECP2 and the other ~50% express a mutant version. 
Skewed X chromosome inactivation (XCI) can therefore result in patients with the same 
MECP2 mutation displaying varied clinical severity. Hemizygous males, having only one X 
chromosome are more severely affected by MECP2 mutations, often die prenatally and those 
that are born display severe encephalopathy (Katz et al., 2016; Schanen et al., 1998). Genetic 
screening is now a routine step as part of the diagnostic criteria for RTT, and 660 different 
MECP2 mutations have been identified and are documented in RettBase 
(http://mecp2.chw.edu.au/) (Christodoulou & Ho, 2003). There are eight recurrent missense 
or nonsense mutations that account for approximately 2/3 of RTT mutations (Leonard et al., 
2017), all of which disrupt the MBD or NID of MeCP2, thus highlighting the importance of 
these two domains for MeCP2 function (Lyst & Bird, 2015) (Figure 1B). 
 
In addition to Rett syndrome, another MeCP2 related disorder has recently been 
characterised called MeCP2 duplication syndrome (Van Esch et al., 2005). It is caused by 
duplications of portions of the X chromosome specifically including MECP2 and IRAK1, but 
duplication size and breakpoint locations vary in the population. Due to the duplication 
occurring most often in cis onto the same X chromosome, the condition affects boys while 
females are protected by random XCI. The frequency of MeCP2 duplication syndrome has 
not been extensively studied as it is a newly recognised disorder and very few cases have 
been reported, however it is predicted to account for 1% of X-linked mental retardation cases 




developmental delay, severe to profound mental retardation, absent speech, progressive 
spasticity and epilepsy (Ramocki et al., 2010). Two mouse models exist, both of which were 
generated prior to the condition being defined. The first model knocked a Mecp2 cDNA 
construct into the Tau locus thus providing neuron-specific MeCP2 overexpression 
(Luikenhuis et al., 2004), while the 2nd model consists of a 99 kb human PAC containing 
MECP2 driven by its own promoter (Collins et al., 2004). Both mouse models exhibit 
similar phenotypes suggesting neuronal MeCP2 overexpression is the major driver of disease 
progression. Phenotypes include growth retardation, progressive neurological symptoms and 
ataxia. The two domains that are implicated in Rett syndrome pathologies (the MBD and the 
NID) are also implicated in MeCP2 duplication syndrome pathologies as mice that 
overexpress MeCP2 containing MBD or NID mutations do not develop phenotypes 
(Heckman et al., 2014; Lamonica et al., 2017). Likewise, overexpression of WT MeCP2 in a 
RTT mutation background can prevent the onset of RTT-like phenotypes in mice 
(Luikenhuis et al., 2004).  
 
RTT is characterised by a normal period of development for the first 6-18 months of life, 
followed by developmental stagnation, developmental delay and subsequent developmental 
regression, all within the first 3 years of life (Kaufmann et al., 2016). Loss of motor skills, 
loss of verbal communication and the replacement of purposeful hand movements with hand 
stereotypies and hand mouthing are hallmarks of RTT. Approximately half the girls can 
walk, however often with an abnormal gait. Microcephaly, seizures, scoliosis, apneas, 
hyperventilation and cardiac problems are all other features of RTT. During the regression 
phase of the disease, girls often develop autism-like behaviours, and while this can continue 
for a minority of patients, RTT is not classified as an autism spectrum disorder (ASD) (Katz 
et al., 2016; Neul et al., 2010). Often a 2nd period of regression can occur at the late 
adolescent stage whereby patients develop Parkinsonian features (Humphreys & 
Barrowman, 2016). Despite these severe symptoms from an early age, women with RTT 
who have the necessary care can survive well in adulthood and the survival rate for the 
disorder at age 45 is over 70% (Tarquinio et al., 2015). 
 
Post-mortem analyses of brains from RTT patients have revealed a number of morphological 




less melanin than age-matched control brains (Armstrong, 2002). When this is looked at in 
closer detail, individual neurons are smaller, have shorter neurites, increased cell packing, 
reduced dendritic complexity and fewer spines (Dawna Armstrong, 2005; Dawna Armstrong 
et al., 1995; Dunn et al., 2014; Kaufmann et al., 2000; M.L. Bauman et al., 1995). While 
these malformations are found throughout the entire brain, the extent varies from region to 
region. For example, the cerebral hemispheres have a more pronounced decrease in volume 
than the cerebellum, which could perhaps reflect the smaller level of expression of MeCP2 in 
the cerebellum compared to other brain regions (Dawna Armstrong, 2005; Ross et al., 2016). 
Other malformations that have been reported include decreased cortical thickness, decreased 
MAP2 expression, decreased dopamine in the hippocampus, increased cell death in the 
subtania nigra pars compacta and decreased choline acetyltransferase in the forebrain 
(Colantuoni et al., 2001; Kaufmann et al., 2000; Kitt & Wilcox, 1995). 
 
While MeCP2 is ubiquitously expressed, its high levels in the brain and the primarily 
neurological symptoms observed in patients with Rett syndrome suggested that the central 
nervous system plays a crucial role in the disease. The first mouse models of RTT 
immediately highlighted this by the use of Cre-loxP technologies to delete MeCP2 from the 
central nervous system using nestin-cre (deletes in neurons and glia from embryonic day 12) 
(Chen et al., 2001; Guy et al., 2001). These studies found a near identical phenotype in these 
mice compared to the ubiquitous-cre KO mice, highlighting the central nervous system as 
being the major contributor to the RTT-like phenotype in mice (Guy et al., 2001). Post-natal 
KO of MeCP2 in post-mitotic neurons using CamK-cre that is expressed from P21 revealed 
that mice were healthy for the first 3 months of life, before developing RTT-like phenotypes 
(Chen et al., 2001). CamK-cre expression deleted MeCP2 from the forebrain, hippocampus 
and brainstem but not from the cerebellum. Interestingly, post-mortem examination of cell 
soma sizes revealed decreases in the cortex and hippocampus but not in the cerebellum, 
highlighting a direct link between MeCP2 deficiency and neuronal soma size in mouse 
models, which recapitulates the phenotype seen in patients (Chen et al., 2001). Of note, the 
CamK-cre mice did not delete MeCP2 from glia, and while the phenotype was similar to that 
of germline-null mice, it was less severe. Whether this absence of a severe phenotype is due 
to MeCP2 expression in glia, in the cerebellum or due to the delayed KO of MeCP2 is 
unknown. Of note, however, mice that have a glial-specific KO of MeCP2 using hGFAP2-
cre display normal lifespan, locomoter functions, anxiety and dendritic branching but exhibit 
hindlimb clasping and irregular breathing, potentially suggesting that the breathing 




populations. Performing the reverse experiment, however, of rescuing null mice with glial-
specific expression does rescue a number of overt RTT-like phenotypes, including breathing 
irregularities and dendritic branching (Lioy et al., 2011). 
 
Through conditional KO studies (cKO) MeCP2 has also been deleted from a range of 
different neuronal sub-types and different brain regions in order to understand the 
contributions of different neurons to disease pathology, reviewed in (Guy et al., 2011). 
Perhaps unsurprisingly, the phenotypes observed in the mice reflect the function of the brain 
region from which MeCP2 was deleted. For example, deletion of MeCP2 specifically in 
areas of the hypothalamus using Sim1-cre results in overweight mice that suffer from 
hyperphagia, but do not have any motor, learning or memory deficits (Fyffe et al., 2008). 
Alternatively, deletion in dopaminergic and noradrenergic neurons using Th-cre results in 
hypoactivity and abnormal motor coordination but normal anxiety levels (Samaco et al., 
2009). Similar results have been found in mouse models using Pet1-cre (serotonergic 
neurons) (Samaco et al., 2009), Viaat-cre (GABAergic neurons) (Chao et al., 2010), Dlx5/6-
cre (forebrain GABAergic neurons) (Chao et al., 2010; Zhang et al., 2014), Emx1-cre 
(forebrain excitatory neurons) (Zhang et al., 2014), PV-cre (parvalbumin neurons) (Ito-Ishida 
et al., 2015), SOM-cre (somatostatin neurons) (Ito-Ishida et al., 2015) and Vglut2-cre 
(glutamatergic neurons) (Meng et al., 2016). These studies have demonstrated the 
importance of MeCP2 in all neuronal sub-types and brain regions. The only cKO mouse that 
has a decreased lifespan is the Viaat-cre line (50% survival at 26 weeks compared to ~8 
weeks for MeCP2 null mice) suggesting that perhaps the loss of MeCP2 in GABAergic 
neurons is more critical for RTT pathologies. In line with this, rescue of MeCP2 expression 
in null mice specifically in GABAergic neurons is able to rescue lifespan, body weight, 
ataxia and apraxia (Ure et al., 2016). Interestingly, while acoustic startle responses and 
tremors are not rescued in this mouse line, these phenotypes are rescued in a glutamatergic 
neuron-specific rescue, which itself also has an improved lifespan but does not rescue motor 
deficits (Meng et al., 2016). 
 
RTT is not considered to be a neurodevelopmental disorder due to the observation that 
reactivation of MeCP2 expression in null mice after symptoms have appeared can reverse the 
neurological phenotype in the mice (Guy et al., 2007). This suggests that the neurological 
defects caused by loss of MeCP2 function are reversible and therefore MeCP2 is required for 
neuronal maintenance but not neuronal development. At the same time, MeCP2 is required 




11 weeks or 20 weeks leads to the onset of RTT-like phenotypes and premature death in 
male mice (Cheval et al., 2012; McGraw et al., 2011). 
 
The discovery in 1999 that the majority of Rett syndrome cases are caused by mutations in 
the X-linked gene MECP2 created a new era in the RTT field, often referred to as the post-
MeCP2 era (Amir et al., 1999). In the pre-MeCP2 era, most clinical trials were based on 
clinical observations, for example the observation that RTT patients had low L-carnitine 
plasma levels led to the clinical trial of L-carnitine which demonstrated some improvements 
in some patients (Ellaway et al., 1999). 
 
Upon the discovery of MeCP2 being the causative agent in Rett syndrome, and knowledge of 
its links to DNA methylation, trials were begun using methyl donors such as folane/betaine 
and creatine. Furthermore, with molecular details emerging that RTT is a disorder of the 
whole brain as opposed to a particular region, clinical trials using pan-specific growth factors 
such as BDNF and IGF-1 in order to restore the functionality of multiple neuronal circuits is 
being assessed as a therapeutic option. At least four clinical trials are ongoing or have been 
completed using this approach. Similarly, restoration of neurotransmitter balance is being 
assessed, however knowledge of which neurotransmitters to use, when in the disease 
progression to begin treatment and which patients will benefit from that particular treatment 
is currently lacking [reviewed in: (Kaufmann et al., 2016)]. 
 
In the post-MeCP2 era, more targeted therapeutic strategies have been explored including 
direct manipulation of MECP2 itself. The key study came in 2007 when restoration of 
MeCP2 in Mecp2-deficient mice led to dramatic restoration of breathing, motor skills and 
other RTT-like phenotypes in the mice (Guy et al., 2007). This strategy provided the 
conclusive evidence that RTT is a reversible disorder in mice, and is therefore potentially 
curable in patients, even after the onset of symptoms. Since then, MeCP2-targeted 
therapeutic strategies have included replacement of MeCP2 via gene or protein therapy, 
reactivation of the inactive MECP2 allele and the use of read-through compounds for those 
patients who have a mutation that produces an early stop codon (Katz et al., 2016; Shah & 
Bird, 2017). 
 
Gene therapy, i.e. providing a WT copy of the MECP2 gene, has so far been the most 




adeno-associated viruses (AAV) containing Mecp2 reverse some of the RTT-like features in 
mice (Gadalla et al., 2013; Garg et al., 2013). AAV vectors for gene therapy are widely used 
for a number of disorders and in some cases the results are very promising, for example 
delivery of rpe65 to the sub-retinal layers in the eye to reverse the blindness observed in 
rpe65 deficiency [reviewed in: (Samulski & Muzyczka, 2014)]. Indeed, AAV vectors are the 
first example of viruses being approved for use in the clinic in the form of Glybera, an AAV 
virus to treat lipoprotein lipase deficiency (Bryant et al., 2013). While AAV vectors seem 
extremely promising, there are some worries over the use of this treatment for Rett 
syndrome. In particular is the risk of curing Rett syndrome, but simultaneously causing 
MeCP2 duplication syndrome, while another issue is inducing liver toxicity. To circumvent 
these potential problems, alternative delivery routes and a range of doses are being tested for 
safety and efficacy in mouse models. Most recently, cerebroventricular injections of 1 x 1011 
vector genomes/mouse were shown to be most effective at achieving phenotypic rescue and 
avoiding liver toxicity (Gadalla et al., 2017). Tight control over the expression of MeCP2 
would also be desirable, but the small packaging size of the AAV genome (~4.7kb) limits the 
possibilities here. Small versions of the endogenous Mecp2 promoter have proven to be 
successful at controlling endogenous expression levels of MeCP2 (Gadalla et al., 2017; 
Rastegar et al., 2009), and the use of smaller, unstable, partially impaired versions of MeCP2 
looks promising too (Lamonica et al., 2017)(Tillotson et al., under review). If reproducible 
dosage regimes can be established through the use of inferior MeCP2 molecules (i.e. 
unstable or partially functional), endogenous promoters and other regulatory elements, there 
is still the concern that the endogenous mutant protein will interfere with the function of the 
exogenously applied WT protein. Recent experiments in mice modelling MeCP2 
overexpression syndrome have suggested that overexpression of T158M, R111G and R306C 
MeCP2 protein in WT male and female mice do not produce any dominant negative effects, 
suggesting that at least for these mutations, this may not be a problem (Heckman et al., 2014; 
Lamonica et al., 2017). 
 
An alternative to gene therapy is protein therapy, i.e. restoring the levels of WT MeCP2 
protein. This could involve the use of read-through compounds to encourage RNA 
polymerase to read-through early stop codons in MECP2, as in the case of R168X (Brendel 
et al., 2011). While this has been successful in cultured mouse cells, this has not been 
translated to in vivo systems and, like the case for reactivation of the inactive X chromosome 
allele, specificity of targeting MECP2 alone is currently limited [reviewed in (Katz et al., 




explored because the chemically basic nature of MeCP2 itself makes it an excellent protein 
candidate for traversing the cellular membrane (discussed in chapter 7) (Kabouridis, 2003; 
Nan et al., 1996). While a patent has been taken out in the United States for the delivery of 
MeCP2 protein as a therapeutic strategy for Rett syndrome (Laccone, 2012), evidence for its 
effectiveness at transducing cells, and in particular neurons, is limiting. Experiments to 
address this will be described at the end of this study in chapter 7. 
 
Mouse models have been an invaluable tool for advancing our knowledge of the function of 
MeCP2 and its role in Rett syndrome (for a full review see (Guy et al., 2011)). The first 
mouse models were reported in 2001 when two separate laboratories created MeCP2-null 
mouse lines via deletion of exon 3 (Chen et al., 2001) and deletion of exons 3 and 4 (Guy et 
al., 2001). Both lines exhibited multiple neurological and motor phenotypes reflective of the 
disease symptoms, including smaller brains, abnormal gait, and breathing abnormalities. 
While the heterozygous female mice are the true RTT model, hemizygous male mice are 
more commonly studied due to the strong phenotype, early death and faster onset of 
symptoms. Furthermore, direct genotype-phenotype correlations can be drawn more easily in 
hemizygous males than they can in mosaic heterozygous females. The observation that a 
central nervous system (CNS)-specific KO of MeCP2 in mice produced extremely similar 
phenotypes to the complete null, led to the generation of multiple brain region-specific KOs 
which were described in Chapter 1.3.2. More recently, KO in peripheral tissues (PKO) 
further confirmed the loss of MeCP2 function in the CNS as being the major contributor to 
RTT-like phenotypes (Ross et al., 2016). Using nestin-cre to remove a floxed STOP cassette 
in the Mecp2 reading frame in mice, expression of MeCP2 could be restored to central 
nervous system tissues while leaving peripheral tissues devoid of MeCP2 expression. The 
only phenotypes in the mice were hypoactivity and decreased bone stiffness, demonstrating 
the importance of MeCP2 expression in the CNS as the primary origin of RTT-like 
phenotypes (Ross et al., 2016). 
 
In addition to Mecp2-null mouse models, there have been a number of lines containing RTT 
patient mutations, the more accurate model system. The first of these was the knock-in (KI) 
of a stop codon at position arginine 168 (R168X) which exhibit the same phenotype as null 
mice lines (Lawson-Yuen et al., 2007). Other RTT nonsense mutation models include 
R255X (Pitcher et al., 2015), R270X-EGFP and R273X-EGFP (Baker et al., 2013). Like 




was observed resulting in a phenotype extremely similar to the null mice (Pitcher et al., 
2015). On the other hand, the R270X-EGFP and R273X-EGFP alleles were introduced as 
transgenes in a null background and mouse lines were selected for based on the expression of 
the truncated protein at similar levels to WT protein in WT mice. Surprisingly the addition of 
3 extra amino acids improves the survival of the mice from 12 weeks to 29 weeks and it was 
believed that the difference in severity was due to the retention of a full AT-hook motif in 
the G273X allele; referred to as AT-hook 2 in Figure 1 (Baker et al., 2013). Recent in vitro 
and in vivo data directly assessing the AT-hook character of this sequence has cast doubt 
over this, finding that it has very weak AT-hook character (Lyst et al., 2016). While the mice 
exhibited differences in lifespan with the two mutations, there is only 1 boy who has been 
reported to have a G273fs mutation and although he lived longer than patients with R270fs 
mutations, it is difficult to draw conclusions on the functional importance of these 3 amino 
acids based on one case (Ravn et al., 2003). There is also one reported case of a female with 
a G273fs mutation but no clinical assessment has been published (Zahorakova et al., 2007). 
Perhaps KI of the two mutations into the endogenous locus would be more informative, 
particularly if the precise clinically observed frameshift and nonsense mutations were 
modelled. There have also been KI or transgenic mice expressing R111G-EGFP, R133C-
EGFP, T158M-EGFP, T158A, R306C and R306C-EGFP mutations (Brown et al., 2016; 
Goffin et al., 2012; Heckman et al., 2014; Lamonica et al., 2017; Lyst et al., 2013). 
Interestingly the clinical severity of point mutations in patients is mirrored by the severity of 
these mutations in mice (Brown et al., 2016). Two other mouse models have been produced 
that do not mimic known RTT mutations; a truncation of MeCP2 in which T308 is converted 
to a stop codon results in a delayed but overt phenotype in the mice (Shahbazian et al., 
2002b). The A140V mutation is not associated with RTT but is observed in several cases of 
X-linked mental retardation. Despite observations of increased cell packing and reduced 
dendritic arborisation in the brain, A140V mice showed no neurological symptoms and had a 
normal lifespan (Jentarra et al., 2010). 
 
Other animals models include Xenopus laevis (Stancheva et al., 2003), a rat KO model 
(SAGE laboratories) and two monkey models (Chen et al., 2017; Liu et al., 2014a; Liu et al., 
2014b). Recent analysis of one of the monkey models revealed a number of phenotypes, 
including those not detected in rodent models, for example male embryonic lethality and 
social withdrawal, although at 20 months of age no developmental delays or growth delays 
were observable (Chen et al., 2017). MeCP2 deficiency in rats results in numerous 




clasping, general lethargy, abnormal gait, reduced exploratory behaviour, decreased 
locomotion and abnormal respiratory patterns including apneas, all of which are observed in 
the mouse models (Patterson et al., 2016). In addition, female MeCP2 KO rats display 
acquirement of fine motor skills followed by regression of development thus mirroring the 
symptom development in RTT patients, a finding that has not yet been observed in mice 
(Veeraragavan et al., 2016). 
 
Finally, a number of neuronal tissue culture systems have been utilised in order to assess the 
molecular function of MeCP2 such as embryonic stem cells (ESCs) and induced pluripotent 
stem cells (iPSCs) from RTT patient fibroblasts. Patient iPSC-derived neuronal lines include 
a wide variety of missense, nonsense and framseshift mutations (Ananiev et al., 2011; 
Cheung et al., 2011; Kim et al., 2011; Marchetto et al., 2010; Tang et al., 2016; Zhang et al., 
2016). In addition, MeCP2 has been knocked out in both mouse and human ESCs and the 
resulting neurons studied (Li et al., 2013c; Yazdani et al., 2012). Many novel phenotypic 
observations have been uncovered using such systems, such as reduced total RNA amount in 
null neurons, strong transcriptional phenotypes and electrophysiological defects which has 
broadened our understanding of the function of MeCP2. Details of experiments using these 
systems will be discussed in Chapter 5 and are detailed in Supplementary Tables 1 - 4. 
 
Mouse studies have been invaluable for determining the physiological relevance of MeCP2 
function in the CNS. Further studies in rats to study the social and fine cognitive defects in 
RTT models may be useful, particularly with relation to testing therapeutic strategies in 
rodent models (Shah & Bird, 2017). Combining model systems will enable a deeper 
understanding of the function of MeCP2 and will help to uncover the molecular details that 
underlie Rett syndrome pathologies. In particular, the use of human neurons in tissue culture 
combined with rodent models may prove to be a powerful pipeline for screening and 
discovery of therapeutics for RTT. Rescue of a particular molecular phenotype in tissue 
culture, combined with observation of improved symptomatic scores in rodents may prove to 
be indicative of a successful drug in clinical trials. 
 
In the gene editing era, the use of human iPSCs as tissue culture models for probing the 
molecular and neuropathological details that underlie complex diseases is a common and 
useful approach to understanding neurological disorders. There are, however, some 




iPS cell lines when they are derived which can impact the subsequent differentiation and 
phenotypic outcome of the experiment (Ardhanareeswaran et al., 2017). Specifically, the 
variety of reprogramming methods that are used (Sendai virus, lentivirus, plasmid 
transfection, protein delivery) may impose some variability between experiments and thus 
make it difficult to compare between individual studies. The same can be said for the variety 
of neuronal differentiation protocols that are used in different laboratories (Broccoli et al., 
2015; Zhang et al., 2013). In addition, a full reset of the epigenetic and transcriptional 
network in cells can sometimes be incomplete, leading to subtle differences between 
individual clonal cell lines (Ardhanareeswaran et al., 2017; Choi et al., 2015; Ohi et al., 
2011). This is particularly critical when studying Rett syndrome, where the disorder appears 
to be defined by small and subtle transcriptional changes. Alternative human neuronal cell 
lines include the SH-SY5Y cell line, CB660 and neural stem cells derived from foetal human 
brain (NSC StemPro). SH-SY5Y cells, however, are a neuroblastoma cell line and contain an 
abnormal karyosome (Krishna et al., 2014), and neural stem cells take a long time to mature, 
expressing markers for neural precursors for 4 weeks (Shin & Vemuri, 2010; Sun et al., 
2008; Tong et al., 2016). 
 
The LUHMES cell line is an alternative and relatively new human neuronal cell line that will 
be used in this study. Mesencephalic cells from an 8-week old female foetus were 
immortalised using a retroviral transgene that constitutively expresses v-myc under the 
control of a tetracyline-controlled promoter (Hoshimaru et al., 1996; Lotharius et al., 2002). 
This keeps LUHMES cells in a proliferative, stem-like, but neuronal-committed state. 
Addition of tetracycline to the cell culture media switches off v-myc expression and 
LUHMES cells are therefore allowed to differentiate into mature, post-mitotic, dopaminergic 
neurons (Scholz et al., 2011). This differentiation is extremely rapid and very robust, 
resulting in the generation of a population of neurons of a single sub-type within one week. 
So far, LUHMES-derived neurons have been used to model Parkinson’s disease (Lotharius 
et al., 2005; Xiang et al., 2013), for cytotoxicity assays (Tong et al., 2016) and for 
technology development (Dinh et al., 2013; Hughes et al., 2014; Ilieva et al., 2013). 
 
The benefits of LUHMES cells over other neuronal tissue culture systems are 3-fold. Firstly, 
the speed of differentiation is extremely advantageous. As differentiation begins from a 
neuronal precursor stage, mature, electrically active neurons expressing a wide complement 










Differentiation is not only quick, but is also rather simple. A single media change from β-
FGF+ proliferative media to GDNF+, tetracycline+ differentiation media is all that is 
required to initiate differentiation. If required, cells can be passaged and counted two days 
after the media change providing a step to control for the number of neurons in the 
experiment; however, differentiation will proceed regardless of this step. Secondly, the 
homogeneous nature of the resulting population of neurons is extremely attractive. It has 
been proposed that gene expression studies using Mecp2-/y mouse brain samples are 
hampered by heterogeneous populations of different cell types which may mask significant 
gene expression changes of a single cell type. Studying a population of neurons, and indeed a 
population of a single subtype of neurons, may reveal robust and consistent effects that can 
be observed in population analysis experiments. Of note, current iPSC differentiation 
protocols are capable of producing populations of neurons with around 90% homogeneity 
when FACS-based enrichment approaches are used (Israel et al., 2012) or by expression of 
neurogenin-2 in combination with astrocyte co-culture to produce excitatory neurons (Zhang 
et al., 2013). Occasionally, however, these neurons can be a mix of neuronal subtypes, for 
example 15% of neurons being VGluT1-positive and 8% GABA-positive (Israel et al., 
2012). Thirdly, the fact that they are human cells may prove to be beneficial. LUHMES cells 
provide an easy to handle system within which to study the biology of endogenous MeCP2 
in human neurons. There are numerous similarities between mouse and human samples, 
which is reflected in the 95% identical MeCP2 amino acid sequence between the two species 
and the strong phenotypic correlations when MeCP2 mutations are introduced (Brown et al., 
2016). Some of the more fundamental biology may, however, differ between the two species, 
for example different methods of MeCP2 protein regulation, different gene expression 
profiles, and different expression levels of MeCP2 partner proteins may exist. 
 
On the other hand, iPSCs and NPCs offer the flexibility to differentiate into a variety of 
different neuronal subtypes as well as astrocytes (Chandrasekaran et al., 2016; Dolmetsch & 
Geschwind, 2011; Juopperi et al., 2012), whereas LUHMES cells are limited to a 
dopaminergic lineage (although the removal of cAMP and GDNF from the culture media can 




heterogeneity in differentiation potential, hiPSCs can be used to develop 3D organoids for 
more complex analysis (Ardhanareeswaran et al., 2017) and it remains to be seen if co-
culture with astrocytes or 3-dimensional culture conditions will be suitable for LUHMES-
derived neurons. Nevertheless, the other benefits of hiPSCs also apply to LUHMES cells; 
human genetics and proteomics, use of isogenic controls, high proportion of neurons in the 
sample and large sample sizes. 
 
It is hoped that LUHMES cells will provide a simple, efficient and novel system within 
which to study MeCP2. In this study I will describe the use of gene editing techniques and a 
variety of experimental protocols in order to determine the utility of LUHMES-derived 
neurons for modelling and studying the molecular phenotypes involved in Rett syndrome. It 
is hoped that experiments using human neurons and a simplified, homogeneous model 
system will aid efforts towards deciphering the exact molecular function of MeCP2.  
 
 
The CRISPR locus was first observed in 1987 when Ishino and colleagues were sequencing 
the iap locus in E. coli and came across five highly homologous sequences of 29 nucleotides 
long that were separated by 32 nucleotide spacers (Ishino et al., 1987). In 2000, another 
group studied the locus in a multitude of different bacteria and archaea and coined the term 
SRSRs (Short Regularly Spaced Repeats), although the function of these repeats was still 
unknown (Mojica et al., 2000). In 2002 the name was changed to CRISPR which stands for 
Clustered Regularly Interspaced Short Palindromic Repeats and CRISPR-associated (Cas) 
proteins (Cas) were identified, two of which were predicted to function as a DNA helicase 
and as an exonuclease based on motif similarities to known proteins (Jansen et al., 2002). In 
silico analyses found that the spacers in the CRISPR locus were homologous to 
bacteriophage DNA sequences and thus the hypothesis was put forward that the CRISPR 
locus functions as an RNA interference based immune response against invading 
bacteriophage (Bolotin et al., 2005; Makarova et al., 2006; Mojica et al., 2005; Pourcel et 
al., 2005). This hypothesis was confirmed in 2007, when Barrangou and colleagues noticed 
that upon bacteriophage challenge in Streptococcus thermophilus novel spacers that were 
homologous to portions of the bacteriophage genome were incorporated into the S. 
thermophilus genome at the CRISPR locus (Barrangou et al., 2007). Furthermore deletion 
and addition of spacers into the CRISPR locus resulted in loss and gain of bacteriophage 




importance of these proteins for bacteriophage resistance and for acquisition of novel spacers 
into the locus (Barrangou et al., 2007). 
 
The CRISPR system is composed of two main elements, all of which are transcribed from a 
single CRISPR locus. The first element is the long stretch of repeats and spacers that are 
transcribed as one long pre-mRNA transcript in the cell. This transcript is eventually 
processed into individual crRNAs (CRISPR RNAs), each one containing a single spacer 
element and therefore being able to target a single invading DNA sequence. The second 
element is the array of Cas proteins that recognise, process and bind to the crRNAs. There 
are multiple types of CRISPR systems across the 40% of bacteria and 90% of archaea that 
express this small-RNA based, adaptive immune system (Sorek et al., 2008; Terns & Terns, 
2011; Wiedenheft et al., 2012). 
 
The ability of an organism to remember previous infections and viral challenges and to 
initiate an immune response based around this memory can be found in the cellular processes 
of RNA interference, PIWI RNAs and in the form of antibodies and lymphocytes. The 
discovery of an apparent immune memory that exists solely in bacteria and archaea therefore 
sparked much interest (Sorek et al., 2008; Wiedenheft et al., 2012). 
 
While the components between different systems vary greatly, the overall mechanism of the 
“immune response” is conserved and consists of three stages: adaptation, crRNA biogenesis, 
and targeting of invader elements. In the adaptation stage, the acquisition of novel spacers 
into the CRISPR locus is achieved, and the more spacers derived from a single organism, the 
greater the “immune” response for the host cell. In the second stage the CRISPR locus is 
transcribed as one long pre-mRNA molecule that is processed to create individual crRNAs, 
which could be viewed as the equivalent of antibodies. For targeting, each crRNA forms a 
complex with Cas proteins and directs the Cas protein(s) (or CASCADE complex in some 
CRISPR systems) to the foreign genetic element via complementary base pairing. The Cas 
proteins then degrade the invading genetic material by introducing a double-strand break 
(DSB), and a successful immune response is achieved. The mechanistic details of the entire 





The discovery of an adaptive, directed, nuclease-based immune response was immediately 
recognised for its potential benefits in molecular biology and beyond. Providing phage 
resistance for economically important bacteria (for example in the food industry), being a 
tool for manipulation of nucleic acids, and limiting the spread of antibiotic resistance were 
among the first suggestions (Wiedenheft et al., 2012). The adaptation of CRISPR systems 
for site-directed double-strand break (DSB) activity in heterologous cells was quickly 
established. Historically, targeted DSBs was achieved by meganucleases, zinc finger 
nucleases (ZFNs) and TAL effector nucleases (TALENs), all protein-based complexes that 
required complex cloning of a new protein every time a new locus wanted to be targeted for 
DSBs (Damian & Porteus, 2013). CRISPR, on-the-other-hand, had the potential to be a small 
RNA-based targeting technology, thus dramatically simplifying the cloning steps that would 
be needed for each new targeting experiment. 
 
Two steps were required to repurpose CRISPR as a targeted DSB technology in heterologous 
cells. Identification of the minimal Cas proteins that are required to induce the DSB and 
identification of the minimal crRNA species necessary for direction of the Cas proteins to 
the targeted DNA locus. The Type II CRISPR system contains only 1 protein, Cas9, which is 
an endonuclease that binds to two RNA species; a crRNA and a tracrRNA (Charpentier & 
Doudna, 2013; Jinek et al., 2012). The discovery that the two RNA molecules could be 
combined into a single guide RNA (sgRNA) was critical for repurposing the CRISPR system 
into a targeted DSB technology for use in mammalian cells (Jinek et al., 2012). The first 
studies to take the CRISPR technology and utilise it in mammalian cells for targeted DSB 
purposes utilised the easy-to-transfect human embryonic kidney cell line, Hek293 cells 
(Cong et al., 2013; Jinek et al., 2013). Since then, CRISPR has been used to induce targeted 
DSBs in loci of interest in a plethora of cell lines and organisms including tobacco and rice 
(Jiang et al., 2013b), miPSCs (Li et al., 2016), hiPSCs (Mali et al., 2013), C. elegans 
(Friedland et al., 2013), D. melanogaster (Gratz et al., 2013), Zebrafish (Hwang et al., 
2013), rats (Li et al., 2013a; Li et al., 2013b), pigs (Hai et al., 2014) and monkeys (Niu et al., 
2014a). The generation of genetically modified mice has been performed by modifying the 
ESCs that are used to produce the mice or by direct injection of CRISPR molecules into the 
zygote (Wang et al., 2013a). This technology has also been used to correct disease-causing 
mutations in mice as proof-of-principle studies for the use of CRISPR in the clinic, for 





The most common mechanism for cellular repair of a double-strand break is to engage the 
non-homologous end joining (NHEJ) pathway which is inherently inaccurate and will result 
in the insertion and deletion of nucleic acids at the break point (Lieber, 2010). This non-
precise process, however, has the advantage of inactivating the gene of interest and thus 
resulting in a functional gene knock-out (KO). In particular a gene KO will occur if an out-
of-frame repair product is produced which results in an early stop codon in the reading frame 
and thus a truncated RNA product. If truncated early enough, this RNA will likely be 
degraded by nonsense mediated decay and result in a protein KO (Houseley & Tollervey, 
2009). Alternatively, if the stop codon occurs later in the RNA molecule, a truncated (and 
potentially non-functional) version of the protein of interest may be produced. Another 
possibility is that the repair process will produce an in-frame repair product that maintains 
the reading frame of the RNA species and results in a mutated protein. If this mutation 
occurs in a critical portion of the protein of interest, this can be used to study the presence of 
a non-functional protein in the cell type of interest. 
 
A less efficient, but often more desirable, repair outcome utilises homology-directed repair 
(HDR). In this instance a template is used as a donor molecule to encourage sequence-
specific repair of the DSB. This type of repair is most frequently used during late S and G2 
stages of the cell cycle when sister chromatids and homologous chromosomes are available 
for accurate HDR (Heyer et al., 2010). Exogenous molecules, however, that have arms of 
homology surrounding the DSB can be used as an alternative donor molecule for HDR. 
Conventional targeting techniques involve using a large plasmid as a donor molecule, which 
contains many kilobases of DNA as the homology arms (Smithies et al., 1985; Thomas & 
Capecchi, 1987). With the advent of CRISPR technologies, these arms can be significantly 
reduced in size without a loss of efficiency, and small single stranded oligodeoxynucleotides 
(ssODNs) have also been shown to be effective donor molecules for knocking in (KI) point 
mutations and small tags into a gene of interest (Ding et al., 2013). 
 
The level of HDR differs dramatically between different tissues and cell types (Miyaoka et 
al., 2016), with mESCs exhibiting the highest levels and levels as low as 0.05-1.5% being 
reported in hiPSCs (Kime et al., 2016). Efforts to improve efficiencies are being assessed 
from multiple angles, including the use of small molecules to increase HDR/NHEJ ratios and 
intelligent design of cut sites and donor molecules to encourage the use of specific repair 
pathways. Recent improvements will be discussed in Chapter 4.6 and are reviewed in 




While in vivo editing is becoming more routine and model organisms are providing proof-of-
principle evidence that at a molecular level many genetic diseases can be fixed by correcting 
the mutated gene, attention is turning to gene editing in the clinic and editing of human 
embryos (Plaza Reyes & Lanner, 2017). While editing human embryos is controversial, 
some institutes have been granted permission to modify human embryo’s in the laboratory. 
The first account of editing human embryos was published in 2015 when Liang and 
colleagues edited tripronuclear zygotes; polyspermic zygotes that are generated during in 
vitro fertilisation and usually discarded (Liang et al., 2015a). They reported editing 
efficiencies of ~52% in embryos that received Cas9 + sgRNA RNA molecules and 14% 
HDR editing when a ssODN molecule was co-injected. These low levels of editing, mosaic 
editing and observed off-target editing underscore the challenges that clinical gene editing 
faces and highlights the improbability of success using the current systems. A year later 
another group reported NHEJ rates of 47-63%, and HDR rates of 5% when using a ssODN 
or 7% when using a 1 kb plasmid (Kang et al., 2016). Interestingly the 32 bp deletion that 
they were introducing by HDR was more efficiently inserted when two sgRNAs surrounding 
the region to be deleted were used, producing an editing efficiency of 15%. Again the 
resulting 6-18 cell embryos that were analysed were mosaic for the mutation, however no 
off-target editing was observed this time (Kang et al., 2016). 
 
Despite these limitations, CRISPR is already being used in clinical trials, with explanted 
cells being edited and returned to patients with the hope of alleviating disease symptoms. 
This was performed first by a group at Sichuan University in China who removed T cells 
from a patient with non-small cell lung cancer, used CRISPR to inactivate the PD-1 gene, 
and then injected the edited T cells back into the patient (Sheridan, 2017). This approach is 
reminiscent of previous clinical trials using ZFNs to edit the CCR5 gene in T cells from HIV 
patients (Tebas et al., 2014). The ZFN introduced a 32bp deletion into the CCR5 gene thus 
was the same deletion as was being tested in human tripronuclear zygotes described above 
(Kang et al., 2016). While the edited T cells were insufficient in number to prevent further 
HIV infection, this clinical trial did demonstrate that ZFN edited T cells were safe for use in 
patients (Tebas et al., 2014). In addition to the current CRISPR PD-1 trial, seven other 
programs are awaiting approval, targeting a wide range of diseases from sickle cell anaemia, 
multiple myeloma and beta-thalassemia. Most of these trials aim to perform the editing ex 
vivo, although some wish to tackle the more difficult challenge of delivering CRISPR 




targeting, safety is more of a concern due to the presence of a bacterial Cas9 protein being 
expressed in the human body with an unknown half-life. 
 
Editing in human embryos has flagged up a number of concerns for in vivo editing, but many 
groups are pushing towards the use of CRISPR gene editing for treatment of genetic 
diseases. In this study, I will use CRISPR gene editing to target the MECP2 gene in 
LUHMES neuronal progenitors, primarily for the purpose of creating model neuronal cell 













The major goal of this project is to determine if the LUHMES cell line and its derived human 
neurons will be a useful model system for studying MeCP2 and Rett syndrome. This goal 
can be broken down into a few main aims: 
 
1. Characterise the LUHMES cell line in terms of differentiation dynamics and assess 
MeCP2 expression dynamics 
2. Determine if the LUHMES cell line can be transfected, cloned and genetically 
manipulated using CRISPR technologies 
3. Create a panel of MeCP2-mutated LUHMES cell lines 
4. Analyse the morphological consequences of MeCP2 mutation and knock-out on 
LUHMES-derived neurons 
5. Analyse gene expression changes in MeCP2 mutant LUHMES-derived neurons 
6. Propose a mechanism for MeCP2 function with respect to transcriptional regulation 















1% (w/v) Bacto tryptone, 0.5% (w/v) Bacto yeast extract, 1% (w/v) NaCl (Fisher Scientific 
5/3160/63) (adjusted to pH 7.0 with 5 M NaOH) 
 
Ampicillin: 
Stock 50 mg/ml in water (Fisher Scientific T-22943) 
 
Kanamycin: 
Stock 20 mg/ml in water (Gibco 11815-024) 
 
TE buffer: 
10 mM Tris HCl (from 1M pH 7.5 stock; Invitrogen 15504-020), 1mM EDTA (VMR 
20302.236; from 0.5M pH 8.0 stock) 
 
1X TAE: 
40 mM Tris (Invitrogen 15504-020), 1.142% (v/v) glacial acetic acid (Fisher Scientific 
A/0400/PB17), 1 mM EDTA (VMR 20302.236; from 0.5M pH 8.0 stock) 
 
1X SDS running buffer: 
24.8 mM Tris (Invitrogen 15504-020), 192 mM glycine (Sigma G8790), 1% (w/v) SDS 
(Sigma L4509) 
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1X Transfer buffer: 
25 mM Tris (Invitrogen 15504-020), 190 mM glycine (Sigma G8790) 
 
TBS: 
Dissolve 0.5 M Tris (Invitrogen 15504-020) and pH to 8.0 with HCl (Fisher Scientific 
H/1200/PB17), add 1.5 M NaCl (Fisher Scientific 5/3160/63). 
 
PBS: 
1 tablet (Fisher BR14a) per 100ml 
 
HBS: 
16g NaCl, 0.74g KCl, 0.252g Na2PO4 (dihydrate), 2g D-Glucose (Dextrose), 10g HEPES 
with 180ml H2O, pH to 7.2, top up with H2O to 200ml and filter-sterilised. 1X HBS made 
using sterile H2O. 
 
Ponceau S: 
0.1% (w/v) ponceau (Sigma P 7767) in 5% acetic acid (Fisher Scientific A/0400/PB17) in 
water. 
 
HBSS + HEPES buffer for calcium imaging: 
Remove 10 ml from a 500 ml bottle of HBSS (either with or without calcium + magnesium). 
Add 10 ml of 1 M HEPES (Sigma, 3537).  
 
Calcium buffers for calcium imaging: 
0 mM Ca2+ solution: 5.2 ml of 5M NaCl, 360 µl of 3M KCl, 100 µl of 1M MgCl2, 0.076g 
EGTA + ddH2O to 200ml. 
8mM Ca2+ solution: To 50 ml of 0 mM solution add 400 µl of 1M CaCl2. 
For range in between serial dilute the 0 mM and 8 mM Ca2+ solutions to create 6 mM, 4 mM, 
2 mM, 1 mM, 0.5 mM, 0.25 mM and 0.125 mM solutions. 
 
EGTA for negative control for calcium imaging: 
Make a 40 X dilution by dissolving 0.936 g EGTA powder in 5 ml distilled water. Add 750 
µl of 40X EGTA to 15 ml HBSS+Ca2++Mg2++HEPES to make 2X EGTA. Aliquot into 1 ml 





A23187 Calcium ionophore for positive control for calcium imaging: 
To the 1 mg stock add 710 µl of DMSO. Take 20 µl of the reconstituted ionophore and add it 
to 2 ml HBSS+Ca2++Mg2++HEPES to make a 2X calcium ionophore stock. Aliquot as 50 µl 
and store at -20oC. 
 
KCl for calcium imaging: 
0.29 g in 30 ml HBSS+Ca2++Mg2++HEPES gives a 130 mM KCl stock. 
0.58 g in 30 ml HBSS+Ca2++Mg2++HEPES gives a 260 mM KCl stock. 
 
Antibody Company + Catalogue 
Number 
Experiment Dilution Species RRID 
MeCP2 Sigma 7443 WB; IF 1000X Mouse monoclonal AB_477235 
MeCP2 Sigma 6818 WB 1000X Mouse monoclonal AB_262075 
MeCP2 Cell signalling D4F3 WB; IF 1000X Rabbit monoclonal AB_2143849 
GAPDH Cell Signalling 5174 WB 5000X Rabbit monoclonal AB_10622025 
H3 Abcam 1791 WB 5000X Rabbit polyclonal AB_302613 
mCherry Abcam 167453 WB, IF 1000X Rabbit polyclonal AB_2571870 
Neurofilament Covance SMI-311R-
100 
IF 500X Mouse monoclonal AB_509991 
MAP2 Abcam 5392 IF 5000X Chicken polyclonal AB_2138153 
NeuN Millipore, ABN78 IF 500X, 
1000X 
Rabbit polyclonal AB_10807945 
Tyrosine 
Hydroxylase 
Millipore, AB152 IF 200X Rabbit polyclonal AB_390204 
DAT Millipore, MAB369 IF 1000X Rabbit monoclonal AB_2190413 
LaminB1 Abcam, ab16048 IF 500X Rabbit polyclonal AB_443298 
HDAC3 Sigma, 3E11 WB 1000X Mouse monoclonal AB_1841895 
TBLR1 Abcam, ab24548 WB 1000X Rabbit polyclonal AB_2199904 
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All primers were ordered as standard desalted oligonucleotides from Sigma and were 
reconstituted in Nuclease-free H2O (Ambion, AM9937) to make 100 µM stocks that were 
stored at -20oC. Working dilutions of 10 µM or 3.2 pM were stored at 4oC. 
 
Primer name Sequence Experiment 
hMeCP2_1_F GATCAATCCCCAGGGAAAAG Various PCR + sequencing 
hMeCP2_1_R CCTCTCCCAGTTACCGTGAA Various PCR + sequencing 
hMeCP2_2_F GAGACCGTACTCCCCATCAA Various PCR + sequencing 
hMeCP2_2_R AGTCCTTTCCCGCTCTTCTC Various PCR + sequencing 
hMeCP2_3_F CAAGGCCAAACAGAGAGGAG Various PCR + sequencing 
hMeCP2_3_R CAATCCGCTCCGTGTAAAGT Various PCR + sequencing 
hMeCP2_4_F AGCCAAATGACTGAAAGCACT Various PCR + sequencing 
hMeCP2_4_R CCATACGGGTCTGGAGCAG Various PCR + sequencing 
hMeCP2_5_F AGCTCCTTGTCAAGATGCCT Various PCR + sequencing 
hMeCP2_5_R CCAACTACTCCCACCCTGAA Various PCR + sequencing 
hMeCP2_6_F CGCTCTGCTGGGAAGTATGA Various PCR + sequencing 
hMeCP2_6_R GCTACTTCTGGCCCTGGTTA Various PCR + sequencing 
hMeCP2_7_F AGGGCTCAGGGAAGAAAAGT Various PCR + sequencing 
hMeCP2_7_R CTTTTCCCTGGGGATTGAT Various PCR + sequencing 
hMeCP2_8_F GGGCTCAGGGAAGAAAAGTC Various PCR + sequencing 
hMeCP2_8_R GCAGAAATGGAAGGGGAGAA Various PCR + sequencing 
hMeCP2_9_F TGTTAGGGCTCAGGGAAGAA Various PCR + sequencing 
hMeCP2_9_R GGACGGAGGAAGGGAAAGAA mCherry PCR screens 
hMeCP2_exon1_F GGAGAGAGGGCTGTGGTAA Various PCR + sequencing 
hMeCP2_exon1_R AGTCTCTCCTCCTCGCCTC Various PCR + sequencing 
hMeCP2_exon2_F GCTCCATAAAAATACAGACTCA Various PCR + sequencing 
hMeCP2_exon2_R CTGAGCCCTAACATCCCAG Various PCR + sequencing 
hMeCP2_exon3_F GGAAGAAAAGTCAGAAGACCA Various PCR + sequencing 
hMeCP2_exon3_R TTGATCAAATACACATCATACTT Various PCR + sequencing 
hMeCP2_exon4_F TCCCCAGGGAAAAGCCTTTC Various PCR + sequencing 
hMeCP2_exon4_R AGCTGCCTTTATTCTTGTTGG Various PCR + sequencing 
hMeCP2_intron2_F CCACAGCCCAAATTCCTAAA Various PCR + sequencing 
hMeCP2_intron2_2F TCCCTTGAAGTGCGACTCAT mCherry PCR screens 
hMeCP2_intron3_F GTCTTTCTGTTTGTCCCCACA Various PCR + sequencing 
hMeCP2_intron3_2F CAGACGAGTGAGTGGCTTTG Various PCR + sequencing 
V1_full_F ATGGTAGCTGGGATGTTAGG Various PCR + sequencing 
V1_full_R TCAGCTAACTCTCTCGGTCA Various PCR + sequencing 




hGAPDH_3_R TGTGGTCATGAGTCCTTCCA qPCR 
pLKO1_5 GACTATCATATGCTTACCGT pCRISPR sequencing primer 
SNAPC4_F CACAGTACATGGTCCCGGAC Off-target locus for sgRNA16 
SNAPC4_R CTTTGTGGCTGGCACTCTTT Off-target locus for sgRNA16 
SNAPC4_F2 CCAATGACTCCCAGGACAGA Off-target locus for sgRNA16 
MYOZ1_F AACTGTCGCTGCTTACCAAC Off-target locus for sgRNA16 
MYOZ1_R TCGGCTTTCATCTGCTCTCA Off-target locus for sgRNA16 
MYOZ1_F2 ACAGCTGGTCAGGGATTCTC Off-target locus for sgRNA16 
MYOZ1_R2 ACCACCCCTACCTGTTGAAG Off-target locus for sgRNA16 
KIAA1324_F ACAGAGGGAGGAGGAAGGAT Off-target locus for sgRNA16 
KIAA1324_R2 TCATCCCTCTCGCACATCTC Off-target locus for sgRNA16 
KIAA1324_R GGCAATGTTTCTCACCAGCA Off-target locus for sgRNA16 
MAP7D3_F CACGGAACATAGGAGAGGGT Off-target locus for sgRNA17 
MAP7D3_F2 GCAGCCCATCCTTGAGAGA Off-target locus for sgRNA17 
MAP7D3_F3 CGGCAGCCCATCCTTGAG Off-target locus for sgRNA17 
MAP7D3_R TCTGAAGTGCTGATTCCCGT Off-target locus for sgRNA17 
MAP7D3_R2 GAGGACCAGATAGCACGAGG Off-target locus for sgRNA17 
MAP7D3_R3 CCAGGGAAAAGTTTTGTGGC Off-target locus for sgRNA17 
TRPV3_F TGTGAGTGGCATCTGGTGAT Off-target locus for sgRNA17 
TRPV3_R AACCCCGCGTATAGTAGAGC Off-target locus for sgRNA17 
ZCCH14_F TTTAGCACTGGAAGCCTCAG Off-target locus for sgRNA15 
ZCCH14_R GGAGTTGAACCGTTGACACC Off-target locus for sgRNA15 
WNK1_F GGTTTCTCAGCAGCCGTTAA Off-target locus for sgRNA15 
WNK1_R AGCCGACCGTTTCTATTCCT Off-target locus for sgRNA15 
MMP14_F ACAGCTATCCTTTGCCCACT Off-target locus for sgRNA15 
MMP14_R GTTTTCCACACAGCACTCCC Off-target locus for sgRNA15 
hSox2_f CAAGATGCACAACTCGGAGA qPCR 
hSox2_r GCTTAGCCTCGTCGATGAAC qPCR 
hNestin_f TGCGGGCTACTGAAAAGTTC qPCR 
hNestin_r GAGCGATCTGGCTCTGTAGG qPCR 
Ki67_2_F TGGGCGAAGTTCACAGTCAA qPCR 
Ki67_2_R TGAGCACTCTGTAGGGTCGA qPCR 
hCDK6_f TGCACAGTGTCACGAACAGA qPCR 
hCDK6_r ACCTCGGAGAAGCTGAAACA qPCR 
PAX6_f AGCCCCATATTCGAGCCCCG qPCR 
PAX6_r TCGGGAAATGTCGCACGGCC qPCR 
hPax3_f AGGCATGGATTTTCCAGCTA qPCR 
hPax3_r AGTCTGGGGCTGATGAGGTA qPCR 
hNEUROD1_1_f GCCCCAGGGTTATGAGACTA qPCR 
hNEUROD1_1_r CTCGCTGTACGATTTGGTCA qPCR 
hNDNF_f CAGATGGAGCTGAAATTAGCA qPCR 
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hNDNF_r CTCAGCTTCCACTCCAAAGG qPCR 
TUBB3_f CGCCCAGTATGAGGGAGAT qPCR 
TUBB3_r AGTCGCCCACGTAGTTGC qPCR 
hFox-3_f CCGACCCTACAGAGAAGCAG qPCR 
hFox-3_r GAATTGCCCGAACATTTGC qPCR 
hDCX_1_f ACCGCTACTTCAAGGGGATT qPCR 
hDCX_1_r AGACAGAGATCGCGTCAGGT qPCR 
hSEZL6_1_f TGTACTCCCACCCCTACAGC qPCR 
hSEZL6_1_r TTCCCCTGTCTCGTAAATGG qPCR 
hSEZL6_2_f GATCCAGAATGGCTGGAAAA qPCR 
hSEZL6_2_r ACTCCCCACGATGTCATAGC qPCR 
hSEMA4D_f TGCAGTGATGTTTGGGACAG qPCR 
hSEMA4D_r TGTCTGGCTCATGAAACTGC qPCR 
SYP_f TGCCAACAAGACCGAGAGTG qPCR 
SYP_r TTCGGCTGACGAGGAGTAGT qPCR 
SYN1_f TCAGACCTTCTACCCCAATCA qPCR 
SYN1_r GTCCTGGAAGTCATGCTGGT qPCR 
DLG4_f CACTCCTCACAGTGCTGCAT qPCR 
DLG4_r TGTCTTCATCTTGGTAGCGG qPCR 
GRIN1_F AAGCCCAACGCCATCCAGAT qPCR 
GRIN1_R GAGTGAAGTGGTCGTTGGGGGTA qPCR 
NLGN1_f ATGATGGAAGTGTCTTGGCA qPCR 
NLGN1_r ATAGTTCCCCTTTGCAGCCT qPCR 
SV2A_F AGATCGGCAGGCTCAGAAT qPCR 
SV2A_R GACAGGAAGAAGCAGGAGACA qPCR 
SNAP25_f CTGTCTTTCCTTCCCTCCCT qPCR 
SNAP25_r GGGTCAGTGACGGGTTTG qPCR 
hTH_f GTGTTCCAGTGCACCCAGTA qPCR 
hTH_r GCCAATGTCCTGCGAGAA qPCR 
hDAT_f AGTGGCCTGGTTCTATGGTG qPCR 
hDAT_r GACCACGAACAGGAGAAAGC qPCR 
hDRD2_f GGAGGTGGTAGGTGAGTGGA qPCR 
hDRD2_r GATGCTGATGGCACACAAGT qPCR 
hEN1_f AAAACTGACTCGCAGCAGCC qPCR 
hEN1_r TGCTCCGTGATGTAGCGGTT qPCR 
hSHH_f CCAATTACAACCCCGACATC qPCR 
hSHH_r CAGTTTCACTCCTGGCCACT qPCR 
VMAT-2_f TGGGGAGGTGGCTTTGTGCT qPCR 
VMAT-2_r CCCATAGACGGACACGTGCC qPCR 
hGIRK2_F GACCTGCCAAGACACATCAG qPCR 




Cre_1_F GGCGTTTTCTGAGCATACCT AAV testing 
Cre_1_R ATCTTCAGGTTCTGCGGGAA AAV testing 
Cre_2_F ATTGGCAGAACGAAAACGCT AAV testing 
Cre_2_R ATCAGCTACACCAGAGACGG AAV testing 
EGFP_1_F GGTGAACTTCAAGATCCGCC AAV testing 
EGFP_1_R GGTGCTCAGGTAGTGGTTGT AAV testing 
EGFP_2_F CAAAGACCCCAACGAGAAGC AAV testing 
EGFP_2_R TCCATGCCGAGAGTGATCC AAV testing 
attB1_hPGK GGGGACAAGTTTGTACAAAAAAGCAGGC
TTTGGGGTTGGGGTTGCGCCTT 
















Gateway cloning for pAAV 
mCherry targeting plasmid 
attB4_MeCP2_stopR GGGGACAACTTTGTATAGAAAAGTTGGGT
GGCTAACTCTCTCGGTCACGG 
Gateway cloning for pAAV 
mCherry targeting plasmid 
attB3_MeCP2_stopF GGGGACAACTTTGTATAATAAAGTTGTGA
CTTTACACGGAGCGGAT 
Gateway cloning for pAAV 
mCherry targeting plasmid 
attB2_MeCP2_8R GGGGACCACTTTGTACAAGAAAGCTGGGT
AGCAGAAATGGAAGGGGAGAA 
Gateway cloning for pAAV 
mCherry targeting plasmid 
mCherry_IF_Tm_B4r GGGGACAACTTTTCTATACAAAGTTGTTA
TGGTGAGCAAGGGCGA 
Gateway cloning for pAAV 
mCherry targeting plasmid 
mCherry_IF_Tm_B3r GGGGACAACTTTATTATACAAAGTTGTCT
ACTTGTACAGCTCGTCCATGC 
Gateway cloning for pAAV 
mCherry targeting plasmid 
pAAV_Gateway_F AAGCAGCGTATCCACATAGC Check final pAAV sequence 
pAAV_Gateway_F2 TGATTGCCCCACCATTTTGT Check final pAAV sequence 
pAAV_Gateway_F3 AGAGTTCTTGCAGCTCGGTGAC Check final pAAV sequence 
pAAV_Gateway_R CTTCTCCTCCGGGCTGTAAT Check final pAAV sequence 
pAAV_Gateway_R2 GAATCACCGACCTCTCTCCC Check final pAAV sequence 
pAAV_Gateway_R3 CAACCTCCCCTTCTACGAGC Check final pAAV sequence 
R306C_F TCCCCATCAAGAAGTGCAAGACCCGGGA
G 
Site-directed mutagenesis of 
R306C targeting plasmid 
R306C_R 
CTCCCGGGTCTTGCACTTCTTGATGGGGA 
Site-directed mutagenesis of 
R306C targeting plasmid 
5_6_PAM_F ATCGAGGTCAAAGAAGTGGTGAAGCCCCT
GCTAGTGTCCACCCTCG 
Site-directed mutagenesis of 
R306C targeting plasmid 
5_6_PAM_R CGAGGGTGGACACTAGCAGGGGCTTCACC
ACTTCTTTGACCTCGAT 
Site-directed mutagenesis of 
R306C targeting plasmid 









Site-directed mutagenesis of 
R111G plenti 
mCherry_BamH1_F ACCGAGAGAGTTAGCTGTAAGG Clone mCherry into pRRLSIN 
mCherry_Sal1_R GTGCGTCGACTTATACTTGTACAG Clone mCherry into pRRLSIN 
All tissue culture was performed at 37°C in a humidified 5% CO2 atmosphere. LUHMES 
tissue culture medium and methods were as described in Scholz et al, 2011, with some minor 
alterations. LUHMES cells were propagated in Nunclon cell culture flasks (Thermo 
Scientific) that were pre-coated with 43 µg/ml poly-L-ornithine (Sigma) and 1 µg/ml 
fibronectin (Sigma) in H2O overnight at 37°C. The next day coating solution was aspirated; 
flasks were washed with H2O and air-dried before cell seeding. Vessels for differentiation 
were used fresh, however vessels for proliferating LUHMES cells could be stored post-
coating at 4oC for up to one week. Cells were routinely seeded at a density of 2x106 
cells/T75, and passaged every 2 days. LUHMES cell proliferation medium consists of 
Advanced DMEM/F12 (Gibco, 12634) supplemented with 2 mM L-Glutamine (Sigma), 1X 
N2 (Gibco) and 40 ng/ml β-FGF (R&D Systems) while differentiation medium consisted of 
Advanced DMEM/F12 supplemented with 2 mM L-Glutamine, 1X N2, 1 mM cAMP 
(Sigma), 1 µg/ml tetracycline (Sigma) and 2 ng/ml GDNF (R&D Systems). All proliferation 
and differentiation medium was filtered through a 0.22 µm PES filter (Millex GP, 
SLGP033RS) prior to use and could be stored for up to one week. When culturing the 
puromycin-resistant, lentivirus-infected LUHMES cell lines, 0.25 µg/ml puromycin was 
included in the proliferation medium, however no puromycin was added to differentiation 
medium. For cell detachment, cells were incubated with Trypsin (Invitrogen) for 1 minute at 
37oC, collected in Advanced DMEM/F12 medium and centrifuged at 1300 rpm for 5 minutes 
at room temperature. The cell pellet was resuspended in Advanced DMEM/F12 medium, 
counted using a Scepter device (Millipore) and seeded at the appropriate density (Table 3). 
When seeding cells on 19 mm coverslips (VWR, Thickness No 1.5) for immunofluorescent 
imaging coverslips were placed in 12-well plates and coated in 1 ml of coating solution; day 
2 neurons were seeded as 0.15 x 106 cells in a 150 µl drop onto the coverslip itself. Cells 




of differentiation media was added to each well. The same approach was used for seeding 1 
x 106 day 2 cells on 25 mm coverslips (Harvard Apparatus UK, Thickness No 1.5) in 6-well 
plates for calcium imaging. During all differentiations a half-media change was performed 






















































































































































































3.5 0.1x106    0.35x106 
(0.15 on a 
coverslip) 
1ml 1ml 150ul 1ml 
6-well 
plate 
9.6 0.25x106    1x106 2ml 2ml 200ul 2ml 
T75 
flask 
75 2x106 1x106  2.5x106 8x106 8ml 10ml 4ml 10ml 
T175 
flask 
175 4.8x106   6x106 20x106 16ml 30ml  20ml 
6cm 
dish 
21     2x106 4ml 4ml   
10cm 
dish 
60 1.6x106 0.8x106 0.35x106 2x106 6x106 6ml 8ml 3ml 8ml 
15cm 
dish 
140 3.7x106    16x106 12ml 25ml  20ml 
 
Hek293FT cell culture medium consisted of DMEM (Gibco, 49166) medium supplemented 
with 10% fetal bovine serum (Gibco), 2 mM L-Glutamine (Gibco), 10X non-essential amino 
acids (Gibco), 100 U/ml penicillin (Gibco) and 100 µg/ml streptomycin (Gibco). Cells were 
propagated in T75 cell culture flasks in 20ml complete medium, and were split 1:10 or 1:20 
when reaching 80-90% confluency by washing with PBS, trypsinisation and centrifugation. 
All CRISPR plasmids were purchased from Addgene and originated from the Feng Zhang 
lab (pX330 #42230, pX335 #42335, pX458 #48138, plentiCRISPR #52961). The 
crispr.mit.edu online webtool was used for sgRNA design (Table 4). Cloning of sgRNAs 
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into CRISPR plasmids was performed following the protocol from the Zhang lab, available 
online at genome-engineering.org and described in ref (Cong et al., 2013). All ssODNs were 
ordered from Sigma as desalted oligonucleotides (Table 5). 
Gateway cloning (Invitrogen) was used to create all AAV plasmids, as well as the mCherry 
targeting plasmid and the pPuro puromycin resistance plasmid. The pmaxGFP plasmid was 
provided with the Nucleofection kit bought from Lonza. Lentiviral packaging plasmids were 
bought from Addgene from Didier Trono; pMD2.G (Addgene #12259) and psPax2 
(Addgene #12260). The transfer plasmids for the mutant MeCP2 over-expression viruses 
were based on a pLKO.1 backbone (from Bob Weinberg Addgene #84530) and were cloned 
by performing site-directed mutagenesis using the pLKO_CMV_MeCP2v2_WPRE plasmid 
created by Dr Justyna Cholewa-Waclaw. The transfer plasmid for the mCherry expressing 
lentivirus was created by amplifying a BamH1-mCherry-Sal1 construct from 
pBSMe2NSmCherry (gift from Dr Jacky Guy), and ligating it into pRRLSIN.cPPT.PGK-
GFP (gift from Dr Michael Robson). 
 
The R306C targeting plasmid was created by firstly performing a PCR reaction using 
Phusion polymerase in GC buffer (NEB) with approximately 100-250 ng LUHMES genomic 
DNA in a 25 µl reaction volume. Subcloning was performed using 2 µl of this PCR mix with 
the Zero Blunt TOPO PCR cloning kit (Invitrogen) and 2 µl of the subcloning reaction was 
transformed into DH5ɑ cells. The following day two colonies were picked into 3 ml cultures 
of LB/kanamycin and grown overnight by shaking at 37oC. The next day plasmids were 
extracted from 1.5 ml of culture using the Plasmid Miniprep kit (Qiagen) and sequenced 
using primers spanning the MECP2 locus. After sequencing confirmed error-free 
incorporation of the MECP2 fragment into the pTOPO vector, 50 ml cultures of 
LB/kanamycin were set up using the remaining 1.5 ml of bacterial culture and grown 
overnight by shaking at 37oC. The next day plasmids were extracted using the Plasmid 
Maxiprep kit (Qiagen). This plasmid was subjected to site-directed mutagenesis using the 
QuickChange II XL kit (Agilent) following the manufacturer’s instructions. Two rounds of 
mutagenesis PCRs were used to incorporate first the R306C point mutation, and then two 









sgRNA name Experiment Sequence (5’  3’) 
sgRNA 1 Knock-in of R306C-MECP2 GTCTTCTATCCGATCTGTGC 
sgRNA 2 Knock-in of R306C-MECP2 GTACGGTCTCCTGCACAGAT 
sgRNA 3 Knock-in of R306C-MECP2 GCGGGTCTTGCGCTTCTTGAT 
sgRNA 4 Knock-in of R306C-MECP2 GCCGGGAGACGGTCAGCATCG 
sgRNA 5 (2) Knock-in of R306C-MECP2 GACGGTCAGCATCGAGGTCA 
sgRNA 6 Knock-in of R306C-MECP2 GGAAGTGGTGAAGCCCCTGC 
sgRNA 11 (C) Knock in of mCherry tag into MECP2 GTTAGCTGACTTTACACGGAG 
sgRNA 12  Knock in of mCherry tag into MECP2 GCAGCTAACTCTCTCGGTCAC 
sgRNA 13 Knock in of mCherry tag into MECP2 GACGGGCGTCCGGCTGTCCAC 
sgRNA 15 (1) Knock-in of R306C-MECP2 GCCATCAAGAAGCGCAAGACC 
sgRNA 16 (A) Knock-out of MeCP2 GAGAAGCTTCCGGCACAGCCG 
sgRNA 17 (B) Knock-out of MeCP2 GCGCTCCATCATCCGTGACCG 
sgRNA K1  Knock-in of R111G-MECP2 GAGGAAATCTGGCCGCTCTGC 
sgRNA K2 (3) Knock-in of R111G-MECP2 GGACACGGAAGCTTAAGCAA 
sgRNA K3 Knock-in of R133C-MECP2 GTTCGCTCTAAAGTGGAGTTG 
sgRNA K4 (4) Knock-in of R133C-MECP2 GAAAAGCCTTTCGCTCTAAAG 
sgRNA K5 (5) Knock-in of T158M-MECP2 GATTTTGACTTCACGGTAAC 
sgRNA K6 (6) Knock-in of T158M-MECP2 GATTTTGACTTCACGGTAACT 
ssODN Experiment Sequence (5’  3’) 




























Hek293FT cells were transfected using Lipofectamine-2000, the amount of which depended 
on the number of cells to be transfected (Table 2.6). The protocol consisted of mixing 
optiMEM solution (Gibco) with Lipofectamine-2000 (Thermo Fisher) and letting this sit at 
room temperature for 5 minutes. Then a DNA:optiMEM mix was added dropwise into the 
Lipofectamine-2000:optiMEM mix and this was left for at least 20 minutes at room 
temperature. Meanwhile Hek293FT cells were trypsinised and counted using a Scepter 
device (Millipore). The appropriate number of cells was seeded using medium absent of 
penicillin and streptomycin. Immediately after seeding cells (i.e. while cells are still in 
suspension) the DNA:Lipofectamine-2000:optiMEM mix was added dropwise onto the cells 
and mixed by swirling. The following day medium was changed for fresh medium 
containing penicillin and streptomycin. 
Culture vessel 6-well plate 10cm dish 
Number of Hek293FT 1 x 106  6 x 106 
OptiMEM volume 150 µl 1.5 ml 
Lipofectamine-2000 volume 7.5 µl 36 µl 
Approximate DNA amount 2.5 µg 12 µg 
Test transfections of LUHMES cells were performed using a Neon Transfection system 
(Invitrogen) following the manufacturer’s instructions. Briefly, cells were trypsinised and 
washed in PBS prior to mixing with plasmid DNA. Cells and DNA were then transferred 
into the Neon pipette, transfected via an electrical pulse and immediately seeded into a 24-
well plate. 
 
Test transfections of LUHMES cells using JetPrime (Polyplus) were performed according to 
the manufacturer’s instructions. 
 
Test electroporation’s of LUHMES cells were performed using a GenePulser XCell 
electroporation machine (Bio-Rad). Each electroporation contained 1 µg of pmaxGFP 
(Lonza), 1 x 106 cells and 600 µl of ice-cold 1X HBS, pH 7. Immediately after 
electroporation cells were rested at room temperature for 2 minutes before seeding into a 





LUHMES cells were routinely transfected by Nucleofection (Lonza) using a Basic 
Nucleofector kit for primary neurons (Lonza, VAPI-1003) and a Nucleofector II device. 
LUHMES cells were dissociated with 4 ml of trypsin, centrifuged at 13000 rpm for 5 
minutes and resuspended in PBS for cell counting using a Scepter device. Aliquots of 2x106 
cells were pipetted into 15ml Falcons and these were centrifuged at 13000 rpm for 5 
minutes. PBS was removed from all 15ml Falcons and the appropriate volume of each 
plasmid/ssODN was added to each tube. One by one cells and plasmids were then 
resuspended in 90µl of the Nucleofection solution and immediately transferred into a cuvette 
(provided in the kit) for electroporation with program D-33 unless otherwise stated in the 
results section. After electroporation, RPMI medium (Sigma) was added using the pipette 
provided in the kit and cells were moved into 15ml Falcons and incubated at 37oC for 5 
minutes before plating out into 6-well plates containing pre-warmed LUHMES proliferation 
media. Media was changed after a minimum of 4 hours. 
For flow cytometry sorting of single LUHMES cells into individual wells of a 96-well plate, 
96-well plates (Greiner) were pre-coated overnight in PLO/fibronectin as described in 
section 2.1. Proliferation medium was supplemented with 1X B27 (Sigma), 100 U/ml 
penicillin (Gibco) and 100 µg/ml streptomycin (Gibco) and 100 µl was added to each well. 
Plates were stored in a plastic box kept in the 37oC incubator while cells were harvested. 
LUHMES cells were trypsinised and centrifuged in a 15ml Falcon tube as described in 
section 2.1 and resuspended in 1 ml of Advanced DMEM/F12 supplemented with 10 µM 
HEPES (Sigma, H3537). Cells, 96-well plates and spare Advanced DMEM/F12 + HEPES 
were taken over to the Ashworth FACS facility and cells were sorted using a 100 µm nozzle 
with a FACSaria (BD Biosciences) machine at room temperature by Dr Martin Waterfall. 
 
For analysis of fluorescence only, the LSRFortessa (BD Biosciences) machine was used with 
the help of Dr Martin Waterfall. Neurons were detached by treatment with ESGRO 
Complete Accutase (Millipore) for 3 minutes followed by centrifugation at 1300 rpm for 5 
minutes at room temperature. Neurons were resuspended in Advanced DMEM/F12 for flow 
cytometry analysis. For assessment of dead cells, samples were incubated with LIVE/DEAD 
Fixation Far-Red Dead Cell Stain Kit (Life Technologies, L10120) at a concentration of 
1:5000 for 30 minutes. The dye was washed out by centrifugation prior to flow cytometry 
analysis. 
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Day 1 – Thaw low passage number LUHMES 
Day 3 – Passage once 
Day 5 – Nucleofect and change media after 4 hours 
Day 7 – Take for FACS sorting of single GFP-positive cells into a 96-well plate 
Day 13 – Top up 96-well plate with 100ul of media 
Day 16 – Start moving clones from 96-well plates to 24-well plates 
Day 17 onwards – Split individual clones in a 24-well plate as they become confluent, freeze 
half the well for liquid nitrogen, move the other half to a new well in a 24-well plate. 
Adeno-associated viruses with serotype AAV1/2 were produced as described in Reference 
(McClure et al., 2011). To produce rAAV-rh10 virus, pRV1 (rAAV1-specific) and pH21 
(rAAV2-specific) were replaced with pAAV-rh10 plasmid (Penn Vector Core, School of 
Medicine, gene therapy program, University of Pennsylvania). To test AAV aliquots on 
Hek293FT or LUHMES cells, cells were grown in 6-well plates and viruses were thawed 
quickly in a 37oC water-bath, vortexed briefly and the desired volume of virus was added to 
2 ml aliquots of proliferation medium. Medium was aspirated from cells in the 6-well plate 
and replaced with medium containing virus. After 24 hours of incubation medium was again 
changed to normal proliferative medium. 
To produce lentiviruses Hek293FT cells were transfected with lipofectamine-2000 as 
described in section 2.3. Each transfection contained 6 x 106 cells, 4.6 µg of psPax2 2nd 
generation packaging plasmid, 2.8 µg of pMD2.G VSV-G envelope expressing plasmid and 
7.5 µg of transfer plasmid. Media was changed 24 hours later and initial expression of 
fluorescent reporters (when present in the transfer plasmid) was determined by UV 
microscopy to confirm expression. A further 48 hours later cell media was transferred to 15 
ml Falcon tubes and centrifuged at 3200 xg for 15 minutes at 4oC. Supernatant was poured 
into new 15ml Falcon tubes and 2.5 ml PEG solution from the PEG virus precipitation kit 
(BioVision) was added and thoroughly mixed before storage at 4oC overnight. The next day 
15 ml Falcons were centrifuged at 3200 xg for 30 minutes at 4oC. Pellets were resuspended 





For test infections of lentiviruses that confer puromycin resistance, LUHMES cells were 
seeded at 0.2 x 106 cells/well in a 6-well plate two days prior to infection. On the day of 
infection (day 0) the vials of viruses to be tested were put on dry ice and thawed quickly in a 
37oC waterbath, straight from dry ice. Once the viruses were thawed, they could be kept at 
room temperature for as long as was necessary. Media was changed in all wells, then 5 µl, 10 
µl or 20 µl of the virus was added to each well, leaving one well as a non-infected control. 
The next morning media was changed and 24 hours after virus addition, 10 µl of 0.1 mg/ml 
puromycin was added to every well to give a final concentration of 0.5 µg/ml. On day 2 the 
optimal volume of virus to provide efficient LUHMES cell infection could be approximated 
based on cell survival of puromycin treatment. All wells were trypsinised and centrifuged as 
described in section 2.1 and each entire well from the 6-well plate was seeded into a 10cm 
dish in proliferation media containing 0.25 µg/ml puromycin. On day 4 all of the non-
infected WT LUHMES cells were dead, and samples that were efficiently infected with an 
appropriate amount of lentivirus will survive the puromycin selection. If samples were to be 
subjected to single-cell cloning, two days after they were moved to 10cm dishes, samples 
were taken to FACS sorting as described in section 2.4. 
For extracting the genomic DNA from tissue culture samples, Puregene Core Kit A (Qiagen) 
was used following manufacturer’s instructions. Occasionally when RNA and DNA was 
required from a single sample, the Allprep DNA/RNA Mini kit (Qiagen) was used. 
 
For large scale genomic DNA extraction from LUHMES single cell clones in a 24-well plate 
an alternative approach was used. Individual clones when confluent were trypsinised and 
centrifuged and incubated in 400 µl lysis buffer (50 mM Tris pH 9.0, 20 mM EDTA pH 8.0, 
40 mM NaCl, 1% SDS, 0.5 mg/ml proteinase K) overnight at 55oC. The next day 300 µl 
saturated NaCl was added to each sample, mixed by vigorous shaking for 1 minute and 
centrifuged at 14000 rpm for 10 minutes at room temperature. The supernatant was 
transferred to an Eppendorf containing 500 µl isopropanol, mixed by inversion and 
centrifuged at 14000 rpm for 10 minutes at 4oC. The DNA pellet was washed with 750 µl 
70% ethanol, mixed by inversion, and centrifuged at 14000 rpm for 10 minutes at 4oC. The 
DNA pellet was air dried, resuspended in 50 µl TE and allowed to dissolve at 55oC 
overnight. 
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RNA was extracted using RNeasy Mini Kit (Qiagen) following manufacturer’s instructions. 
RNA concentration was measured using a Nanodrop 1000 (Thermo Scientific) and 10 µg 
RNA was taken for DNase1 treatment (Ambion) for 1 hour at 37oC. DNA-free RNA 
concentration was measured using a Nanodrop 1000 and 1 µg taken for cDNA synthesis 
using qScript cDNA Supermix (Quanta). DNA-free RNA was tested for the presence of 
genomic DNA by performing a PCR using GoTaq Polymerase (Promega) and primers for an 
intron-exon region within GAPDH. If cDNA was to be used for quantitative PCR analysis, 
the 20 µl cDNA reaction was diluted 10-fold using ddH2O. The SensiMix SYBR and 
Fluorescein mix (Biolines) was used for qPCR reactions using a LightCycler480 machine 
(Roche). If qPCR was performed in a 96-well plate, 25 µl reactions were used, however if a 
384-well plate was used, 12.5 µl reactions were used by halving the amount of each 
component as described in the Biolines protocol. Each sample for qPCR analysis was 
performed in technical triplicate and standard curves were made for every set of primers 
using 5 different dilutions. Analysis was performed as follows: using the standard curve the 
normalised Cp value of each sample was calculated, denoted Xtarget. The value of 10Xtarget was 
calculated and the ratio of this for each experimental sample was compared to that of the 
control GAPDH: 10Xtarget/10XGAPDH. This number was averaged for the technical triplicates. 
As samples were performed in biological triplicate (three neuronal differentiations that were 
set up at different times), the values shown in all graphs are the mean of these biological 
triplicates with the SEM plotted as error bars. 
 
Phusion polymerase in GC buffer (NEB) was used to PCR amplify 100-250 ng genomic 
DNA in a 50 µl reaction volume and 5 µl of the reaction was ran out on an agarose/TAE gel 
to confirm efficient amplification. To the remaining 45µl PCR mix, 5 µl of Buffer 2 (NEB) 
was added and the reactions were heated at 95oC for 10 minutes in a PCR machine and 
cooled slowly to 25oC to produce heteroduplexes. Each reaction was split in half and to one 
half 1µl of T7E1 (NEB) was added. All reactions were incubated at 37oC for 30 minutes, 
followed by addition of 10 µl of 6X loading dye (NEB) and analysis on an agarose/TAE gel. 
 
Phusion polymerase in GC buffer was used to PCR amplify 100-250 ng genomic DNA in a 




remaining PCR mix 29 µl of H2O, 5 µl of CutSmart buffer (NEB) and 0.5 µl of the 
appropriate enzyme was added. Reactions were incubated at the necessary temperature and 
length of time as appropriate for each enzyme and were analysed by electrophoresis in an 
agarose/TAE gel. 
Phusion polymerase in GC buffer was used to PCR amplify genomic DNA in a 25 µl 
reaction volume and 10 µl of the reaction was ran out on an agarose/TAE gel. Each amplicon 
was subcloned using the Strataclone blunt PCR cloning kit (Agilent Technologies) following 
the manufacturer’s instructions and transformed into Strataclone Solopack competent 
bacteria (Agilent Technologies). The next day single colonies were picked and colony PCR 
was performed using either Phusion polymerase or DreamTaq polymerase in a 25 µl volume. 
For confirmation of PCR, 10 µl of each colony PCR reaction was analysed by agarose/TAE 
gel electrophoresis. Positive colony PCRs were treated with 0.25 µl Exonuclease I (NEB) 
and 0.25 µl FastAP alkaline phosphatase (Thermo) in a 28 µl total volume at 37oC for 15 
minutes followed by inactivation at 85oC for 15 minutes. Sequencing was performed using 
BigDye Terminator v2.1 reaction mix (Life Technologies) using 3.5 µl of each sample and 
3.2 pmol of primer. PCR reactions were sequenced by Edinburgh Genomics using Sanger 
sequencing. 
 
Whole cell protein extracts were prepared by homogenising cell pellets in NE1 buffer (10 
mM HEPES pH 7.9, 10 mM KCl, 1 mM MgCl2, 0.5 mM DTT, 0.1% Triton-X 100, 20% 
glycerol and 1X protease inhibitor cocktail (Roche)). Homogenates were treated with 
benzonase for 15 minutes at room temperature and then measured for protein concentration 
using a Bradford assay (Protein Assay Dye Reagent concentrate, BioRad). 
 
Nuclear extracts were prepared by resuspension of cell pellets into Buffer A (10 mM Tris pH 
7.4, 10 mM NaCl, 3 mM MgCl2, 0.1% Igepal CA-630, 0.5 mM DTT, 1X protease inhibitor 
cocktail) and incubating on ice for 10-15 minutes. Cells were then dounced in a glass 
homogeniser (or for volumes smaller than 500 µl in a 1.5 ml Eppendorf with a plastic 
dounce) to release nuclei and nuclei were pelleted by centrifugation at 2400 rpm for 5 
minutes at 4oC. Nuclei were resuspended in NE1, and counted on a haemocytometer using 
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trypan blue staining if accurate nuclei concentrations were required. Nuclei were then treated 
with benzonase for 15 minutes at room temperature. 
 
All samples were mixed with 2X Sample Buffer, Laemmli loading dye (S3401-1VL) prior to 
storage at -20oC and loading on SDS-PAGE gels. 
 
Samples were loaded onto pre-cast 4-20% Mini-PROTEAN TGX gels (BioRad) and ran at 
200V for approximately 30-40 minutes. Gels were transferred onto nitrocellulose membrane 
by transfer at 25V overnight (~18 hours) at 4oC. A second membrane was used in the 
transfer in order to monitor excessive protein transfer. The gel was stained with a coomassie 
stain (InstantBlue, Expedeon) for 1 hour after transfer to determine the efficiency of transfer 
of proteins out of the gel. The two membranes were stained with Ponceau S for 2 minutes to 
monitor the transfer of proteins onto the 1st and 2nd membranes. Membranes were then de-
stained with 0.1% Tween-20 in PBS, blocked in 5% milk, 0.1% Tween-20 in TBS for 30 
minutes and probed with primary antibodies in blocking solution for 1 hour at room 
temperature (Section 2.2). Membranes were washed 3 times with 0.1% Tween-20/PBS. 
IRDye 800CW ɑ-mouse and IRDye 680LT ɑ-rabbit secondary antibodies (Licor) were 
probed for 1 hour at room temperature in blocking buffer at a concentration of 1:10000 and 
scans were taken using a Licor Odyssey machine. 
 
Cells grown on coverslips were fixed in 4% formaldehyde for 10 minutes, permeabilised 
with 0.2% Triton-X/PBS for 10 minutes and blocked for 30 minutes in 10% fetal bovine 
serum in PBS (FBS/PBS). Coverslips were incubated in the presence of primary antibodies 
(Table 2.5) in 1% FBS/0.1% Tween-20/PBS for one hour room temperature (section 2.2). 
Coverslips were washed with 0.1% Tween-20/PBS, and incubated for one hour at room 
temperature with Alexa Fluor secondary antibodies (1000X dilution, Invitrogen) in 1% 
FBS/0.1% Tween-20/PBS. Secondary antibodies: ɑ-mouse 488, ɑ-rabbit 555 and ɑ-chicken 
633. Coverslips were finally stained with DAPI (5000X dilution in PBS, Sigma, D9542) for 
10 minutes at RT and mounted onto microscope slides using Prolong Diamond solution 
(Thermo Fisher). Z-stack images were taken using a Leica SP5 microscope and z-stacks 





Phase contrast images were taken on an Eclipse TS100 microscope (Nikon) using QCapture 
Pro software version 5.1.1.14 (QImaging). UV fluorescence was used to take GFP pictures 
of cells. The IncuCyte microscope (Essen Biosciences) was used to take phase contract and 
GFP fluorescent images and ZOOM software (Essen biosciences) was used to extract and 
export the images. 
To karyotype LUHMES progenitor cells, LUHMES cells were cultured as described in 
section 2.2. The day before preparation of metaphase spreads, 0.5 x 106 LUHMES cells were 
seeded in a 6cm dish. The next day media was removed and fresh proliferation medium 
containing 0.1 µg/ml colcemid was added. After incubation for 3 hours, cells were washed 
twice with pre-warmed PBS, harvested by trypsinisation and resuspended in 300 µl medium 
with 5 ml 0.4% KCl. Cells were incubated in a 37oC waterbath for 10 minutes then 100 µl of 
a 3:1 methanol:acetic acid mix was added to cells and mixed by gentle inversion. Cells were 
pelleted by centrifugation at 300 x g for 5 minutes and supernatant was removed. Cells were 
resuspended in 5 ml 3:1 methanol:acetic acid and incubated at room temperature for 20 
minutes. Again cells were centrifuged at 300 x g for 5 minutes and supernatant was removed. 
The pellet was resuspended in 200 µl 3:1 methanol:acetic acid. This mixture was dropped 
onto pre-chilled microscope slides from an approximate 30 cm height and dried overnight at 
room temperature. The next day coverslips were mounted onto the slides using Vectorshield 
containing DAPI (Vectorlabs) and images were captured using a Zeiss AxioImager.Z1 
microscope and counted using ImageJ 1.47v software. 
RNA and DNA FISH of LUHMES cells was performed in collaboration with Dr Ronan 
Chaligne and Prof Edith Heard at the Institut Curie in Paris. The Heard lab provided me with 
paraformaldehyde (PFA) and VRC (RNase inhibitor) which were stored at -20oC prior to 
use. LUHMES cells were cultured on Nunc Lab-Tek II chamber slides (Thermo, 154453) 
that contained 1 well and were provided with a lid for a sterile tissue culture environment. 
Proliferating LUHMES cells were seeded at a density of 0.36 x 106 cells/slide and fixed 2 
days later, or at a density of 0.6 x 106 cells/slide and fixed the following day. LUHMES cells 
on day 2 of differentiation were seeded at a density of 1.2 x 106 cells/slide and fixed on day 6 
of differentiation. On the day of fixation, cell culture medium was aspirated and cells were 
washed once with PBS. At this stage the plastic cover surrounding the glass slide was 
removed to allow fixation and permeabilisation on the naked slides in plastic Coplin jars 
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(Heathrow Scientific, HS15986). Cells were fixed for 10 minutes at room temperature in 3% 
PFA/PBS, followed by permeabilisation in pre-chilled 0.5% Triton-X/1% VRC/PBS for 5 
minutes on ice. Cells were then washed once in PBS, twice in 70% ethanol/DEPC-treated 
water, and stored in the plastic Coplin jars in 70% ethanol at -20oC. Slides were then shipped 
to Paris in these jars and surrounded by ice blocks that had been cooled to -20oC. Dr 
Chaligne then performed DNA and RNA FISH as described in (Chaumeil et al., 2008). 
BAC-based probes were used for detection of MECP2 and ATRX (RP11-119A22 and RP11-
42M11 respectively). Probes for XIST RNA detection have been used previously, as 
described in (Chaligne et al., 2015). 
Neurons were grown on 19 mm coverslips until day 9 and then fixed and stained against 
laminB1 as described in section 2.17. Z-stack images were taken on a Leica SP5 confocal 
microscope and analysed using ImagePro Premier software. The software identified spheres 
of laminB1 staining and calculated the volume within this. I manually went through each 
image of nuclei spheres and altered the size range for each image to exclude laminB1 
staining of small debris and adjacent nuclei that were counted as one. 
 
For all calcium imaging experiments, neurons were grown on 25 mm coverslips, thickness 
#1.5 (Warner Instruments, 64-0715) in 6-well plates. At the desired age, neurons were 
washed twice with HBSS lacking calcium and magnesium (Lonza, 10547F) supplemented 
with 10 µM HEPES and then loaded with the required loading solution. For trials of calcium 
imaging, the loading solutions are described in Table 7. 
 
The incubation time for Fluo-4 samples was 1 hour at 37oC, while the incubation of Rhod-3 
samples was at room temperature for 1 hour. After Rhod-3 loading buffer incubation, 
coverslips were washed twice with HBSS+HEPES and then incubated for a further hour at 
room temperature in HBSS+HEPES+2.5 mM probenecid. After incubation, coverslips were 
washed once with HBSS+HEPES and then an HBSS containing calcium and magnesium 
(Lonza, BE10527F) + 10 µM HEPES solution was added to the cells, plates were wrapped in 














Final Fluo-4 concentration 
(µM) 
4 - - 1 2 
7 - - 1 3.5 
10 - - 1 5 
4 20 20 0.976 2 
7 20 20 0.973 3.5 
10 20 20 0.970 5 











4 20 20 0.976 20 
4 - - 1 20 
2 20 20 0.978 10 
2 - - 1 10 
1 20 20 0.979 5 
1 - - 1 5 
 
Plates containing coverslips in HBSS were kept in a 37oC incubator. One by one coverslips 
were placed into a coverslip holder and 200 µl HBSS+Ca2++Mg2++HEPES was added to the 
cells and placed on the Leica SP5 microscope with a 40X objective. Once neurons were in 
focus, filming began and after 20 frames of imaging “resting neurons”, 200 µl of solution A 
was added to the coverslip and neurons were imaged for a further 500 image frames. Note 
that 1 frame is the equivalent of 0.65 seconds; therefore the total imaging time for a single 
field of view was 338 seconds, or 5 minutes and 38 seconds. For a negative control, solution 
A was 2X EGTA (Sigma-Aldrich, E8145); for a positive control, solution A was 2X A23187 
calcium ionophore (Fisher Scientific, 10284963); and for experimental studies, solution A 
was either 130mM or 260mM KCl (Fisher Scientific - P/4280/6). 
 
After trials, all experiments were performed using 2 µM Fluo-4 were loaded for 1 hour at 
37oC with Fluo-4 in DMSO, Pluronic-F127 (Biotium, 59004), HBSS and 10 µM HEPES. 
For example, for 6 coverslips a total of 12ml of loading buffer is needed. This will consist of 
12 ml HBSS+HEPES and 32 µl of 1 mM Fluo-4, where the 32 µl consists of 16 µl of Fluo-4 
in DMSO and 16 µl of Pluronic-F127. Note each 50 µg vial of Fluo-4 was freshly 
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reconstituted in 23 µl DMSO and any reconstituted Fluo-4 that was not used was returned to 
-20oC for storage and would only be thawed once.  
 
Analysis was performed by picking a minimum of 6 different cell bodies per video, and 
defining the recording area as a circle encompassing the total cell body area. The mean 
fluorescence intensity in this area was calculated for the duration of the time course and this 
was averaged among the 6 replicates. The maximum fluorescence intensity from this 
averaged time course was defined and this was plotted with respect to the calcium 
concentration. The Kd for Fluo-4 was then established by reading the calcium ion 
concentration for the 50% fluorescence intensity from the graph. 
 
High performance liquid chromatography was performed in collaboration with Dr Bernard 
Ramsahoye in order to measure total RNA and DNA amounts. LUHMES cells were 
proliferated in a 6-well plate until confluent or differentiated in 6-well plates and harvested 
on day 9. One well of a 6-well plate provided enough material for undifferentiated samples, 
but neuronal samples required two wells of a 6-well plate to be pooled. Cells were washed 
once with PBS, then scraped in 500 µl ice-cold lysis buffer (10 mM Tris-HCl pH 7.5, 100 
mM EDTA) and transferred into round-bottomed 2 ml Eppendorf tubes on ice. Once all 
samples had been harvested, 7.5 µl of 20 mg/ml Proteinase K and 12.5 µl of 20% SDS was 
added to each sample and mixed by flicking and inversion. Samples were put to 55oC for 1 
hour before being transported to Dr Ramsahoye at room temperature for HPLC analysis. 11-
week old R306C male mice and wild-type littermate’s brain sections were harvested by Dr 
Jim Selfridge and stored in liquid nitrogen as a whole hypothalamus, ½ cortex and ½ 
cerebellum samples. Each mouse brain section was homogenised using a glass hand-held 
homogeniser in 400 µl ice-cold lysis buffer containing 300 µg/ml Proteinase K using 
approximately 10 strokes and then stored on ice. Once all samples had been homogenised, 
10 µl 20% SDS was added to each sample and mixed by inversion. Samples were incubated 
at 55oC for 30 minutes and then transported to Dr Ramsahoye at room temperature for HPLC 
analysis. 
LUHMES cells were differentiated in 6-well plates to day 9 with three wells being pooled to 




extract total RNA and DNA from each sample eluting in 40 µl and 100 µl respectively. RNA 
and DNA concentrations were measured using a Qubit fluorometer (Invitrogen) using the 
RNA broad-range and the DNA high-sensitivity kits for RNA samples and the DNA broad-
range and RNA high-sensitivity kits for RNA samples. After removal of 1 µl of sample, to 
the 39 µl remaining RNA sample, 5 µl buffer, 5 µl H2O and 1 µl rDNaseI (Ambion) was 
added and samples were incubated at 37oC for 40 minutes to digest the DNA. RNA samples 
were again measured on the Qubit using the RNA broad-range and DNA high-sensitivity 
kits. A PCR to check for zero genomic DNA contamination was performed using 1 µl of 
each sample (plus the 1 µl of each sample prior to rDNaseI treatment) using GoTaq 
polymerase (Promega) and primers crossing an intron-exon boundary of GAPDH. RNA 
samples were then assessed for quality using a RNA Nano 6000 chip on the Bioanalyser 
2100 machine (Agilent). 
 
The ScriptSeq Complete kit for human/mouse/rat (Epicentre) was used for removal of rRNA, 
fragmentation of RNA, preparation of cDNA and PCR amplification by following the 
manufacturer’s instructions. Briefly, magnetic beads for rRNA removal were washed in 
batches of 6 using gentle vortexing and were stored at room temperature with 1 µl 
RiboGuard RNase Inhibitor until needed.  To 2.5 µg of DNA-free RNA, Ribo-Zero solutions 
were added in a reaction that included 5 µl of 100X ERCC spike-in mix (Thermo Fisher); 
components were added individually to each reaction. Samples were then applied to the 
prepared magnetic beads and the supernatant from this step was cleaned up using an 
Agencourt RNAClean XP kit (Beckman Coulter). The mRNA samples were then tested for 
quality using an mRNA Pico chip on the Bioanalyser and were quantified using the Qubit 
fluorometer and a RNA high-sensitivity kit. At this stage mRNA samples were frozen at -
80oC. For fragmentation of RNA, 8 ng of mRNA was used. Synthesis of cDNA was then 
performed, 3’ terminal tagging and purification of cDNA using AMPure XP beads 
(Beckman Coulter). Library amplification was then performed using the forward primer in 
this ScriptSeq Complete kit and reverse primers from the ScriptSeq Index PCR primers kit 
(EpiCentre) in order to index the individual samples and 13 cycles of PCR amplification. 
PCR samples were then cleaned up using AMPure XP beads and library quality was assessed 
using a high sensitivity DNA chip on the Bioanalyser machine before being sent off for 
sequencing at the Sanger institute in Cambridge using Illumina HiSeq 2500 paired-end 
sequencing on 4 lanes (equivalent to 2 rapid runs, 6 samples per run). 
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RNA-sequencing analysis was performed by Kashyap Chaatbar as follows. Poor quality raw 
sequencing reads are removed and the remaining reads are adapter trimmed using 
Trimmomatic v0.33 (Bolger et al., 2014). The remaining reads are aligned to the hg19 
version of Human genome assembly (Consortium, 2001) using STAR v2.4.2a (Dobin et al., 
2013). Genomic features are taken from Ensembl release 74 (Yates et al., 2016).  The 
number of reads mapping to each genomic feature is quantified using featureCounts v1.5.0 
(Liao et al., 2014). After the quantification of the mapped reads, differential gene expression 
is calculated using DESeq2 v1.10.1 (Love et al., 2014). The command line arguments used 
to perform these analyses is as follows: 
 
java -jar trimmomatic-0.33.jar PE ILLUMINACLIP:TruSeq2-PE.fa:2:30:10 LEADING:3 
TRAILING:3 SLIDINGWINDOW:4:30 MINLEN:30 
 
STAR --runThreadN 10 --runMode alignReads --genomeDir hg19 --outFilterIntronMotifs 
RemoveNoncanonicalUnannotated --outSAMtype BAM SortedByCoordinate 
 
featureCounts -T 10 -p -s 1 --primary -t exon -g gene_id -a hg19.gtf 
 
Calculation of mCpG densities were performed as follows: 




𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒎𝒆𝒕𝒉𝒚𝒍𝒂𝒕𝒆𝒅 𝒓𝒆𝒂𝒅𝒔 𝒐𝒏 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒖𝒍𝒂𝒓 𝑪𝒑𝑮
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒓𝒆𝒂𝒅𝒔 𝒂𝒕 𝒕𝒉𝒂𝒕 𝑪𝒑𝑮
𝑳𝒆𝒏𝒈𝒕𝒉 𝒐𝒇 𝒓𝒆𝒈𝒊𝒐𝒏 (𝒌𝒃)
 
 
𝑥=   
𝜮 
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒎𝒆𝒕𝒉𝒚𝒍𝒂𝒕𝒆𝒅 𝒓𝒆𝒂𝒅𝒔 𝒐𝒏 𝒂 𝒑𝒂𝒓𝒕𝒊𝒄𝒖𝒍𝒂𝒓 𝑪𝒑𝑮
𝑻𝒐𝒕𝒂𝒍 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒓𝒆𝒂𝒅𝒔 𝒂𝒕 𝒕𝒉𝒂𝒕 𝑪𝒑𝑮
𝑵𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝑪𝒑𝑮 𝒊𝒏 𝒕𝒉𝒆 𝒓𝒆𝒈𝒊𝒐𝒏
 
 
Gene length, promoter length and gene body length were calculated as follows: Gene 
features for human genome assembly GRCh37 were taken from Ensembl version 74 and 
represent regions between the annotated TSS and TES. Promoters were defined as 2kb 
regions centred around the TSS. To create gene body annotations we first removed all genes 




lead to the TES. In other words: Gene = Annotated TSS to TES; Promoter = 1kb either side 
of TSS; Gene body = Remove genes < 3.5kb in length, take 3kb downstream of TSS to TES. 
 
Long-term image analysis of differentiating and maturing LUHMES neurons was performed 
in an IncuCyte machine (Essen Biosciences). Neurons were differentiated in both 6-well and 
96-well plates (TPP, Sigma) and every well was imaged at 4 time points during a 12-hour 
period. Images were analysed using the ZOOM software (Essen Biosciences) with the 
NeuroTrack software able to measure the length of neurites during the differentiation time 
course. The All Older processing definition was designed in this project. The parameters for 
the All Older processing definition are as follows; segmentation mode brightness, 
segmentation adjustment 1.1, neurite filtering best, neurite sensitivity 0.35 and neurite width 
1 µm.  
LUHMES neurons were grown on 14 mm coverslips (Thermo) and transported in a 
polystyrene box heated to 37oC to Dr Sean McKay who performed patch-clamping 
experiments. Coverslips were transferred to a recording chamber perfused (at a flow rate of 
3–5 ml/min) with an external recording solution composed of (in mM): 150 NaCl, 2.8 KCl, 
10 HEPES, 2 CaCl2, 1 MgCl2, and 10 glucose, pH 7.3 (320–330 mOsm). Patch-pipettes 
were made from thick-walled borosilicate glass (Harvard Apparatus), and when filled with 
the internal recording solution had tip resistances of 4–8 MΩ. A K-gluconate-based internal 
solution was used for patching neurons composed of (in mM): 141 K-gluconate, 2.5 NaCl, 
10 HEPES, and 11 EGTA; pH 7.3 with KOH. Recordings were initially made in voltage-
clamp and rejected if the holding current was greater than −100 pA or if the series resistance 
drifted by more than 20% of its initial value (< 30 MΩ) by the end of the recording. During 
the current-clamp recordings, no current was injected at the resting membrane potential and 
neuronal firing was induced by current injections from -20pA to +50pA in incremental 5pA 
steps. Input resistance was significantly lower than primary mouse cultures recorded the 
same day (data not shown). Recordings were at room temperature (21 ± 2 °C) using a 
Multiclamp 200B amplifier (Molecular Devices). Recordings were filtered at 5 kHz and 
digitized online at 20 kHz via a BNC- 2090A/PCI-6251 DAQ board interface (National 
Instruments) and analysed using WinEDR 3.6 software (Dr John Dempster, University of 
Strathclyde). 
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Wild-type human MeCP2_e1 isoform MeCP2 was made by Dr Matthew Lyst as described 
previously (Klose & Bird, 2004) with some minor alterations; BL21 codon plus bacteria 
were swopped for pLysS, Tris-HCl was exchanged for HEPES in the buffers, NP-40 was 
exchanged for TritonX-100, SP-sepharose columns were performed prior to Ni-NTA, and no 
Sephacryl S-300 26/60 or MonoS column purifications strategies were performed. 
MeCP2_e1 protein was stored in aliquots at -20oC. Chloroquine (Sigma, C6628-25G) was 
prepared fresh by dissolving 0.1 g of powder in 1 ml tissue-culture grade PBS (Gibco, 
14190). 
 
Wild-type and MeCP2 KO (2_7 cell line) LUHMES-derived neurons were differentiated in 6 
cm dishes or on coverslips. Each experiment contained 5 samples: WT cells, KO cells, KO 
cells + choloroquine, KO cells + protein, KO cells + chloroquine + protein. Human On day 9 
of differentiation, media was removed from all dishes, mixed in a 1:1 ratio with fresh 
LUHMES differentiation medium and 4 ml aliquots were made. To each aliquot the required 
amount of protein and/or chloroquine was added (Table 2.8), mixed by inversion and added 
to neurons. A media change was also performed for WT or KO neurons that were not treated 
with protein or chloroquine. After the desired incubation time neurons were either fixed for 
immunofluorescence analysis, or harvested by washing once in tissue-culture grade PBS, 
scraping in ice-cold PBS and centrifugation at 300 x g for 5 minutes at 4oC. Cell pellets were 
snap-frozen on dry ice and stored at -80oC. 
 
 Old protein prep 
6cm dish 
Old protein prep 
Coverslip 
New protein prep 
6cm dish 
New protein prep 
24-well plate 
Cells seeded 2 x 106 0.15 x 106 2 x 106 0.15 x 106 
Media volume 2 ml 1 ml 2 ml 0.5 ml 
Chloroquine (100 mM) 2 µl 0.5 µl 4 µl 0.1 µl 
MeCP2 (3.8 or 1 mg/ml) 25 µg (6.58 µl) 1.9 µg (0.5 µl) 2.5 µg (2.5 µl) 0.125 µg (0.125 µl) 










The LUHMES human, pre-neuronal cell line was established in 2005 (Lotharius et al., 
2005). There has been extensive RT-qPCR and immunofluorescence analysis of the 
differentiation dynamics of the cells which demonstrate the neuronal-committed nature of 
the progenitors and their relatively homogeneous differentiation towards a dopaminergic 
lineage (Scholz et al., 2011). Furthermore, a quick and efficient differentiation protocol has 
been described (Scholz et al., 2011), and overexpression of proteins in progenitors via 
lentiviruses and siRNA knock-down of protein in 2-day old pre-differentiated cells via 
Lipofectamine-2000 transfection has been demonstrated, indicating an ability to manipulate 
these cells (Schildknecht et al., 2013). The ease of differentiation, the ability to manipulate 
and the homogeneous nature of this human neuronal cell line make them an attractive tool 
for the study of MeCP2 and Rett syndrome. 
 
Much of our MeCP2-focussed work has involved whole organism studies of mutant mouse 
lines combined with transfection experiments in mouse NIH3T3 or human HeLa cell lines. 
The LUHMES cell line can potentially provide a half-way point between these two. The 
overall aim of this project is to genetically manipulate the endogenous MECP2 gene in 
LUHMES cells in order to create human neurons where the endogenous protein can be 
studied in its native context. I aim to show that LUHMES cells can be handled in a high-
throughput manner and that there are a range of experiments that can be performed leading 
to novel discoveries. I do not wish to propose that LUHMES cells will be an alternative to 
mouse models and work-horse cell lines, but I do believe that they will complement these 
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studies by providing an easy-to-manipulate, human neuronal environment for study of the 
MeCP2 protein. 
 
In order to establish the LUHMES cell line as a model system for the laboratory, it is first 
necessary to perform some basic characterisations of these cells. Are LUHMES cells an easy 
to handle and karyotypically normal cell line? Do they express high levels of MeCP2, as 
would be expected of a neuronal cell line? Can they be transfected at the progenitor stage in 
order to produce stocks of genetically modified cell lines? Are they amenable to basic 
electrophysiology experiments that could be useful for downstream analysis if mutant cell 
lines can be generated? This chapter will address these questions. 
 
LUHMES cells were established as an immortalised cell line by infecting midbrain-isolated 
neuronal progenitor cells with a retroviral vector, called LINXv-myc, that expresses the v-
myc oncogene from an altered CMV promoter (Hoshimaru et al., 1996). The promoter 
(officially termed PhCMV*-1) is a minimal promoter from human cytomegalovirus that is fused 
to tetracycline operon sequences (Gossen & Bujard, 1992). Upstream of this PhCMV*-1-v-myc 
element is an expression construct for a tetracycline-controlled transactivator that acts upon 
PhCMV*-1 to induce high levels of transcription in the absence of tetracycline. Upon addition of 
tetcracyline to the cell culture medium, the drug binds to the transactivator, inhibits its ability 
to regulate PhCMV*-1 (Gossen & Bujard, 1992), and shuts off v-myc expression, thus allowing 
exogenous control over endogenous v-myc expression. Once v-myc is down-regulated, the 
LUHMES progenitors rapidly differentiate into a population of neurons, according to their 
cell fate and differentiation potential (Figure 3A). 
 
Figure 3B illustrates the differentiation time course and rapid changes in morphology upon 
tetracycline addition to the cell culture media. Two days after tetracycline addition, the cells 
are expected to have shut down v-myc expression and therefore on this day cells are 
trypsinised and counted in order to seed a known number of cells into new vessels and thus 















Analysis of the expression of various markers of mature neurons shows that 9-day old 
LUHMES-derived neurons express high levels of MAP2, NeuN and neurofilament (Figure 
4A+B). Indeed even the progenitor cells express neurofilament at low levels indicating their 
commitment to a neuronal lineage and absence of a stem cell-like, pluripotent state. 
Expression of tyrosine hydroxylase (TH) is observed at day 9, indicating the dopaminergic 
lineage of the neurons, (Figure 4C) and MeCP2 expression is gradually up-regulated during 
the differentiation process, characteristic of in vivo neuronal differentiation profiles (Figure 
4D). 
 
In order to assess the dynamics of LUHMES cell differentiation into neurons, I performed 
RT-qPCR analysis of 25 different mRNAs, including markers of proliferating cells, 
immature neurons, mature neurons, and dopaminergic neurons, with the aim of establishing 
the dynamics of neuronal differentiation. Many primer pairs were provided by Dr Justyna 
Cholewa-Waclaw, whereas others were designed anew. To test the integrity of these new 
primer pairs melt curve analysis was performed (Supplementary Figure 1). Three primer 
pairs unfortunately consistently produced secondary products during the amplification phase 
of the qPCR reaction at three different annealing temperatures as indicated by melt curve 
analysis (Supplementary Figure 1A) and by running the final qPCR samples on an agarose 
gel (Supplementary Figure 1B+C). The remaining 10 primer pairs, however, produced clean 
melt curves indicating efficient amplification of a single product during the qPCR reaction 
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Figure 5 shows the qPCR analysis for all 25 mRNA species assessed. Markers of progenitor 
cells rapidly decrease as differentiation progresses (A), while markers for committed (B) and 
mature neurons (C) increase during differentiation. Seven markers of synaptic proteins (D) 
also increase their expression during differentiation and four markers for dopaminergic 
neurons (E) are up-regulated indicating the differentiation of LUHMES progenitors into 
mature, dopaminergic neurons. One dopaminergic marker, EN1 (engrailed 1), does not 
upregulate its expression during differentiation, but remains expressed at all ages, consistent 
with its role as a transcription factor that functions throughout the development of midbrain 
dopaminergic neurons (Rekaik et al., 2015). PAX3 mRNA, a transcription factor found in 
migrating neuroblasts, could not be detected at any stage of differentiation ( 
 
 
Figure 5F). While previous analysis of PAX3 could detect mRNA at days 0 and 5 of 
differentiation, no PAX3 protein was detected (Scholz et al., 2011). The data thus indicates 
that this protein is most likely not expressed in LUHMES cells or their derived neurons. 
SEZL6 is a transmembrane protein whose molecular function is unknown but is thought to 
involve cell surface signalling (Pigoni et al., 2016). Using two different sets of primers, 
SEZL6 could not be detected in proliferating or immature neurons, but a small level of 
expression (almost equivalent to NeuN expression in undifferentiated cells) was detected in 
9-day old neurons ( 
 
 
Figure 5F). These qPCR experiments demonstrate the fast dynamics of LUHMES cell 
differentiation into mature neurons expressing a complement of transcription factors (EN1, 
NEUROD1), synaptic proteins (SYN1, SNAP25, SV2A), structural proteins (TUBB3, 
NESTIN), signalling proteins (NDNF, DCX) and cell surface proteins (DRD2, DAT, GIRK2, 




















The LUHMES cell line is derived from healthy, wild-type tissue and might be predicted to 
have a stable karyotype. The LUHMES-precursor cell line, MESC2.10 cells, contain a 
normal complement of chromosomes (Paul et al., 2007), but as this has not been 
demonstrated before in LUHMES cells themselves I chose to perform karyotyping. I 
generated metaphase spreads of LUHMES progenitors (Figure 6A) and counted the number 
of chromosomes per nucleus. The quantification shown in Figure 6B shows a broad 
distribution of chromosome numbers. This broad distribution can be accounted for by the 
presence of nuclei that had lost one or even three chromosomes from their spread, and 
therefore would be counted as 45 and 43 in the analysis (Figure 6A). Furthermore when two 
nuclei were overlapping or very close together it became difficult to accurately quantify the 
number of chromosomes in each spread (Figure 6A). This analysis was performed once, but 
with a median chromosome count of 46, I inferred a normal karyotype for LUHMES cells. 
Part of this study will deal with CRISPR targeting experiments of the X-linked MECP2 gene 
and as LUHMES cells are female cells with two X chromosomes it was important to 
determine if both X chromosomes were active or if, as might be expected, one X 
chromosome was already established in the inactive state in progenitor LUHMES cells. I 
fixed and permeabilised progenitor cells as well as 6-day old neurons and Dr Ronan 
Chaligné (Prof Edith Heard’s lab, Institut Curie, Paris, France) performed RNA and DNA 
FISH experiments using ATRX and FMR1 as X-chromosome located controls. As shown in 
Figure 6C, a cloud denoting XIST RNA coating the inactive X chromosome was observed in 
progenitor cells and 6-day old neurons. A single focus of MECP2 RNA expression was 
observed in the undifferentiated sample thus establishing that X inactivation is present in the 
progenitor cell line. MECP2 is reported to escape X chromosome inactivation in trophoblast 
giant cells (Corbel et al., 2013), in the subventricular zone in vivo (Gendrel et al., 2014), and 
in mouse embryonic stem cells that are differentiated into neural precursors (Prof Edith 
Heard, personal communication). We observed 4% of LUHMES progenitors and 6-day old 
neurons expressing MECP2 from the inactive X chromosome (Figure 6D and white 
arrowhead in Figure 6C). This percentage is much reduced compared to published reports of 
this phenomenon (30-40% in TGCs and 20% in the SVZ) and thus I conclude that the 
MECP2 locus does not exhibit bi-allelic expression in LUHMES cells nor in LUHMES-
derived neurons. Finally, DNA FISH confirmed the presence of two alleles of MECP2 
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genomic DNA in LUHMES progenitors, one of which co-localised with a cloud of XIST 
RNA expression (Figure 6E), thus providing further evidence for a stable genotype in this 
human cell line. To conclude, LUHMES cells have only two copies of the MECP2 allele in 






MeCP2 is known to increase its abundance throughout neuronal development and maturation 
in both mice (Kishi & Macklis, 2004) and humans (Balmer et al., 2003), and I therefore 
wanted to understand the dynamics of MeCP2 expression during LUHMES cell 
differentiation. My previous immunofluorescence analysis suggested an increase in the 
expression level from day 0 to day 12 (Figure 4D). To assess this in a more quantitative 
manner I performed Western blotting analysis on nuclear extracts from LUHMES cells at 
different stages of differentiation. By comparing the MeCP2 signal to known loaded amounts 
of recombinant MeCP2 protein I could estimate the amount of MeCP2/nucleus in LUHMES-
derived neurons (Figure 7A). Mouse whole brain nuclear extracts were provided by Dr 
Sabine Lagger to compare LUHMES MeCP2 levels to that in vivo in mice. By comparing 
the band intensities of MeCP2 in the samples to that of the recombinant protein the 
nanogram amount of MeCP2 in the loaded sample could be estimated. Then, using 
Avogadro’s number (6 x 1023) and the molecular weight of MeCP2 (52.3 kDa) the number of 
MeCP2 molecules per nucleus in each sample was calculated. 
 
As can be seen in Figure 7B, the number of MeCP2 molecules per nucleus increases during 
LUHMES cell differentiation, reaching a maximum after about 6 days, which coincides with 
the peak expression of many markers of mature neurons such as Synapsin1, DLG4, βIII-
tubulin and NeuN (Scholz et al., 2011). The 3 x 106 molecules of MeCP2/nucleus in 6-day 
old LUHMES-derived neurons is 5-fold lower than the 15 x 106 molecules/nucleus obtained 
here for mouse whole brain nuclear extract (Table 9). This number is somewhat higher than 
a previous estimation by Dr Pete Skene which found that mouse whole brain has 6 x 106 
molecules/nucleus (Skene et al., 2010), thus if I compare to the published data LUHMES 
cells have 50% less MeCP2 protein than the mouse whole brain. 
 
 





There are a number of reasons why the MeCP2 amount in LUHMES-derived neurons could 
be lower than in mice. Firstly, 9-day old LUMHES-derived neurons are younger compared 
to a 10-12 week old mouse, and secondly, neurons in vivo in the mouse brain are supported 




2007; Tang et al., 2013) whereas isolated LUHMES-derived neurons in a dish will not 
receive that stimulus. In conclusion, the amount of MeCP2 protein in LUHMES-derived 
neurons increases during differentiation in accordance with in vivo development, and reaches 
a high level of expression that is approximately 5-fold lower than that in mouse whole brain. 
 
Sample MeCP2 fg/nucleus MeCP2 molecules/nucleus 
Mouse whole brain 1301.82 1.5 x 107 
Day 0 LUHMES 88.12 1.0 x 106 
Day 2 LUHMES 184.43 2.1 x 106 
Day 6 LUHMES 256.55 2.9 x 106 
Day 9 LUHMES 201.26 2.3 x 106 
Day 12 LUHMES 209.92 2.4 x 106 
 
I also assessed the expression dynamics of MECP2 mRNA during LUHMES cell 
differentiation and found that, similar to the protein dynamics, the level of MECP2 mRNA 
increases during differentiation (Figure 7C). Surprisingly though, the mRNA level drops off 
after day 6, while the protein amount remains high which perhaps is indicative of a high 
stability of MeCP2 protein. 
 
If LUHMES-derived neurons are to be used in the laboratory as a model system for studying 
MeCP2 and its function in neurons, then it is important to establish that proteins that are 
known interactors of MeCP2 are expressed. I performed Western blot analysis on HDAC3 
and TBL1, two proteins that are part of the NCoR/SMRT repressor complex, which interacts 
with the NID of MeCP2, and are thought to contribute to MeCP2-mediated gene repression 
(Gabel et al., 2015; Lyst et al., 2013). For this experiment I obtained regions of mouse brain 
tissue from Dr Jacky Guy to assess the protein levels in vivo as well. Figure 7D shows a 
representative Western blot, probing for MeCP2, HDAC3 and TBL1, with H3 as the loading 
control. A first interesting observation is the presence of multiple bands that are picked up by 
the TBL1 antibody. The X-chromosomal TBL1 protein (also known as TBL1X) has an 
autosomal paralogue called TBL1R1. The antibody used here is reported on the Abcam 
website to not cross-react with TBL1R1 yet it was generated against the full-length TBL1 
protein. With 86% homology between the two proteins (Choi et al., 2011), perhaps the 
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multiple bands picked up by Western blot analysis are the two TBL paralogues. While the 
lower TBL1 band appears to be more abundant in the spinal cord, replicate Western blots 
using samples from multiple mice established that in all brain regions, the upper band is 
more abundant (Supplementary Figure 2). There is a third unexplained band in the two 
LUHMES-derived neuron samples. This could be a third paralogue, a modified version of 
the protein or non-specific antibody reactivity. Performing a co-IP experiment by 
immunoprecipitating MeCP2, and probing the extract with the TBL1 antibody might help 
determine the functional significance of this third band. Of note, the cerebellum contains 
lower levels of MeCP2 (Figure 7E), consistent with reports from mouse (Ross et al., 2016), 
as well as low levels of HDAC3 and TBL1 (Figure 7F+G). In conclusion, the two MeCP2-
interaction partners HDAC3 and TBL1 are expressed in LUHMES-derived neurons, and the 
level of these two proteins (as well as MeCP2) is comparable to the mouse brain. 
 
A previous publication using LUHMES cells described Lipofectamine-2000 transfection and 
electroporation of LUHMES cells as being highly variable (Schildknecht et al., 2013). In 
that study they optimised Nucleofection of cells after differentiation for two days and 
demonstrated efficient transfection. Their approach is useful for immediate analysis of 
neurons after Nucleofection, but is not suitable for the generation of a stock of proliferating, 
genetically modified LUHMES cells, as is the aim of this project. Therefore I tested a 
number of different transfection and transduction techniques with the proliferative LUHMES 
cell line. 
 
I began with viral transduction experiments. Lentiviruses have been successfully used to 
transduce undifferentiated LUHMES cells (Schildknecht et al., 2013) and the technique has 
been used in our group by Dr Justyna Cholewa-Waclaw. Based on this success I was keen to 
explore the efficiency of adeno-associated virus (AAV) transduction of LUHMES cells. The 
benefits of AAVs over lentiviruses are 3-fold. First, as these viruses cannot self-replicate 
they are safer than lentiviruses and can therefore be produced and used in a Category I, 
rather than in a Category II tissue culture facility (Samulski & Muzyczka, 2014). Second, as 
rAAV DNA does not tend to insert into the genome of the host cell, rAAVs do not pose the 
risk of insertional mutagenesis (Buning et al., 2008). Third, rAAVs are a promising system 




mouse model organisms (Gadalla et al., 2017) and have been used directly in the clinic 
(Gaudet et al., 2016). As there are a number of different AAV serotypes available, each of 
which has a different efficacy for different types of cells and tissues, I trialled four separate 
viruses on LUHMES cells. The scAAV9, ssAAV9 and rAAVrh10 viruses were already 
present in the lab, and rAAV1/2 was a kind gift from Dr Matt Nolan’s lab. These viruses 
were applied in different titres to LUHMES cells, RNA was acquired after 48 hours, and 
expression of the virally-provided transgene was assessed by RT-qPCR analysis. Two 
viruses (ssAAV9 and scAAV9) appeared to be ineffective at delivering the CBA-Mecp2_e1 
and MeP-Mecp2_e1 cargo respectively to LUHMES cells (Figure 8A), although detecting 
the expression of MECP2 RNA on top of endogenous MECP2 may have affected the 
experimental interpretation. However both the rAAVrh10 virus (delivering CAG-Cre) and 
the rAAV1/2 virus (delivering CAG-EGFP) were effective at infecting and expressing their 
transgene in LUHMES cells, in a manner that was dose-dependent (Figure 8A). As the 
rAAV1/2 virus was effective at transducing LUHMES cells, and an efficient published 
protocol existed for generation of rAAV1/2 viruses (McClure et al., 2011), I used Gateway 
cloning to generate AAV-compatible plasmids containing EGFP and puromycin resistant 
(PuroR) cassettes which were both driven by the human PGK promoter (phosphoglycerate 
kinase). Lipofectamine-2000 mediated transfection of these plasmids into Hek293FT cells 
confirmed correct cloning of both plasmids (Figure 8B+C), thus I proceeded to make AAV 
viruses. Both viruses were successful at infecting Hek293FT cells, creating EGFP-
expressing Hek293FT cells (Figure 8D) as well as Hek293FT cells that were resistant to 
puromycin treatment, even after 12 days (Figure 8E). When testing both viruses on 
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LUHMES progenitor cells neither EGFP expression (
 
 






Figure 9B) was achieved, indicating that although functional AAV viruses had been made, 
neither viral prep effectively transduced LUHMES cells. Perhaps the viral preparations were 














As an alternative to AAV, I then optimised Nucleofection of proliferating, progenitor 
LUHMES cells. Nucleofection is a transfection technique that combines electroporation (the 
parameters of which are defined by set programs in the Nucleofector device), and 
resuspension of cells into a buffer that is amenable to transfection. Nucleofection is typically 
used for cells that are hard to transfect by other means. Five programs were tested using the 
basic Nucleofection kit for primary neurons in combination with pmaxGFP, the plasmid 
provided in the kit (Figure legend is over-page. 
Figure 10A). RT-qPCR showed extremely high levels of EGFP expression when using 
program A-33 (Figure legend is over-page. 
Figure 10B) and so 18 similar programs were tested to find a program that yielded the best 
balance of transfection and survival (Figure legend is over-page. 
Figure 10C). Notably, LUHMES cells are sensitive to the amount of plasmid that is 
transfected; 10 µg plasmid induces large amounts of cell death (Figure legend is over-page. 
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Figure 10D). Furthermore plasmids that are endotoxin-free result in improved cell survival, 
but phenol-chloroform extraction of the plasmid for further purity did not improve this 
(Figure legend is over-page. 
Figure 10E+F). Finally, it was noticed that incubation of LUHMES cells in a low-calcium 
media (such as RPMI) for 5 minutes at 37oC post-Nucleofection further improved the 










Other transfection procedures were tested including electroporation (Figure 11A), Neon 
transfection (Figure 11B), JetPrime polyplus and calcium phosphate transfection but none of 
these techniques yielded transfected LUHMES cells that were healthy for continued growth. 
In conclusion, Nuclofection of proliferating LUHMES cells is a reproducible and effective 
method for transfection of DNA (and potentially RNA) into cells and was considered 
suitable for the generation of genetically modified cell lines. 
The LUHMES cell line is a clonal cell line that was established by serial dilution of cells into 
a 96-well plate. The ability to generate a single clonal cell line containing only the 
genetically engineered mutation of interest would be extremely beneficial for this project. 
Therefore, serial dilution into a 96-well plate, colony picking and FACS sorting of single 
cells into a 96-well plate were each tested. LUHMES cells were not able to form colonies 
suitable for picking, even with the addition of laminin and B27 to the tissue culture medium 
to improve colony formation indicating that this strategy was unsuccessful. Serial dilution 
into a 96-well plate successfully generated single colonies of LUHMES cells that established 
a clonal cell line, although only 10-15 wells per 96-well plate actually contained colonies 
and often these were derived from multiple different cells (see Chapter 4.3.2). FACS sorting, 
however, successfully isolated single LUHMES cells and after being left in culture for 1.5 
weeks, individual colonies of LUHMES cells appeared and could be dissociated and 
transferred to a 24-well plate for expansion. 
 
Thus, the combination of Nucleofection and FACS sorting of single cells into a 96-well plate 
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Several studies using MeCP2-mutant neurons have demonstrated defects in 
electrophysiological properties. Here I briefly summarise the results from three of these 
studies in order of increasing phenotypic severity. In 2010, Alysson Muotri and colleagues 
generated hiPSCs using fibroblasts from four patients containing different Rett syndrome 
causing mutations, differentiated them into neurons and performed extensive characterisation 
of these neurons in tissue culture (Marchetto et al., 2010). They performed whole-cell patch 
clamping experiments using WT and 1155del32 iPSC-neurons, which contain a deletion of 
32 nucleotides in the C-terminus of the protein resulting in a frameshift mutation. Both 
genotypes displayed the same inward sodium and outward potassium currents in response to 
various voltage depolarisations in voltage-clamp conditions, as well as similar action 
potentials evoked by current injections in current-clamp conditions. Yet a difference in 
electrophysiological properties was observed when they assessed spontaneous inhibitory and 
excitatory postsynaptic currents (siPSCs and sEPSCs). The effects were small, although 
reduced amplitudes and lower frequencies of sEPSCs were shown in the 1155del32 neurons. 
In addition to this, Farra and colleagues in 2012 reported reduced sodium and potassium 
currents and reduced amplitude of sEPSCs in neurons derived from miPSCs from a female 
heterozygous mouse that has a truncation at position threonine 308 (Farra et al., 2012). 
Finally, Li and colleagues in 2013 used TALENs to knock-out MeCP2 in hESCs, which they 
then differentiated into neurons and demonstrated a complete loss of all spontaneous 
electrical activity using multi-electrode array dishes (Li et al., 2013c). 
 
I was keen to assess the electrophysiological properties of LUHMES-derived neurons, with 
the hope of being able to establish a reproducible technique that could be used to assess the 
electrophysiological properties of WT and MeCP2 mutant LUHMES-derived neurons. 
Whole-cell voltage clamp recordings of LUHMES-derived neurons were previously 
published demonstrating that they are electrically responsive from day 3, and continue to 
increase their activity as they mature (Scholz et al., 2011). Furthermore, tests using 
tetrodotoxin and tetraethylammonium chloride have indicated functioning Na+ and K+ 
voltage-gated channels respectively (Scholz et al., 2011). Here, I collaborated with Dr Sean 
McKay (Prof Giles Hardingham’s lab, Centre for Integrative Physiology, Edinburgh, UK) to 




on 13-day old LUHMES-derived neurons and as can be seen in Figure 12A, neurons were 
responsive to current injections at this age. As expected, negative current injections (-20pA 
to -5pA) resulted in hyperpolarisation of neurons, while positive current injections (5pA to 
50pA) resulted in depolarisation of neurons. Perhaps if LUHMES cells were co-cultured 
with astrocytes a more robust electrical activity profile could be induced where the response 
of the neuron continues to spike over time (Johnson et al., 2007; Kuijlaars et al., 2016; 
Odawara et al., 2014; Tang et al., 2013). The response gained after only 13 days of 
differentiation is robust enough, that defects due to MeCP2 mutation could be investigated in 
future experiments. Unfortunately, due to time constraints, these experiments have not been 
performed as part of this study. 
 
To complement the patch-clamp recordings which focus on a single cell, I also performed 
calcium imaging experiments in order to assess the dynamics of the whole culture in 
response to KCl-induced depolarisation. Calcium imaging is a microscopy-based technique 
that assesses the calcium properties of a cell. For neurons, depolarisation results in the 
opening of voltage-gated calcium channels, thus allowing extracellular calcium to flood into 
the cell. This rise in intracellular calcium levels in the neuron triggers pathways that lead to 
the release of neurotransmitters from the cell, which will bind to receptors on neighbouring 
neurons and stimulate the depolarisation and formation of action potentials, thus propagating 
a signal. If the neurons are loaded with a dye that fluoresces upon binding to the calcium ion 
(Ca2+) then fluorescence microscopy can be used to read the network activity of a population 
of neurons. Alterations to calcium homeostasis have been reported in some MeCP2 mutant 
models. Neurons obtained from differentiating hiPSCs from patients with the 1155del32 
mutation show a decrease in spontaneous network activity as demonstrated by Fluo-4 
calcium imaging (Marchetto et al., 2010), and KCl-induced calcium transients in mouse 
brain slices evoked larger calcium amplitudes that decayed more slowly in MeCP2-null 
samples compared to WT (Mironov et al., 2009). Other than using calcium imaging to assess 
the neuronal properties of MeCP2 mutant LUHMES-derived neurons that will be generated 
in this study, I was also keen to assess the calcium properties of WT LUHMES-derived 
neurons as they differentiate and mature. 
 







Calcium imaging is not a technique that has been performed in our lab before and there were 
multiple parameters that needed to be tested to find an optimal protocol; for example calcium 
indicator of choice, cell loading parameters and imaging parameters. I tested two different 
calcium fluorophores: Fluo-4 (excitation at 488nm) and Rhod-3 (excitation at 550nm). 
PowerLoad and probenecid are two supplements that are provided with the Rhod-3 imaging 
kit; PowerLoad aids the solubilisation of the calcium indicators, while probenecid is an 
inhibitor of organic-anion transporters that can function to extrude the indicator from cells 
(Di Virgilio et al., 1990). In addition to testing the two different calcium indicators, I also 
tested these two supplements for improved imaging. 
 
Three different Rhod-3 concentrations were tested and increases in fluorescence were 
observed after KCl application. Unfortunately there was high background fluorescence as 
indicated by speckled dots across the coverslip (Figure 12B). I hypothesized that this 
background fluorescence could be due to Rhod-3 indicator that was inefficiently dissolved in 
the HBSS buffer. Unfortunately though, this background fluorescence could not be removed 
by overnight incubation of Rhod-3 in the HBSS buffer or by vortexing (Figure 12B). The 
presence of this large amount of background fluorescence would preclude any analysis of 
these cultures and thus Rhod-3 was exchanged for Fluo-4. Three different Fluo-4 
concentrations were loaded into WT LUHMES-derived neurons, all of which produced 
substantial increases in fluorescence upon KCl addition (Figure 13A, C and E). Addition of 
100X PowerLoad and probenecid to the loading buffer did not improve this detection further 
(Figure 13B, D and F). 
 
As strong fluorescence increases were observed with Fluo-4, I assessed the responsiveness of 
WT LUHMES-derived neurons to KCl during differentiation. Undifferentiated and 4-day old 
neurons were not responsive, but neurons that were 10 days old and above produced strong 
calcium transients ( 
Figure 14). As 3-day old neurons are reported to be electrically active as judged by patch 
clamp experiments (Scholz et al., 2011), it is possible that at this early age LUHMES-
derived neurons are electrically active and can produce action potentials, yet they do not 
express the complement of voltage-gated calcium channels required for calcium imaging 
experiments. Alternatively, the Fluo-4 indicator might not be loaded at a high enough 
concentration to detect small changes in calcium transients in these cells. Treatment of 4-day 
old neurons with a calcium ionophore (A-23187) to increase the permeability of the cellular 
membrane to divalent cations would allow Ca2+ to enter the neurons in the absence of 
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voltage-gated calcium channels. If fluorescence increases were observed, it could be 
concluded that 4-day old LUHMES neurons lack the required calcium channels. 
 
In order to perform quantitative calcium imaging, which would allow meaningful 
comparisons between mutant and WT samples in the future, I attempted to establish calcium 
calibration curves for 2 µM Fluo-4 in 21-day old WT LUHMES-derived neurons. This 
involved adding buffers containing different concentrations of Ca2+ to cells in the presence of 
the A-23187 calcium ionophore to allow the extra-cellular applied Ca2+ to enter the cell in 
the absence of KCl-induced depolarisation. As a result the amount of fluorescence from the 
Fluo-4 dye will be directly proportional to the amount of Ca2+ that was present in the extra-
cellular HBSS buffer. Initially, fluorescence increases were observed when using the 0 mM 
Ca2+ buffer (Figure 15A), suggesting that intracellular stores of calcium were being released 
by the calcium ionophore and were binding to Fluo-4. By first depleting all intracellular 
stores by incubation with 2 µl A-23187 in 400 µl 0 mM Ca2+ for 500 frames, and then adding 
the required calcium concentration buffer with A-23187, a gradient of fluorescence changes 
could then be obtained with increasing Ca2+ concentrations (Figure 15B+C). Quantification 
of this data for two replicates produced two different calcium calibration curves ( 
Figure 16). The first set of data produced a calibration curve ( 
Figure 16A), that in the log scale forms a straight line ( 
Figure 16B), with only one data point (0.5 mM Ca2+) deviating from the trend line. The 
image for this particular calcium concentration (Figure 15Biv) shows a lack of fluorescence 
thus explaining the deviation from the trend line. The lack of fluorescence could be due to 
improper focussing of the sample prior to imaging. The 2nd set of data does not form a linear 
trend line with increasing calcium concentration ( 
Figure 16D). In order to investigate the reason for the scattered data in this experiment, the 
resting fluorescence level of individual cells post intracellular store depletion was plotted ( 
Figure 16E). This showed that the resting fluorescence value was more variable among and 
between coverslips in the 2nd experiment compared to the 1st, and this probably accounts for 
the lack of a reliable calcium calibration curve. 
 
Unfortunately, due to time restraints, replicate calcium calibration curves were not generated 
and calcium imaging of WT and mutant neurons was not performed in this project. To 
conclude, calcium imaging has been optimised for use in LUHMES-derived neurons and it 




















This chapter has dealt with the characterisation of LUHMES cells and their derived neurons 
as a model system for studying MeCP2 and Rett syndrome. No hypothesis was being tested 
here, yet the insights gained in this chapter are very promising for the use of LUHMES cells 
as a neuronal tissue culture system and have laid the groundwork for the future use of this 
cell line by us and others. One drawback for many tissue culture cell lines is the fact that 
they are generated from cancerous tissue and therefore have an unstable and highly 
duplicated genome. This is the case for workhorse cell lines such as HeLa and Hek293T 
cells, however is also the case for some widely used neuronal cell lines such as SH-SY5Y 
(Krishna et al., 2014). The demonstration here that LUHMES cells have a normal karyotype 
is encouraging from multiple perspectives; not only does it make future genetic targeting 
experiments less complicated, it also establishes these cells as a realistic version of the in 
vivo neurons that they represent. In order to further assess the genomic integrity of LUHMES 
cells, SNP arrays to detect microdeletions and other genomic rearrangements could be 
performed (Nowak et al., 2009). In particular analysis of young passage number LUHMES 
cells (for example P8, which would correspond to the RNA FISH data) as well as old 
passage number LUHMES cells (for example P25) would give confidence in the genomic 
stability of the cells as they are kept in tissue culture. 
 
The generation of an efficient and reproducible transfection technique will prove to be vital 
for the genetic manipulation of LUHMES cells by CRISPR technologies. Furthermore, 
Nucleofected LUHMES cells are amenable to FACS sorting of single-cells into a 96-well 
plate two days post-Nucleofection and from here multiple clonal cell lines can be 
established. 
 
Finally, the demonstration that techniques such as calcium imaging and patch clamp 
experiments can be performed with LUHMES-derived neurons establishes that this cell line 
can be used to explore the electrophysiological aspects of mutant neurons. Such experiments 
would complement in vivo datasets in order to bridge the gap between disease-causing 












Since demonstrating efficient transfection and single-cell cloning of LUHMES cells, the next 
aim of this project was to genetically manipulate the endogenous MECP2 locus using 
CRISPR technologies, in order to create a panel of MECP2 mutant cell lines. The ability to 
knock-in (KI) RTT-causing mutations into the LUHMES cell line will generate useful 
models that can be studied for biochemical, transcriptional and neurological phenotypes. 
Such studies will help to gain insight into the function of MeCP2 in human neurons, and the 
molecular consequences that lead to Rett syndrome when this protein is mutated. 
 
Part of this work was published in Wellcome Open Research in November 2016 (specifically 
Chapter 4.3) and therefore I have gained permission from my supervisor, Prof Adrian Bird, 
as well as the co-authors to include the results from the paper as part of this thesis. There are, 
however, some experiments in the paper that I did not perform and therefore other author’s 
contributions are detailed in the appropriate figure legends throughout this chapter. 
 
In order to first trial sgRNAs and to confirm correct sgRNA design, I tested the CRISPR 
system in Hek293FT (human embryonic kidney) cells which are an easy to transfect cell line 
with high transfection efficiencies (~80%) (Lagger et al., 2017). Seven sgRNAs targeting 
exon 4 of the MECP2 locus, which lies on the X chromosome, were designed and 
individually cloned into a plasmid, pX330, that also expresses Cas9 (Figure 17A+B). 
Hek293FT cells were transfected and a T7 Endonuclease I (T7E1) assay was performed 








which confirmed correct targeting of all sgRNAs to the MECP2 locus (Figure 17C). 
LUHMES cells were then Nucleofected with the same plasmids, positively transfected cells 
were selected by an overnight puromycin selection (with resistance conferred by co-
transfection of a 2nd plasmid pAAV-PuroR), and genomic DNA was harvested 3-5 days post 
Nucleofection. The T7E1 assay was performed to asses for INDEL formation at the MECP2 
locus (Figure 17D), and genetic alterations were confirmed by sequencing of genomic DNA 
(Figure 17E). As can be seen, sgRNAs 1, 2, 5, 6 and 15 all induce INDEL formation in 
LUHMES cells with a good efficiency. On the other hand, sgRNA 3 does not appear to have 
induced INDEL formation at a high enough frequency for the T7E1 assay to reasonably 
detect (arrow in Figure 17D). The presence of the sgRNA 3 targeting sequence was 
confirmed in LUHMES cells by genomic DNA sequencing (Figure 17E), indicating that the 
low INDEL efficiency is not due to SNPs. These results indicate that sgRNA efficiency can 
vary quite dramatically between two alternative human cell lines (also reported in (Swiech et 
al., 2015)), and reinforces the conclusion that multiple sgRNAs should be designed for a 
single targeting experiment, and they should be tested for functionality in the cell line of 
interest. 
 
The advent of technologies that introduce targeted mutations into the genome has 
dramatically changed the way in which genetic diseases can be modelled and studied. The 
most recent development in the genome editing field, the clustered regularly interspaced 
short palindromic repeats (CRISPR) and CRISPR associated 9 (Cas9) system, has proven to 
be extremely successful, due in part to its ease of use and efficient implementation in a 
variety of cell lines (Cong et al., 2013; Jinek et al., 2013; Liang et al., 2015a) and model 
organisms (Friedland et al., 2013; Gratz et al., 2013; Hai et al., 2014; Hwang et al., 2013; 
Jiang et al., 2013b; Li et al., 2013b; Niu et al., 2014b; Wang et al., 2013a). The coupling of 
CRISPR gene editing technology with human induced pluripotent stem cells (iPSCs) has 
rapidly expanded the number of neurological disorders that can be modelled in a human 
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neuronal background and is allowing researchers to probe the underlying molecular 
mechanisms in unprecedented detail (Howden et al., 2016; Merkert & Martin, 2016; 
Mungenast et al., 2016). In particular, the ability to genetically modify a hiPSC line to create 
isogenic cell lines, which are genetically identical (bar the disease causing mutation), and 
differentiate these into neurons for phenotypic analysis is extremely powerful. However, 
despite advances in hiPSC culture and neuronal differentiation protocols, there are still some 
limitations to this strategy. One obstacle is the large variability of clonal iPS cell lines when 
they are derived, which can have negative downstream effects on CRISPR targeting 
efficiency, single cell cloning and particularly on phenotypic outcomes. Furthermore, there is 
still debate as to the robustness of the epigenome in iPSCs after reprogramming (Kim et al., 
2010; Ohi et al., 2011). 
 
Alternative human neuronal progenitor cell lines are available including the SH-SY5Y line 
and neural stem cells derived from fetal human brain or human embryonic stem cells. Yet 
each of these models has drawbacks. SH-5YSY cells are a neuroblastoma cell line with 
multiple chromosomal duplications and deletions (Krishna et al., 2014) and neural stem cells 
take a long time to mature during the differentiation process, expressing markers specific for 
neuronal progenitors for at least four weeks (Shin & Vemuri, 2010; Sun et al., 2008; Tong et 
al., 2016). The LUHMES neuronal progenitor cell line is a recent alternative that is proving 
to be highly useful in the neuroscience field (Lotharius et al., 2002). These female “pre-
neuronal” cells are forced to proliferate in an immature state by expression of the retroviral 
element v-myc (Hoshimaru et al., 1996). V-myc expression is under the control of 
tetracycline so by simple administration of the drug to cell culture medium, LUHMES cells 
undergo a rapid and robust differentiation into a homogeneous population of electrically 
active, post-mitotic, mature dopaminergic neurons in just 1 week (Lotharius et al., 2002). . 
The resulting neurons have thus far been used to model Parkinson’s disease (Lotharius et al., 
2005; Xiang et al., 2013), for cytotoxicity assays (Tong et al., 2016) and for technology 
development (Dinh et al., 2013; Hughes et al., 2014; Ilieva et al., 2013). 
 
In order to make this cell line more widely applicable for the neuroscience field, it would be 
beneficial to routinely genetically modify LUHMES cells to create a variety of cell lines for 
disease modelling and drug-screening purposes. Historically genetic manipulation via 
homology-directed repair (HDR) of somatic cells has been difficult, with the most successful 
approaches involving rAAV-delivered homology arms to produce targeting efficiencies of 




advent of CRISPR technologies, HDR targeting efficiencies in somatic cells has increased 
somewhat, although to different extents in different systems, for example 1.3% in primary 
neonatal fibroblasts (Lin et al., 2014), 1.8% in vivo by AAV delivery to mouse lung tissue 
(Platt et al., 2014) and 17% in T cells using Cas9 ribonucleoprotein complexes (Schumann et 
al., 2015). 
 
Here we describe a robust and reproducible method for the efficient transfection of 
LUHMES cells, and demonstrate various ways in which this cell line can be genetically 
manipulated using CRISPR engineering to create human models for the study of 
neurological disorders. 
 
Transfection of proliferating LUHMES cells using Nucleofection  
In this study we sought to edit the endogenous genome of the pre-neuronal somatic 
LUHMES cell line in three ways: i) by disrupting a target gene; ii) by introducing discrete 
mutations into the protein coding region; iii) by adding a relatively large protein tag to 
generate a fusion protein (Figure 18A). Karyotyping confirmed that LUHMES cells have a 
normal diploid chromosome complement (Supplementary Figure 3A) and RNA FISH 
demonstrated X inactivation to be established in the pre-neuronal cells prior to 
differentiation (Supplementary Figure 3B). As a first step in editing the genome, a 
reproducible method of plasmid transfection needed to be established for these cells. 
LUHMES cells have proven to be difficult to transfect (Schildknecht et al., 2013) and as a 
result previous studies relied on lentiviruses. In our hands transient transfection methods 
such as electroporation, Lipofectamine-2000, Neon transfection and JetPrime Polyplus all 
resulted in cell death or extremely low levels of transfection (unpublished report, RRS, JCW, 
AB). Nucleofection has previously proven to be successful, but only after differentiating the 
cells for 2 days prior to trypsinisation and Nucleofection (Schildknecht et al., 2013). For the 
generation of genetically modified cell lines, this protocol is undesirable as any transfected 
cells will be immediately differentiated into post-mitotic neurons, and no stock of 
proliferating, genetically modified cells remains. In order to optimise Nucleofection 
conditions in proliferating LUHMES neuronal progenitor cells, the Amaxa Basic 
Nucleofector Kit for primary neurons was used with 20 different Nucleofection programs to 
find the optimal balance between transfection efficiency and cell viability (Supplementary 
Figure 3C). Program D33 reproducibly yielded transfection efficiencies of 25-30%, as 
judged by the number of GFP-positive cells in the population (Figure 18B). Of note, 
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transfection of plasmids that have been prepared in an endotoxin-free environment resulted 
in increased cell viability, but purification of plasmids by ethanol precipitation did not 
improve this (Supplementary Figure 3E+F). In this way we achieved efficient and 





Generation of a MeCP2 knock-out cell line 
We next tested the ability of CRISPR/Cas9 to generate a knock-out LUHMES cell line. For 
this the MECP2 locus was chosen. The MeCP2 protein is highly expressed in neurons 
(Shahbazian et al., 2002a; Skene et al., 2010) and mutations within this protein lead to the 
autism-spectrum disorder Rett syndrome (Amir et al., 1999). Multiple mouse models of Rett 
syndrome have been developed, including mice containing Rett syndrome-causing point 
mutations (Brown et al., 2016) as well as knock-out alleles (Chen et al., 2001; Guy et al., 
2001). The MECP2 gene has four exons, with different isoforms being expressed from exons 
1 and 2. As exon 3 is the first shared exon among all isoforms, this was chosen for targeting 




(Figure 19A) and were individually cloned into a plasmid that also encodes Cas9 and a 
puromycin resistance gene (Figure 19B) (Sanjana et al., 2014). LUHMES cells were 
Nucleofected (Supplementary Figure 4A) and after selecting for positively transfected cells 
using puromycin resistance both sgRNAs were confirmed to be functional by the T7E1 assay 
(Figure 19C) and single-cell colonies were established by serial dilution in 96-well plates. 
The genomic DNA from single cell colonies was extracted and sequenced in order to 
identify potential positive KO clones. The genomic DNA sequencing from two different cell 
lines is shown in Figure 19D, KO1 has a homozygous deletion of 9bp whereas KO2 has a 
heterozygous deletion of 14bp, with the second allele being unaltered. As MECP2 resides on 
the X chromosome and LUHMES cells are female cells with one X chromosome already in 
the inactive state (Supplementary Figure 3B), the homozygous 9bp deletion in KO1 suggests 
that the inactive X chromosome can be edited by the CRISPR/Cas9 system. Overall, out of 
13 colonies that were sequenced, 11 contained INDELs thus giving a targeting efficiency of 
85%. 
 
To determine the genotype of the actively expressed MECP2 mRNA in these cell lines, 
cDNA sequencing was performed (Figure 19E). The 14bp deletion allele in KO2 appears to 
reside on the active X chromosome as all cDNA sequence reads from this cell line contained 
this out-of-frame deletion, highly indicative of a protein KO phenotype. Surprisingly the 9bp 
in-frame deletion in the middle of exon 3 of KO1 resulted in the whole of exon 3 being 
removed from the mature mRNA transcript, causing exons 2 and 4 to be spliced together in-
frame. Western blot analysis confirmed the complete absence of any full length MeCP2 
protein in both cell lines (Figure 19G). In order to identify clones that might contain 
truncated protein, Western blot analysis was performed using two different antibodies, one 
against the N-terminus of MeCP2 and another against the C-terminus, and this revealed that 
KO1 has very low levels of a truncated protein (Supplementary Figure 4B).  Even though 
this cell line cannot technically be referred to as a protein KO cell line, the extremely low 
MeCP2 protein level that remains (and the removal of critical residues via deletion of exon 
3) probably results in a cell line that is phenotypically null, as has been observed in mice 
(Chen et al., 2001). Finally, the top off-target loci for each sgRNA were sequenced for off-
target INDEL formation and as expected based on recent findings in hiPSCs (Paquet et al., 
2016), no off-target cutting was observed (Figure 19H). These experiments confirm Cas9-
induced INDEL formation to be successful, specific and highly efficient in LUHMES cells. 








Insertion of Rett syndrome-causing point mutations into MECP2  
We also explored the possibility of introducing specific point mutations into LUHMES cells, 
historically a more challenging procedure for somatic cells (Hendrie & Russell, 2005). The 
MECP2 locus is an ideal candidate for use in optimising CRISPR knock-in (KI) conditions 
as there are a number of disease-causing point mutations throughout the locus (Lyst & Bird, 
2015). Furthermore, the manipulation of this X-linked gene offers the opportunity to explore 
the ability of the CRISPR/Cas9 system to genetically manipulate genes on the inactive X 
chromosome. 
 
In the previous experiment serial dilution was used to generate single cell colonies but we 
found that this method led to low efficiency of cloning and some colonies were derived from 
more than one genetically modified cell line, as several expressed alleles were detected in 
cDNA sequencing (Supplementary Figure 4C). In order to improve clonal selection we used 
FACS sorting to cleanly isolate single cells into a 96-well plate. LUHMES cells were 
amenable to this manipulation, with approximately 50-60% of wells repopulating to produce 
single-cell colonies. 
 
First, the ability to knock-in the Rett syndrome-causing missense mutation of arginine at 
position 306 to cysteine (R306C) was tested (Figure 20A). The R306C mutation itself 
(CGCTGC) creates a novel target sequence for the restriction enzyme HpyCH4V (Figure 
20B). This allowed for easy screening of genomic DNA from single-cell clones using a 
restriction fragment length polymorphism assay (RFLP), with the positive clones from this 
assay being confirmed by sequencing. Initially, a plasmid targeting vector containing 2044bp 
of homology was used to deliver the R306C point mutation and a silent PAM-abolishing 
mutation to prevent re-cutting of a recombined allele. Out of 191 single cell clones that were 
screened using the HpyCH4V RFLP assay, 0 appeared to be positive (experiment 1 in Table 
10). Next a 110bp single-stranded oligodeoxynucleotide (ssODN) was used in combination 
with a non-complementary sgRNA that cuts 6bp away from R306, and in this instance 1 cell 
line out of 69 was positive, giving a KI efficiency of 1.6% (Figure 20A+C+D, experiment 2 
in Table 10). Again analysis of this cell line demonstrated no off-target cutting (Figure 20E). 
An alternative sgRNA:ssODN pair where sgRNA 2 cuts 31bp away from R306, but the 
sgRNA and ssODN were complementary to one another was also tested (Figure 21A). This 
combination produced two positive R306C cell lines (KI efficiency of 2.9%, experiment 3 in 
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Table 10), but both cell lines contained downstream deletions at the site of the double-strand 
break (DSB) (Figure 21B). These results suggest that a large distance between the point 
mutation and the DSB could be more susceptible to error-prone recombination and therefore 
subsequent INDEL formation. 
 
 
In an attempt to increase the efficiency of KI the CRISPR plasmid that encodes puromycin 
resistance was exchanged for a CRISPR plasmid that encodes for green fluorescent protein 









cells to puromycin selection and FACS sorting, these two steps were combined into one by 
using the presence of GFP in cells two days after Nucleofection to identify positively 
transfected cells and to sort them into a 96-well plate. Using this new strategy three new Rett 
syndrome-causing point mutations, R111G, R133C and T158M, were targeted using 
ssODNs (Supplementary Figure 5). Two of these three point mutations do not introduce a 
novel restriction enzyme target sequence and so one was engineered into the ssODN for ease 
of screening. Each 100bp ssODN contained point mutations to introduce the following 
motifs: the mutation of interest, a silent PAM abolishing mutation, and a silent mutation to 
insert a novel restriction enzyme target sequence (Supplementary Figure 5). All three 
targeting experiments generated positive cell lines as judged by genomic DNA sequencing 
(Figure 21D,E,F) and as can be seen in Table 10, the efficiency of KI for all three point 
mutations is significantly increased relative to the initial efficiency of 1.6%, reaching a 




















1 R306C Puro, 1.2 µg 1.9 µg 2 kb 
plasmid 
- 31 bp 1 0/191 0% 




6 bp 1 1/69 1.6% 
3 R306C GFP, 2.5 µg 8 µl 110 bp 
ssODN 2 
Comp 31 bp 1 2/69 2.9% 
4 R111G GFP, 2 µg 10 µl 100 bp 
ssODN 3 
Comp 3 bp 0 7/27 26% 
5 R133C GFP, 2 µg 10 µl 100 bp 
ssODN 4 
Comp 6 bp 2 2/54 3.7% 
6 T158M GFP, 2 µg 10 µl 100 bp 
ssODN 5 
Comp 4 bp 1 1/18 5.5% 
7 T158M GFP, 2 µg 10 µl 100 bp 
ssODN 5 





As shown in Table 10, several factors could contribute to the large variability in targeting 
efficiency. Firstly, the distance of the sgRNA-induced DSB from the point mutation of 
interest varies, and secondly the number of mismatched residues in the ssODN that are 
upstream of the DSB also varies. This latter variable would be in line with evidence that 
mismatches in the non-sgRNA binding DNA strand upstream of the PAM are refractory to 
homology-directed repair (HDR) (Richardson et al., 2016). Despite uncertainty regarding the 
exact constraints on efficient KI of point mutations using CRISPR technology, KI 
efficiencies in the somatic LUHMES neuronal progenitor cells are sufficient to allow the 
rapid generation of cell lines containing disease-causing point mutations with minimal clonal 
selection and screening. 
 
Insertion of a neurodevelopmental disorder-causing point mutation into EEF1A2 
To demonstrate the utility of LUHMES cells as a model system for other neurological 
disorders, and to confirm efficient KI at an autosomal locus, we targeted the D252H 
missense mutation in the EEF1A2 gene that causes severe neurodevelopmental delay and 
intellectual disability (Nakajima et al., 2015). The approach was to use two sgRNAs that cut 
51bp apart, combined with Cas9 nickase protein (Ran et al., 2013a) (Figure 21G) and a 
200bp ssODN. Again the presence of GFP expression in LUHMES cells was used to identify 
positively transfected cells and to sort single cells into 96-well plates. In this experiment a KI 
efficiency of 14% was achieved and interestingly the D252H positive cell line has a KI on 
both alleles and is therefore a homozygous, true positive cell line (Figure 21H). The 
successful knock-in of a point mutation into an autosomal locus and subsequent generation 
of an EEF1A2-D252H cell line demonstrates the ease of genetic manipulation of LUHMES 
cells and highlights its utility for modelling a variety of human neurogenetic disorders. 
 
Knock-in of a large tag into the endogenous MECP2 locus 
Finally, we assessed the ability of the CRISPR/Cas9 system to introduce a large tag into an 
endogenous locus in LUHMES cells. Again the MECP2 locus was targeted and a sgRNA 
that spans the stop codon was used, resulting in its targeting sequence being abolished once a 
successful KI has occurred (Figure 22A). We chose to KI mCherry and use FACS analysis to 
provide an accurate estimate of KI efficiency, i.e. the percentage of mCherry positive cells in 
the whole population. Due to the large size of mCherry (711bp), a plasmid donor was used 
for targeting with 2.3kb and 1.2kb homology arms (Figure 22A). FACS analysis determined 
the percentage of mCherry positive cells in the entire population to be 0.015% (Figure 22B). 
Out of 29 single-cell clones assessed, 25 were MECP2-mCherry positive as judged by a PCR  








assay that used a forward primer in mCherry itself and a reverse primer in the MECP2 gene 
locus, outwith the targeting vector (Figure 22C). Positive cell lines were confirmed by 
immunofluorescence and Western blot analysis (Figure 22D+E +Supplementary Figure 6), 
and two negative cell lines (as determined by PCR analysis) were confirmed by Western blot 
(Figure 22F, clones 22 + 27). These experiments demonstrate successful CRISPR-mediated 
KI of a large tag into LUHMES cells, thus highlighting the variety of genetic alterations that 
are feasible in this cell line. 
 
The LUHMES cell line is an immortalised neuronal cell line derived from an 8-week old 
female foetus that is highly proliferative in a stem-cell like, yet neuronal-committed state, 
and can differentiate into mature dopaminergic neurons via addition of tetracycline to the 
cell culture medium (Scholz et al., 2011). A key advantage of LUHMES cells compared to 
other neuronal differentiation systems is the near 100% homogeneity of differentiation into a 
population of mature, post-mitotic neurons, without the presence of astrocytes or other non-
neuronal cell types. This homogeneity is extremely beneficial for “bulk population” 
experiments such as RNA-sequencing, Western blot analysis and Hi-C studies where mixed 
cell populations could result in skewed data and difficult-to-interpret results. Here we 
describe methods for the successful genetic manipulation of LUHMES cells in order to 
create targeted protein knock-out, disease-causing point mutation knock-in, and large tag 
knock-in cell lines. 
 
The combination of targeted mutagenesis with rapid generation of mutant neuronal cells 
provides a potentially valuable tool for neuroscience. These manipulated cell lines may 
complement in vivo datasets as disease phenotypes obtained using mouse models can be 
coupled with electrophysiological and biochemical data from human neurons in order to 
bridge the gaps between disease causing mutations, neuronal malfunction and whole 
organism pathophysiology. The ease of high-throughput differentiation of this cell line in 96-
well plates opens the door towards drug screening programs like those already being pursued 
using hiPSCs (Cao et al., 2016; Lee et al., 2012). As a potential alternative, LUHMES cells 
simplify the differentiation procedure, speed up the differentiation time course, and ensure 
that a homogeneous population of mature neurons will be screened. Furthermore, although 
downstream applications of genetically modified LUHMES cells might be limited by their 
dopaminergic lineage, removal of supplements from the differentiation medium results in the 
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production of tyrosine hydroxylase-negative cells, that differentiate into morphologically and 
immunocytologically mature neurons for study (Scholz et al., 2011). 
 
Bi-allelic X chromosome targeting 
 
We observed that both alleles undergo HDR at a rather high frequency, regardless of whether 
the 2nd allele is on an autosome or the inactive X chromosome. For the MECP2-R111G 
targeting experiment, out of the seven cell lines that contained a KI of R111G on the active 
X allele, six also contained a KI on the inactive X allele. Likewise, for the MECP2-R133C 
targeting experiment, the two R133C positive cell lines had undergone HDR repair on both 
alleles. It is however important to note that not all HDR events result in a clean integration. 
Partial recombination within the short distance of a 100bp ssODN (Figure 23A+B) and 
multiple integrations of the ssODN in tandem at a locus have been observed (Figure 23E), as 









Surprisingly we found in more than one case that the MEPC2 allele on the inactive X 
chromosome underwent HDR, while the allele on the active X chromosome acquired an 
INDEL. It is expected that the active allele would be more open and accessible to 
recombination compared to the inactive X chromosome, however at least two cell lines were 
observed that have an active allele INDEL and an inactive allele KI (Figure 23C+D). These 
data reflect the large variety of genomic alterations that can be induced by CRISPR/Cas9 and 
demonstrate the somewhat unpredictable nature of HDR-mediated gene targeting. Our 
experiments stress the need for a sgRNA-induced DSB as close as possible to the desired 
genetic alteration and highlight the importance of donor molecule design; in particular use of 
a sgRNA-complementary ssODN that has minimal mismatches upstream of the PAM seems 
to be most efficient. 
 
Further optimisation of KI of large tags 
 
In the mCherry KI experiment the plentiCRISPR plasmid (Sanjana et al., 2014) was used to 
deliver Cas9 and sgRNA, and positively transfected cells were selected using the co-encoded 
puromycin resistance gene (Figure 19B), while the mCherry targeting vector was delivered 
as a separate plasmid. It is possible that a proportion of transfected cells did not take up both 
plasmids (Assur et al., 2012) and this could explain the low targeting efficiency of 0.015% 
observed in this experiment. As such, a double antibiotic selection method could increase 
HDR efficiencies when plasmid donors are necessary, for example by including an 
expression cassette for the bacterial blasticidin resistance gene (bsr) in the targeting plasmid 
and selecting with both puromycin and blasticidin. 
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Design of targeting vectors with alternative homology arm lengths could also improve the 
efficiency of KI. Indeed, others have reported comparable efficiencies with homology arms 
of 175bp compared to 700-900bp in human cell lines (Natsume et al., 2016) Alternatively, 
the use of drugs to inhibit the NHEJ pathway could also boost HDR in LUHMES cells 
(Maruyama et al., 2015; van Overbeek et al., 2016). Even without these enhancements, the 
power of FACS sorting allows efficient selection for the small number of positive cells 
within a large population and, as demonstrated here, this results in a stream-lined and 




In conclusion, we have demonstrated efficient genetic manipulation of the LUHMES female 
human neuronal cell line to create a number of lines harbouring neurological disease-causing 
point mutations ( 
Figure 24). The future phenotypic assessment of these cell lines will provide significant 
insight into the molecular mechanisms of these diseases. Using the methods described here 
LUHMES cells have the potential to be a valuable tool for exploration of the underlying 
biology of neurogenetic disorders and may pave the way for drug development and 
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Supplementary Figure 4B in Chapter 9.5 demonstrates that the insertion of INDELs into 
exon 3 of the MECP2 gene locus can result in the KO of MeCP2 protein from LUHMES 
cells. The other targeting experiments from Chapter 4.3 generated not only positive, point 
mutation-containing cell lines such as R306C and R111G, but also a variety of other cell 
lines containing INDELs of different sizes. There are two questions here: does the insertion 
of R306C or R111G point mutations have any effect on the stability of the MeCP2 protein, 
and to what extent do other INDELs in exons 3 and 4 result in KO or truncation of MeCP2 
protein? The latter question is useful because understanding the effects of random INDELs 
on MeCP2 protein stability will help to guide future experiments which aim to use CRISPR 
to fix particular RTT-causing mutations in MeCP2. 
 
Figure 25A shows cDNA sequencing from the R306C cell line (2_9) and four other cell lines 
that were generated from this targeting experiment (Table 11, experiment number 2). This 
experiment used a sgRNA that targeted the NID of MeCP2, which is encoded by exon 4. The 
effects of the 5bp insertion, 35bp deletion and 27bp insertion on the nucleotide sequence of 
MECP2 are schematically illustrated in Figure 25B, with the two out-of-frame INDELs 
resulting in an early stop codon after 11 or 15 nonsense residues, which would be predicted 
to produce a truncated protein. To assess what effect these INDELs have on the level of 
MeCP2 protein I performed a Western blot (Figure 25C+D). Panel C probes for the N-
terminus of MeCP2 and thus picks up C-terminally truncated proteins, which are not 
detected by the C-terminal antibody in panel D. As predicted, the 4_5 and 4_6 cell lines have 
truncated forms of MeCP2. These proteins run at the predicted ~38kDa mark for their 317 or 
321 amino acid size (Figure 25C). The properties that cause full-length WT MeCP2 protein 
to run at ~80kDa instead of its expected 53kDa size is not present in these C-terminally 
truncated proteins. Both cell lines have a reduced level of MeCP2 compared to WT neurons, 
yet it is surprising that 4_6 is more unstable than 4_5 when there is only a four amino acid 
difference in the size of these two proteins. Could the gain of four extra amino acids be 
enough to stabilise a truncated MeCP2? Perhaps more likely, the deletion of 35bp in the 
RNA species results in decreased levels of mRNA either through reduced transcription and 
processing of transcripts or due to inherent instability of the RNA species itself. The in-
frame insertion of 27bp in cell line 4_18 is predicted to produce a protein that has WT 
sequence until residue 304, with a large nonsense tail afterwards. This causes a complete KO 
of all MeCP2 protein in this cell line (Figure 25C+D). Finally, the 4_20 cell line has 




Figure 25C), yet cDNA sequencing from this cell line was WT (Figure 25A). In order to 
establish the precise mutation in this cell line that results in such an unstable, truncated 
protein, further sequencing of genomic DNA and cDNA should be performed. 
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To explore the effect of MBD-containing INDELs on MeCP2 protein level, clonal cell lines 
from targeting experiments 3 and 6 (
 
 
Table 11) were assessed by Western blot analysis. Each experiment used a sgRNA whose 
target sequence was within the MBD, but experiments 3 and 4 targeted exon 3 of MECP2 
and experiment 6 targeted exon 4 of MECP2. Cell lines 2_7 and 2_20, which were both 
generated from experiment 3, contain an 8bp and a 1bp insertion respectively (Figure 26A, 
Table 11). Both of these out-of-frame insertions are predicted to produce a truncated form of 
MeCP2 protein ( 
 
 
allele 1 allele 2
H4 (KO2) 14bp del WT 14bp del KO
D10 (KO1) 6bp del 6bp del Exon 3 removed KO
1. KO H5* 1bp ins 11bp ins or WT 1bp ins KO
sgRNA 16 or 17 C12 1bp ins or WT 7bp del or 6bp del 1bp ins + 7bp del Practically KO
(puro selection) F9 2bp ins 27bp del 2bp ins + 27bp del Reduced
C11 6bp del 7bp del WT or 7bp del Reduced
A11 WT Equal
2_9 R306C 3bp del R306C Equal
2. R306C 4_5* 5bp ins 5bp ins 5bp ins Truncated, equal
sgRNA 15 4_6 WT 35bp del 35bp del Truncated, reduced
ssODN 1 4_18* 27bp ins 27bp ins 27bp ins KO
(puro selection) 4_20* WT Truncated, v. low
2_7 3 bp del 8 bp ins 8 bp ins KO
2_13 R111G; no RE R111G; RE R111G ± RE Reduced
3. R111G 2_17 R111G; RE R111G; RE R111G ± RE Reduced
sgRNA K2 2_20 R111G; RE; 1 bp ins R111G; no RE R111G + 1bp ins KO
ssODN 4 2_21 R111G; RE; 2 bp sub R111G; no RE R111G ± RE Reduced
2_22 31bp ins R111G; no RE R111G Reduced
2_30 R111G; RE R111G; no RE R111G ± RE Reduced
2_31 R111G; RE R111G; no RE; 1bp ins R111G ± RE Reduced
4_23 7bp del 12 bp del
4. R133C 4_28 KO
sgRNA K4 4_37* 19bp del 19bp del
ssODN 5 4_40 No R133C; RE; mPAM 30bp del










1G10 R133C; RE; mPAM R133C; RE; mPAM; 1bp ins R133C; RE; mPAM
8. R133C 2E8 24bp del
sgRNA K4 2D8 GT to AGG
ssODN 5 2D5 2bp del
2E6 7bp ins
9. R306C 2D4 4bp del R306C; 18bp del R306C; 18bp del
sgRNA 5 2H9 1bp ins




4 R306C; mPAM; 6bp del R306C; mPAM; 6bp del
6bp del Reduced
5_20 T158M; mPAM WT DIED DIED




Figure 26A). On the other hand, cell line 6_48, which was produced from experiment 6, 
contains an in-frame, 6bp deletion which deletes Threonine 158 and Valine 159 (Figure 26B, 
 
 
Table 11). This should produce a protein lacking only two amino acids and therefore is 484 
amino acids long (Figure 26B). Threonine 158 is a critical residue for structural stability in 
allele 1 allele 2
H4 (KO2) 14bp del WT 14bp del KO
D10 (KO1) 6bp del 6bp del Exon 3 removed KO
1. KO H5* 1bp ins 11bp ins or WT 1bp ins KO
sgRNA 16 or 17 C12 1bp ins or WT 7bp del or 6bp del 1bp ins + 7bp del Practically KO
(puro selection) F9 2bp ins 27bp del 2bp ins + 27bp del Reduced
C11 6bp del 7bp del WT or 7bp del Reduced
A11 WT Equal
2_9 R306C 3bp del R306C Equal
2. R306C 4_5* 5bp ins 5bp ins 5bp ins Truncated, equal
sgRNA 15 4_6 WT 35bp del 35bp del Truncated, reduced
ssODN 1 4_18* 27bp ins 27bp ins 27bp ins KO
(puro selection) 4_20* WT Truncated, v. low
2_7 3 bp del 8 bp ins 8 bp ins KO
2_13 R111G; no RE R111G; RE R111G ± RE Reduced
3. R111G 2_17 R111G; RE R111G; RE R111G ± RE Reduced
sgRNA K2 2_20 R111G; RE; 1 bp ins R111G; no RE R111G + 1bp ins KO
ssODN 4 2_21 R111G; RE; 2 bp sub R111G; no RE R111G ± RE Reduced
2_22 31bp ins R111G; no RE R111G Reduced
2_30 R111G; RE R111G; no RE R111G ± RE Reduced
2_31 R111G; RE R111G; no RE; 1bp ins R111G ± RE Reduced
4_23 7bp del 12 bp del
4. R133C 4_28 KO
sgRNA K4 4_37* 19bp del 19bp del
ssODN 5 4_40 No R133C; RE; mPAM 30bp del










1G10 R133C; RE; mPAM R133C; RE; mPAM; 1bp ins R133C; RE; mPAM
8. R133C 2E8 24bp del
sgRNA K4 2D8 GT to AGG
ssODN 5 2D5 2bp del
2E6 7bp ins
9. R306C 2D4 4bp del R306C; 18bp del R306C; 18bp del
sgRNA 5 2H9 1bp ins




4 R306C; mPAM; 6bp del R306C; mPAM; 6bp del
6bp del Reduced
5_20 T158M; mPAM WT DIED DIED
6_48 6bp del T158M; mPAM
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the MBD (Ho et al., 2008), thus it would be expected that the loss of this residue has a 
dramatic effect on the stability of MeCP2. In line with this, a T158M mutant mouse line also 
exhibits decreased protein levels (Brown et al., 2016). Western blot analysis demonstrated 
that the two out of frame INDELs in exon 3 result in a complete KO of MeCP2 protein (2_7 
+ 2_20, Figure 26C+D+E), while cell line 6_48, as expected, has protein that runs at the 
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While I am cautious to draw too many conclusions from observational studies of a small 
number of clonal cell lines, the data suggests that an out-of-frame mutation in the MBD 
results in an early stop codon and a complete KO of protein (2_7, 2_20, KO2, H5) while an 
in-frame mutation is tolerated but results in decreased levels of protein, possibility due to 
instability of the protein itself (6_48). Whereas the opposite is true for mutations in the NID, 
where an out-of-frame mutation produces an early stop codon resulting in reduced levels of a 
truncated protein (4_5 and 4_6), while an in-frame mutation is not tolerated and results in a 
complete KO of protein (4_18). This conclusion is somewhat hypothetical and analysis of 
other LUHMES clonal cell lines described in 
 
 
Table 11 would be necessary to assess this. Larger-scale and more rigorous studies into the 
exact nature of INDEL consequences on MeCP2 protein stability would also be beneficial, 
allele 1 allele 2
H4 (KO2) 14bp del WT 14bp del KO
D10 (KO1) 6bp del 6bp del Exon 3 removed KO
1. KO H5* 1bp ins 11bp ins or WT 1bp ins KO
sgRNA 16 or 17 C12 1bp ins or WT 7bp del or 6bp del 1bp ins + 7bp del Practically KO
(puro selection) F9 2bp ins 27bp del 2bp ins + 27bp del Reduced
C11 6bp del 7bp del WT or 7bp del Reduced
A11 WT Equal
2_9 R306C 3bp del R306C Equal
2. R306C 4_5* 5bp ins 5bp ins 5bp ins Truncated, equal
sgRNA 15 4_6 WT 35bp del 35bp del Truncated, reduced
ssODN 1 4_18* 27bp ins 27bp ins 27bp ins KO
(puro selection) 4_20* WT Truncated, v. low
2_7 3 bp del 8 bp ins 8 bp ins KO
2_13 R111G; no RE R111G; RE R111G ± RE Reduced
3. R111G 2_17 R111G; RE R111G; RE R111G ± RE Reduced
sgRNA K2 2_20 R111G; RE; 1 bp ins R111G; no RE R111G + 1bp ins KO
ssODN 4 2_21 R111G; RE; 2 bp sub R111G; no RE R111G ± RE Reduced
2_22 31bp ins R111G; no RE R111G Reduced
2_30 R111G; RE R111G; no RE R111G ± RE Reduced
2_31 R111G; RE R111G; no RE; 1bp ins R111G ± RE Reduced
4_23 7bp del 12 bp del
4. R133C 4_28 KO
sgRNA K4 4_37* 19bp del 19bp del
ssODN 5 4_40 No R133C; RE; mPAM 30bp del










1G10 R133C; RE; mPAM R133C; RE; mPAM; 1bp ins R133C; RE; mPAM
8. R133C 2E8 24bp del
sgRNA K4 2D8 GT to AGG
ssODN 5 2D5 2bp del
2E6 7bp ins
9. R306C 2D4 4bp del R306C; 18bp del R306C; 18bp del
sgRNA 5 2H9 1bp ins




4 R306C; mPAM; 6bp del R306C; mPAM; 6bp del
6bp del Reduced
5_20 T158M; mPAM WT DIED DIED




especially if approaches using CRISPR technologies are to be explored as methods for 
correction of mutant MECP2 alleles in RTT. 
 
Turning now to the RTT missense mutation cell lines, the R306C point mutation in the NID 
of MeCP2 does not result in a destabilised protein (Figure 25C+D). This is as predicted 
based on a previous study which showed that an EGFP-tagged R306C KI mouse line has 
equal protein levels when compared to an EGFP-tagged WT KI mouse line (Brown et al., 
2016). On the other hand, the R111G point mutation results in reduced levels of MeCP2 
protein that can be observed after only 2 days of differentiation ( 
 
 
Figure 26C+D+E).  While the effect of R111G on methylated DNA binding is well 
established (Free et al., 2001; Nan et al., 2007), its effect on protein stability has not been 
thoroughly assessed. The only in vivo model of this point mutation consists of a transgenic 
mouse line in a null background where R111G-MeCP2 is tagged with EGFP. Unfortunately, 
the transgenic nature of the R111G-MECP2 allele means that allele copy number from 
multiple lentiviral integrations will impact the protein level in this mouse line (Heckman et 
al., 2014). In vitro assessments have found the R111G point mutation to affect the stability 
of the MBD (residues 77-167), although the results are somewhat contradictory. Two-
dimensional nuclear magnetic resonance (NMR) spectroscopy of the MBD of MeCP2 found 
local structural perturbations in the region of 110-120 upon mutation of arginine 111 to 
glycine, but concluded the MBD to have no gross structural changes that would impact 
stability (Free et al., 2001). On the other hand, urea-induced unfolding circular dichroism 
(CD) assays found the R111G MBD to have enhanced stability compared to WT MBD 
(Yang et al., 2016). Furthermore, in a single paper two alternative conclusions were made 
about MBD stability changes induced by R111G. In silico modelling approaches 
4. Efficient and versatile CRISPR engineering of human neurons in culture 
156 
 
hypothesised that R111G would significantly destabilise the MBD, while urea-induced 
denaturation CD experiments found a stabilising effect (Kucukkal et al., 2015). 
 
To conclude, the R306C point mutation in LUHMES-derived neurons, as predicted, does not 
alter the protein level of MeCP2. The assessment of the R111G point mutation here is the 
first experiment in vivo to look at the effect of this mutation on MeCP2 protein levels and 
found that R111G-MeCP2 cell lines have approximately 20-30% protein in human neurons. 
The effect of other variable insertion and deletion mutations on MeCP2 protein level seems 
to depend on the nature of the INDEL itself (in-frame vs out-of-frame) and on the location of 
the mutation within the MeCP2 molecule. 
 
Six different genetic modifications of the MECP2 locus have been generated in LUHMES 





Figure 27) over nine different targeting experiments. 
 
 
Table 11 outlines the genetic structure of all clones generated from these targeting 
experiments, in order to provide an easy-to-reference table. 
 
 
allele 1 allele 2
H4 (KO2) 14bp del WT 14bp del KO
D10 (KO1) 6bp del 6bp del Exon 3 removed KO
1. KO H5* 1bp ins 11bp ins or WT 1bp ins KO
sgRNA 16 or 17 C12 1bp ins or WT 7bp del or 6bp del 1bp ins + 7bp del Practically KO
(puro selection) F9 2bp ins 27bp del 2bp ins + 27bp del Reduced
C11 6bp del 7bp del WT or 7bp del Reduced
A11 WT Equal
2_9 R306C 3bp del R306C Equal
2. R306C 4_5* 5bp ins 5bp ins 5bp ins Truncated, equal
sgRNA 15 4_6 WT 35bp del 35bp del Truncated, reduced
ssODN 1 4_18* 27bp ins 27bp ins 27bp ins KO
(puro selection) 4_20* WT Truncated, v. low
2_7 3 bp del 8 bp ins 8 bp ins KO
2_13 R111G; no RE R111G; RE R111G ± RE Reduced
3. R111G 2_17 R111G; RE R111G; RE R111G ± RE Reduced
sgRNA K2 2_20 R111G; RE; 1 bp ins R111G; no RE R111G + 1bp ins KO
ssODN 4 2_21 R111G; RE; 2 bp sub R111G; no RE R111G ± RE Reduced
2_22 31bp ins R111G; no RE R111G Reduced
2_30 R111G; RE R111G; no RE R111G ± RE Reduced
2_31 R111G; RE R111G; no RE; 1bp ins R111G ± RE Reduced
4_23 7bp del 12 bp del
4. R133C 4_28 KO
sgRNA K4 4_37* 19bp del 19bp del
ssODN 5 4_40 No R133C; RE; mPAM 30bp del










1G10 R133C; RE; mPAM R133C; RE; mPAM; 1bp ins R133C; RE; mPAM
8. R133C 2E8 24bp del
sgRNA K4 2D8 GT to AGG
ssODN 5 2D5 2bp del
2E6 7bp ins
9. R306C 2D4 4bp del R306C; 18bp del R306C; 18bp del
sgRNA 5 2H9 1bp ins




4 R306C; mPAM; 6bp del R306C; mPAM; 6bp del
6bp del Reduced
5_20 T158M; mPAM WT DIED DIED
6_48 6bp del T158M; mPAM




allele 1 allele 2
H4 (KO2) 14bp del WT 14bp del KO
D10 (KO1) 6bp del 6bp del Exon 3 removed KO
1. KO H5* 1bp ins 11bp ins or WT 1bp ins KO
sgRNA 16 or 17 C12 1bp ins or WT 7bp del or 6bp del 1bp ins + 7bp del Practically KO
(puro selection) F9 2bp ins 27bp del 2bp ins + 27bp del Reduced
C11 6bp del 7bp del WT or 7bp del Reduced
A11 WT Equal
2_9 R306C 3bp del R306C Equal
2. R306C 4_5* 5bp ins 5bp ins 5bp ins Truncated, equal
sgRNA 15 4_6 WT 35bp del 35bp del Truncated, reduced
ssODN 1 4_18* 27bp ins 27bp ins 27bp ins KO
(puro selection) 4_20* WT Truncated, v. low
2_7 3 bp del 8 bp ins 8 bp ins KO
2_13 R111G; no RE R111G; RE R111G ± RE Reduced
3. R111G 2_17 R111G; RE R111G; RE R111G ± RE Reduced
sgRNA K2 2_20 R111G; RE; 1 bp ins R111G; no RE R111G + 1bp ins KO
ssODN 4 2_21 R111G; RE; 2 bp sub R111G; no RE R111G ± RE Reduced
2_22 31bp ins R111G; no RE R111G Reduced
2_30 R111G; RE R111G; no RE R111G ± RE Reduced
2_31 R111G; RE R111G; no RE; 1bp ins R111G ± RE Reduced
4_23 7bp del 12 bp del
4. R133C 4_28 KO
sgRNA K4 4_37* 19bp del 19bp del
ssODN 5 4_40 No R133C; RE; mPAM 30bp del










1G10 R133C; RE; mPAM R133C; RE; mPAM; 1bp ins R133C; RE; mPAM
8. R133C 2E8 24bp del
sgRNA K4 2D8 GT to AGG
ssODN 5 2D5 2bp del
2E6 7bp ins
9. R306C 2D4 4bp del R306C; 18bp del R306C; 18bp del
sgRNA 5 2H9 1bp ins




4 R306C; mPAM; 6bp del R306C; mPAM; 6bp del
6bp del Reduced
5_20 T158M; mPAM WT DIED DIED




This chapter has demonstrated the numerous ways in which LUHMES cells can be 
genetically manipulated in order to create novel cell lines. In particular, for this project, the 
MeCP2 KO, R306C KI and MeCP2-mCherry tagged cell lines will be studied in more detail. 
 
While preliminary CRISPR experiments were performed in Hek293FT cells, it became 
apparent that targeting efficiencies of a single sgRNA can vary between these cells and 
LUHMES, as has been observed for other cell lines (Swiech et al., 2015). The dissimilarities 
may be due to inherent differences in the ability of the sgRNA to function in the two cell 
lines, differences in chromatin states or differences in transfection techniques. As repair 
pathways may be active to different degrees in different cell types (Orii et al., 2006; 
Shrivastav et al., 2008; van Overbeek et al., 2016), it is perhaps not surprising that 
efficiencies can vary and emphasises the fact that CRISPR components should be tested in 
the cell line of interest. 
 
There has been much progress from many different angles towards making Cas9 genome 
editing more efficient and more precise. Adoption of some of these novel techniques in 
LUHMES cells will perhaps improve targeting efficiencies, something that would be 
particularly useful when an experimental design involves knocking in a large tag. As an 
alternative to transfecting a plasmid that contains the coding sequence for Cas9 and sgRNA, 
multiple laboratories have demonstrated high levels of INDEL formation and targeted 
editing by transfection of a pre-assembled Cas9/sgRNA ribonucleoprotein complex (RNP) 
into cells, as well as in vivo editing following injection into mice (Kim et al., 2014; Liang et 
al., 2015b; Liu et al., 2015; Wang et al., 2016; Zuris et al., 2015). Further to this, Cas9 RNPs 
seem to induce lower levels of off-target cutting compared to plasmid-expressed Cas9 and 
sgRNA, probably due to its more restricted period of expression (Kim et al., 2014; Liang et 
al., 2015b; Zuris et al., 2015). A combination of Cas9 RNPs with cell cycle inhibitors in 
order to synchronise cells to the same phase of the cell cycle has demonstrated that INDEL 
and HDR events can be improved (Lin et al., 2014). The specific cell cycle inhibitor that 
works for LUHMES cells would need to be trialled, as different cell cycle blocking agents 
worked to different degrees when comparing Hek293T cells, human fibroblasts and hESCs 
(Lin et al., 2014). Using this approach Lin et al managed to improve HDR efficiencies in 
human fibroblasts and hESCs from undetectable with plasmid transfection to 0.6%, 1.3% 
and 2% as judged by the T7E1 assay, but the increase in INDEL efficiency was only 
observed when lower amounts of Cas9 RNP was transfected (Lin et al., 2014). Considering 
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that high amounts of Cas9 RNP induced equal levels of INDEL formation with or without 
cell cycle arrest, and did not result in increased off-target mutagenesis, the use of RNPs 
alone in LUHMES cells may substantially increase editing efficiencies. 
 
As an alternative to transfection of plasmids or Cas9 RNPs, Cas9 has been tagged with a 
cell-penetrating peptide (CPP) to allow for direct delivery into cells, and CPP:sgRNA 
complexes have successfully delivered sgRNAs without the need for transfection techniques 
(Ramakrishna et al., 2014). It is important to note that the Cas9-CPP and sgRNA:CPP 
components were not complexed into a Cas9 RNP molecule prior to addition to cells, and 
perhaps this resulted in variable delivery of the two components into individual cells, as 
population analysis of INDEL efficiencies was fairly low in Hek293T cells (~6-20%). While 
editing efficiencies were low using this approach, the use of a CPP does allow for the 
manipulation of hard to transfect cells; although due to the successful transfection of 
LUHMES cells, perhaps CPPs will not improve efficiencies further. A more relevant 
approach for LUHMES cells would be to combine RNPs with AAV targeting vectors which 
have been shown to dramatically increase HDR editing rates (Gaj et al., 2017). Gaj and 
colleagues knocked in an EGFP-CMV-PuroR cassette into the nestin locus in rat C6 glioma 
cells (neuronal progenitors) using 1kb homology arms. They observed 0.2% EGFP positive 
cells when using plasmid delivered Cas9 and sgRNA with a plasmid donor molecule, but this 
increased to 3.7% when using RNPs and an AAV donor molecule. Thus, such an approach 
could be beneficial for targeted KI of cassettes into LUHMES cells in future targeting 
experiments. 
 
As an alternative to drugs that block cell cycle progression as described above, drugs that 
inhibit the NHEJ pathway have been shown to increase HDR rates. Use of Scr7 (a DNA 
Ligase IV inhibitor) in epithelial cells, melanoma cells, mouse dendritic cells and mouse 
zygotes increased the rate of HDR events 3-19 fold (Maruyama et al., 2015). While the use 
of NU7441 (a DNA-PK inhibitor) resulted in a shift of repair pathways from NHEJ to 
MMEJ in order to introduce large deletions in Hek293T cells (van Overbeek et al., 2016). 
Once the highest non-toxic concentration of Scr7 for LUMHES cells has been established, it 
would be easy to apply the drug immediately after Nucleofection in an attempt to shift the 
balance towards HDR and away from NHEJ in future targeting experiments. 
 
Finally, alternative design strategies for new projects might also help to improve targeting 




Chromosome) which utilises the MMEJ (microhomology-mediated end joining) pathway 
(Nakade et al., 2014), or the HITI method (homology independent targeted integration) 
which utilises the NHEJ pathway (Suzuki et al., 2016) are alternatives to HDR-mediated KI 
of cassettes. Due to the fact that homology-directed repair is not an efficient repair pathway 
in many types of cells, both PITCh and HITI utilise alternative, more efficient repair 
pathways (MMEJ and NHEJ respectively) in order to introduce locus-specific cassettes into 
cells. While HDR-dependent KI of GFP into the Tubb3 locus in mouse primary neuronal 
cultures was approximately 1%, HITI increased this to approximately ~50% by encouraging 
repair using the NHEJ pathway (Suzuki et al., 2016). Alternatively, HDR frequencies can be 
improved by intelligent design of the donor molecule. It has been found that having a ssODN 
that is complementary to the sgRNA and contains all of the mismatched residues 
downstream of the PAM is the most efficient design strategy for HDR-dependent KI 
(Richardson et al., 2016). The same lab has recently discovered that ssODN-mediated KI 
occurs via the Fanconi Anemia DNA repair pathway and does not require Rad51-mediated 
processes, thus implicating a variety of alternative proteins in the repair process (Richardson 
et al., 2017) (note, this is published on the bioRxiv preprint server). This knowledge will no 
doubt lead to drug strategies that target the Fanconi Anemia pathway in order to increase 
HDR-mediated gene targeting. 
 
In conclusion, CRISPR-based genome editing in LUHMES cells is efficient and using these 
techniques I have managed to create a variety of modified cell lines, the first example of 
gene editing in the human pre-neuronal LUHMES cell line. The experiments here have 
provided insights into the outcomes of CRISPR targeting experiments. For example, ssODN 
molecules are more efficient than plasmid donors for insertion of point mutations, sgRNA 
efficiencies can vary between two alternative human cell lines, and Cas9 can target the 
inactive X chromosome for both NHEJ and HDR repair. Furthermore, insights have been 
gained about the protein expression level of the R306C and R111G mutant MeCP2 
molecules, and progress towards understanding whether in-frame or out-of-frame mutations 
introduced at different points in MeCP2 will result in instability or complete protein KO 
have been gained. Future CRISPR work in LUHMES cells could be improved by utilising 
Cas9 RNP molecules, by altering the length of homology arms on plasmid donor molecules 
(or indeed removing them altogether as is the case for HITI) and by testing various inhibitors 












There were two purposes for generating the MeCP2-mCherry cell line; first to assess the 
efficiency of knocking in a large tag into LUHMES cells, and second to generate a 
fluorescently tagged MeCP2 cell line for functional studies. While the first of these two aims 
has been discussed in Chapter 4, the second will be discussed in this chapter. By tagging 
MeCP2 with a fluorescent protein, accurate and sensitive quantifications of MeCP2 protein 
level in LUHMES-derived neurons during differentiation could be assessed by flow 
cytometry analysis. Chapter 3.4 described the use of semi-quantitative Western blotting to 
calculate the molar amount of MeCP2 protein in LUHMES neurons compared to mouse 
whole brain. While Western blotting is an easy technique, it relies on efficient antibody 
detection of the antigen of interest, reliable loading controls (for example H3), and is not 
completely quantitative. Flow cytometry, on the other hand, can measure the amount of a 
fluorescently tagged protein directly, avoiding the use of antibodies, does not require a 
loading control, and is more sensitive than Western blot. As such, flow cytometry analysis of 
the MeCP2-mCherry LUHMES cell line is described in this chapter as a complimentary 
approach to Western blot analysis (Chapter 3.4). 
 
An alternative experiment that I was keen to perform was to use the mCherry tag as an 
efficient tool for enriching MeCP2 and its associated proteins from the nuclear lysate of 
LUHMES-derived neurons. Such a method would be validated by performing Western blots 
probing for TLB1X and HDAC3, known interaction partners of MeCP2, (Lyst et al., 2013), 
using the antibodies that have been validated to work with LUHMES cell extracts in this 
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project (Chapter 3.4.2). Upon validation of successful enrichment of MeCP2 and its known 
interaction partners, samples would be sent to mass spectrometry for sensitive and 
quantitative analysis. To answer relevant biological questions, comparisons between WT and 
mutant cells lines, such as R306C, should be performed. In particular, there would be at least 
two separate hypotheses for an experiment involving an R306C-mCherry tagged cell line. 
First, interactions with members of the NCoR/SMRT corepressor complex should be 
abolished or dramatically reduced in the R306C sample relative to the WT sample. Second, 
interactions in the WT sample that would be suggestive of a link between MeCP2 and RNA 
regulation (for example Eif4a3, Prpf19 and Snrnp70 which were identified in pull-downs 
using MeCP2-GFP from mouse brain, performed by Dr Robert Ekiert) would also be 
abolished in the R306C sample. While this experiment was out-with the scope of this 
project, assessment of the MeCP2 proteome in human neurons is an interesting and relevant 
question in order to comprehensively understand the function of MeCP2 in human neurons. 
 
To create an appropriate mCherry-expressing control cell line I generated lentiviruses 
expressing PGK-mCherry-WPRE using the pLLRSIN.cPPT.PRK.EGFP.WPRE plasmid 
(gift from Dr Michael Robson, Dr Eric Schirmer’s laboratory) and the pBSMe2NSmCherry 
plasmid (gift from Dr Jacky Guy). The WPRE element is the woodchuck hepatitis virus post-
transcriptional regulatory element that increases transgene expression (Higashimoto et al., 
2007). Flow cytometry analysis (Figure 28A) and Incucyte fluorescence imaging (Figure 
28B) confirmed the generation of LUHMES cells expressing mCherry protein ubiquitously 
throughout the cell. As can be seen in Figure 28B, mCherry fluorescence in the MeCP2-
mCherry-8 cell line is localised to nuclei, whereas mCherry fluorescence in the mCherry 
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I used the MeCP2-mCherry tagged cell line in order to sensitively and accurately quantify 
the levels of MeCP2 protein during LUHMES cell differentiation by flow cytometry. Cells 
were differentiated for 0, 2, 5, 9 and 13 days and, as expected, during differentiation and as 
LUHMES-derived neurons matured, the level of mcherry fluorescence increased indicating 
elevated MeCP2 protein levels (Figure 29). At day 9 of differentiation, a shoulder in the 
mCherry fluorescence peak was apparent, and by day 13 a 2nd peak in the mCherry 
fluorescence profile had emerged (Figure 29A). While the mean mCherry fluorescence level 
in the high mCherry peak continues to increase from day 9 to day 13 as expected (Figure 
29B, “high mcherry” row), the appearance of a 2nd population of cells at the latter stages of 
LUHMES neuronal maturation is surprising. 
 
In order to rule out the possibility that this effect is an artefact of a single clone, I repeated 
the experiment using a 2nd MeCP2-mCherry cell line (clone 8) and included the mCherry 
control cell line described in Chapter 5.2. Assessment of mCherry fluorescence levels in 
these cell lines at days 8, 11 and 14 of differentiation confirmed the presence of the 2nd 
mCherry-low population in MeCP2-mCherry cell lines (Figure 30A+B). This mCherry-low 
cell population is not apparent at day 8, the shoulder appears at day 9, a small but distinct 
population is formed by day 11, and the size of this mCherry-low population increases in 
abundance by days 13 and 14. The mCherry control cell line also contains two broad 
populations of fluorescence, but I do not feel that this negates the conclusion that there are 
two populations in the MeCP2-mCherry cell lines for a number of reasons. First, two 
populations of fluorescence are present in the mCherry control cell line before differentiation 
(Figure 28A), indicating that these populations are an intrinsic property of the control cell 
line. Second, these two populations are present at all stages of differentiation tested (Figure 
30A). This indicates that the mCherry high and low populations are not dependent on the 
maturation of LUHMES-derived neurons, whereas the high and low populations in the 
MeCP2-mCherry cell lines are dependent on maturation. Third, no clonal selection was 
performed on this control cell line, and thus the cell population contains a mix of cells that 
have different numbers of lentiviral genomes integrated and thus would contribute to a broad 














In order to rule out the possibility that the mCherry low cell population contained were dead 
or dying neurons that lost fluorescence over time, cells were incubated with the LIVE/DEAD 
Fixable Far-Red Dead Cell Stain (Life Technologies, L10120). This indicated that a portion 
of the low-mCherry cells in the control cell line are in fact dead or dying cells (Figure 30A, 
compare green and purple graphs). The mCherry low population in both MeCP2-mCherry 
cell lines, however, are not dead or dying cells that are auto-fluorescing, as incubation of the 
cells with the LIVE/DEAD Cell Stain established that this mCherry low population is part of 
the live cell population (Figure 29A + Figure 30A, compare purple graphs (all cells) to green 
graphs (live cells)). 
 
While neurons containing low levels of MeCP2 would not be detected by Western blot 
analysis, and my immunofluorescence images shown in Figure 4 of Chapter 3.2.2 cannot 
confirm the presence of an MeCP2-low population of neurons at day 12, the data presented 
here are indicative of a live cell population in LUHMES-derived neurons that express a 
decreased amount of MeCP2 protein. The level of fluorescence in the mCherry high 
population continues to increase during differentiation from an average fluorescence of 
14945 at day 5 to 23554 at day 13, indicative of increased expression of MeCP2 (Figure 
29B). The average fluorescence of the mCherry low population peaks at a level of 6192 at 
day 5, and then decreases to a value of 2466 at day 14 as differentiation progresses (Figure 
29B + Figure 30B). These values average out to create a fairly constant total mCherry 
fluorescence value of ~15000 on day 9 onwards (Figure 29B + Figure 30B), in agreement 
with the result in Figure 7B (Chapter 3.4.1) that the MeCP2 level in LUHMES derived 
neurons did not increase from day 9 to day 12 of differentiation. 
 
To conclude, MeCP2 expression increases during differentiation until day 9, after which the 
total MeCP2 amount appears to level out. This total MeCP2 amount is composed of two 
populations of cells; a low MeCP2 expressing population and a high MeCP2 expressing 
population. The high MeCP2 expressing population continues to increase the expression of 
MeCP2 throughout the entire differentiation process. The low MeCP2 expressing population 
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of cells appears as a separate population of cells at day 11 and while its MeCP2 expression 
level decreases as differentiation progresses, the number of cells in this population increases. 
 
While two MeCP2-mCherry clones have been assessed in detail with respect to MeCP2 
protein levels, 28 clones were generated from the targeting experiment. The following table 
summarises all of the genetic and protein information that has been collected for these clonal 
cell lines. While the WT PCR assay (primers 1+2) was not designed to amplify the WT allele 
alone (Supplementary Figure 9A), it became apparent that this PCR was unable to amplify 
the mCherry allele (Supplementary Figure 9B+C+D). The WT allele is smaller than the 
mCherry allele thus perhaps there is preferential amplification of this allele in the PCR 
reaction. Thus the PCR reactions are unable to determine if a cell line is heterozygous or 
homozygous for the MECP2-mCherry allele. Southern blot analysis (performed by Dr Jim 
Selfridge, see Chapter 5.5) can distinguish between homozygous and heterozygous clones. 
 
The discovery that MeCP2 expression towards the latter stages of LUHMES-derived neuron 
maturation splits into two peaks with different fluorescence levels is surprising. This effect is 
not likely to be an abnormal property of a single clone as two MeCP2-mCherry cell lines 
were assessed. It could be caused by the mCherry tag itself, and thus assessment of WT and 
MeCP2-mCherry neurons by flow cytometry analysis using an Alexa Fluor 647-conjugated, 
anti-MeCP2 antibody should be performed (Tillotson et al., under review; adapted for use in 
LUHMES cells by Laura Fitz-Patrick). The finding that MeCP2 expression is heterogeneous 
is not novel. Indeed, Balmer et al reported a broad peak of MeCP2 expression levels in 
cerebral cortex samples from adults who died of non-neuronal causes (Balmer et al., 2003). 
While there are a range of different cell types in the cerebral cortex of the adult human brain, 
the cortex was chosen for analysis due to its high proportion of neuronal cells. Furthermore, 
comparison of NeuN+ cell populations in the mouse brain (to identify neuronal cells) with 
MeCP2 expression by FACS analysis, also found a broad level of MeCP2 expression in the 
NeuN+ cell population (Skene et al., 2010). Thus the finding that the MeCP2 expression 
level splits as LUHMES-derived neurons mature could perhaps reflect the in vivo situation in 
the adult human brain. Alternatively, perhaps off-target integration of the mCherry targeting 
cassette in-frame into a locus that increases its transcriptional output as LUHMES-derived 














WT  CH 
Southern 
WT  CH    Oth 
Western SP5 Incucyte 
3 Y Y               
6 Y N   Y Y Y N Y Y       
7 Y Y         Y Y 8.8 Y Y Y 
8 Y Y Y Y       Y Y 8.8 Y Y Y 
9 Y Y Y Y       Y Y 8.8   Y 
10 Y Y Y Y       N N (2)   Y 
11 Y Y               
12 N Y     Y Y         
13 N N     Y Y Y N Y Y 8.8   Y 
14 N Y     Y Y         
15 Y N       Y Y+1 Y N 1 Y   
17 Y Y               
18   Y Y N N Δ N Δ N       
19   N Y N N Y N Y Y       
20     Y Y Y Y   Y Y 8.8   Y 
21 Y Y Y Y       Y N 1   Y 
22 Y N            N   
26 Δ N       Δ Y+1       
27 Y N       Y N    N   
33 N N     Y Y Y Y Y Y 8.8   Y 
34     N N Y Y Y Y       
35     Y Y Y Y         
38     N Y Y Y         
39 N N     N N N Y       
40 Y Y               
41 Y N     Y Y N Y       
44 Y Y               
46 Y Y               
 
A more probable explanation, however, is that it is a tissue culture artefact. More analysis 
into the nature of this mcherry low population of cells might be insightful; for example, by 
staining for NeuN, doublecortin and other markers of mature and immature neurons one 
could perhaps discover if there are any intrinsic properties of these cells that differentiate 
them from the mCherry high population. An MeCP2-mCherry mouse model has recently 
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been produced by Dr Jim Selfridge (personal communication). Direct comparison of NeuN+ 
cell populations from different brain regions from this mouse, with MeCP2-mCherry 
LUHMES-derived neurons at different stages of differentiation would be useful in providing 
an accurate, sensitive and direct (i.e. no antibodies) comparison of MeCP2 levels between 
these two systems. 
 
There are a number of potential uses for the MeCP2-mCherry cell line, for example as a 
screening cell line for therapeutics that reactivate the inactive MECP2 allele on the inactive 
X chromosome in human neurons. Briefly, such a project would require identification of 
heterozygous MeCP2-mCherry clones, targeting of the 2nd allele with an alternative 
fluorescent reporter such as GFP, application of drugs or CRISPR transcriptional activation 
molecules, and identification of double fluorescent (i.e. yellow) neurons. In order to assess 
which of my MeCP2-mCherry clones are heterozygous Dr Jim Selfridge performed Southern 
blot analysis probing for exon 4 of MECP2 (Supplementary Figure 7A). While a number of 
clones were heterozygous for MECP2-mCherry, in addition to the WT allele and the KI 
allele, a 3rd band was present in all cell lines that contained the MECP2-mCherry allele (6 
cell lines in total, Supplementary Figure 7B). There were two possibilities for what this 3rd 
band could be. WT AAV genomes are known to integrate into the AAVS1 locus on 
chromosome 19 in the human genome, thus perhaps the 3rd band indicated a single-copy 
integrated plasmid (Kotin et al., 1992; Kotin et al., 1990; Philpott et al., 2002; R.J.Samulski 
et al., 1991). Alternatively, the circular targeting plasmid could exist as an episome and be 
propagated through LUHMES cell division. AAV viruses have been reported to exist as 
episomes in mice, non-human primate and human tissues (Nakai et al., 2001; Penaud-Budloo 
et al., 2008; Schnepp et al., 2003; Schnepp et al., 2005). The fact that the 3rd band is of a 
strikingly similar size as the targeting vector, that the presence of the AAV rep protein (a 
DNA helicase) is required for locus-specific virus integration (Deyle & Russell, 2009; 
McCarty et al., 2004), and that the observed frequency of integration of rAAV genomes is 
approximately 0.1% (McCarty et al., 2004) suggests that the plasmid is more likely to exist 
as an episome. Yet, the single-copy nature of the 3rd band in all cell lines is suggestive of a 
single, integrated copy of the plasmid. In either case, integration and episomal forms have 
been reported for the single-stranded genome of rAAV viruses, but the ability of a double-
stranded plasmid that contains the AAV ITRs but has not been packaged into AAV 
molecules has not been reported before. 
In order to investigate this further, the Southern blot could be stripped and re-probed for 




mediated via the ITRs, and thus only the sequence contained within these elements (i.e. the 
MECP2 targeting cassette) should be integrated. Additionally, micrococcal nuclease 
digestion of chromatin prior to gel analysis using radiolabelled probes could be used to 
assess the chromatin status of the AAV plasmid (Penaud-Budloo et al., 2008). Finally, 
sequencing using primers along the length of the plasmid could be performed in order to 
retrieve a plasmid-DNA junction. If these experiments determine the 3rd band to be an 
integrated copy of the targeting plasmid, then it is exciting to know that highly efficient, site-
specific integration of a cassette can be achieved in LUHMES cells. It would be interesting 
to determine if this integration also occurred in cell lines that did not undergo correctly 
targeted KI. If this is indeed the case, future experiments using this pAAV targeting vector 
(with or without a Cas9 directed towards the AAVS1 locus) could be used for efficient 
integration of expression cassettes into LUHMES cells. 
 
Regardless of whether this 3rd band is indicative of an integrated or an episomal plasmid, it 
would be necessary to determine if the MeCP2-mCherry sequence is expressed, in addition 
to the correctly targeted MeCP2-mCherry KI allele. As the targeting cassette contains no 
mammalian promoters it would be unlikely for expression to occur. Personal communication 
with Dr Christina McClure (Prof Giles Hardingham’s laboratory, who kindly gave me the 
Gateway cloning-compatible pAAV vector) has revealed the presence of a putative promoter 
in the backbone of this plasmid. Analysis of the sequence following this putative promoter 
has revealed that a stop codon exists between the first ATG downstream of the promoter and 
the beginning of exon 3 of MECP2 thus suggesting that if any transcription were to occur, it 
would only produce a short, 102 bp transcript (Supplementary Figure 7C). In support of this 
hypothesis, Figure 22B in Chapter 4.3.2 shows that LUMHES cells that were transfected 
with the mCherry targeting plasmid alone do not exhibit any mCherry fluorescence as 
assessed by flow cytometry analysis. Furthermore, LUHMES cells that were transfected with 
an alternative pAAV plasmid which contains a PGK-puromycinR-WPRE cassette instead of 
the MECP2-mCherry targeting cassette, do not retain resistance to puromycin after 3 
passages, 1.5 weeks of culture and freeze-thawing ( 
Supplementary Figure 8). This suggests that the pAAV plasmid, whatever its state in 
LUHMES cells, is not expressed. In contrast to this, MeCP2-mCherry cell lines 10, 15 and 
21 which do not have a correctly targeted allele by Southern blot analysis (Supplementary 
Figure 7B), are mCherry positive by Incucyte or Western blot analysis (Table 12). This 
could suggest that the high molecular weight bands found in Southern blot analysis of these 
cell lines correspond to random integrated plasmid or episomal plasmid that is expressed. 
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Alternatively, these bands may represent correctly targeted MECP2-mCherry alleles that 
have undergone further genomic rearrangements to disrupt the BamH1 site that was used in 
the Southern blot analysis. Indeed, PCR analysis of cell line 15 produces a large product that 
could correspond to the ~7kb Southern blot band (Supplementary Figure 9D). A hypothetical 
genetic structure of this allele is schematically illustrated in Supplementary Figure 9D, which 
could explain the PCR and Southern blot band patterns as well as the positive MeCP2-
mCherry protein expression observed by Western blot (Figure 22E, Chapter 4.3.2). Similar 
genetic rearrangements may also occur in cell lines 10 and 21 to account for the positive 
mCherry expression but the lack of a clean MECP2-mCherry allele. 
 
Aside from being used to assess the MeCP2 proteome and potentially being used for an 
inactive MECP2 reactivation project, there are a number of other uses for the MeCP2-
mCherry cell line. One potential therapeutic angle for treating MeCP2 duplication syndrome 
would be to use CRISPR targeting in order to KO one MECP2 allele in each cell. While the 
MeCP2-mCherry cells are not a model system for studying MeCP2 duplication syndrome, 
the fluorescent reporter that the MECP2 allele provides would be a useful tool to assess the 
efficiency of targeted KO in a population of human neurons using virally-delivered CRISPR 
components. In line with this, if a stop codon was inserted into the MECP2 gene locus, drugs 
that allow read-through of the stop codon (and therefore cause an increase in mCherry 
fluorescence) could be screened for efficacy as therapeutics for Rett syndrome cases which 
are caused by nonsense mutations. If the mCherry targeting plasmid is found to exist in an 
episomal form, these cell lines could be used to directly compare CRISPR targeting 
efficiencies of plasmid and chromosomal DNA in the same cellular environment. 
 
In conclusion, I successfully managed to generate MeCP2-mcherry tagged cell lines, along 
with an appropriate mCherry-expressing control cell line. Analysis of these cell lines has 
revealed the surprising result that at the latter stages of LUHMES cell maturation, two 
populations of neurons exist that are separated based on their level of MeCP2 protein 
expression. Further flow cytometry analysis of WT neurons will need to be performed in 
order to confirm this. While the presence of an integrated or episomal vector in the MeCP2-
mCherry cell lines is possible, the lack of expression from this vector indicates that these cell 
lines will still be useful tools for future projects. Never-the-less future targeting experiments 
















In order to understand the cellular and molecular consequences of loss or mutation of 
MeCP2 on human neuron homeostasis, a number of assays were performed using the 
MeCP2 null and R306C LUHMES cell lines. These include morphological assessments such 
as of the ability of mutant neurons to differentiate into mature neurons, as well as 
transcriptional analysis of mutant cell lines by RNA-sequencing analysis. While a number of 
defects have been reported before for mouse and human mutant neurons, such as decreased 
nuclear volume and shorter and less complex neurites (see Supplementary Tables 1 - 4), 
these analyses have often been performed on neurons from adult mouse brain, or in tissue 
culture systems where neurons have been differentiated for a number of weeks. The data 
here will be the first time such assessments have been performed on young neurons that are 
only 9-days old, and even on neuronal precursors. As a result, the primary and secondary 
effects of MeCP2 loss or mutation on neuronal function may be detected. 
 
Throughout this chapter, six different cell lines will be referred to in experiments; WT, E10, 
F6, KO1, KO2 and R306C (Supplementary Figure 10A). WT denotes the pool of wild-type 
LUHMES cells from which I perform the targeting experiments. E10 and F6 are two clonal 
cell lines that have a WT genotype. E10 was derived from the same targeting experiment as 
the KO clones, and therefore experienced the Nucleofection, puromycin selection and single 
cell cloning procedures at the same time as the KO clones. E10 was referred to as WTC in 
Chapter 4.3. F6 was derived from single cell sorting of WT cells and therefore has not 
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experienced any Nucleofection or puromycin selection conditions. KO1 and KO2 are as 
described in Chapter 4.3.2 and Figure 19, both are CRISPR-targeted cell lines and while 
KO2 has a complete KO of MeCP2 protein, KO1 has a small amount of truncated MeCP2 
protein remaining (Supplementary Figure 4B). The genetic alteration of KO1 (removal of 
exon 3) is the same as a published MeCP2-null mouse model, which also appears to display 
low levels of a truncated protein by Western blot analysis and is phenotypically similar to 
true MeCP2-null mice (Chen et al., 2001). Thus cell line KO1 is referred to as a MeCP2 null 
cell line throughout this project. R306C refers to the cell line that contains the Rett 
syndrome-causing point mutation of arginine at position 306 to cysteine, which is described 
in Chapter 4.3.2. 
 
While normal neuronal differentiation is observed in mouse models (Chen et al., 2001; Guy 
et al., 2001; Moretti et al., 2006) and in most tissue culture neuronal differentiation models 
(Farra et al., 2012; Li et al., 2013c; Marchetto et al., 2010; Yazdani et al., 2012), one study 
found reduced levels of TuJ (βIII-tubulin) in neurons derived from RTT patient iPSCs 
indicating reduced neuronal differentiation potential (Kim et al., 2011). In order to assess the 
ability of MeCP2-null LUHMES neuronal precursors to differentiate into neurons, phase 
contrast images following the time course of differentiation were taken. There were no gross 
morphological alterations observed between two WT clones and two KO clones at day 0, 2, 
5 or 9 of differentiation (Figure 31A). In line with this, expression of neurofilament (NF) at 
day 9 of differentiation was unaltered between all four cell lines (Figure 31B). Staining for 
MeCP2 using a C-terminal antibody that recognises the truncated protein in KO1 confirms a 
complete KO of MeCP2 in KO2, and low levels of protein in KO1 (Figure 31B). Further 
immunofluorescence analysis of NeuN and MAP2 confirms efficient differentiation of 
MeCP2 KO neuronal precursors into mature neurons (Figure 32A), and analysis of DAT and 
TH confirms differentiation towards a dopaminergic lineage (Figure 32B). It is interesting to 
note how DAT and TH staining do not seem to co-localise in the same neurons (Figure 32B). 
While TH (tyrosine hydroxylase) is a cytoplasmic enzymatic protein in the dopamine 
synthesis pathway, and DAT (the dopamine transporter) is localised to the cellular 














expressed simultaneously in the same neurons (Liu et al., 2016). Further analysis of this 
observation should be performed using higher magnifications and alternative antibodies. 
Overall, these phase contrast and immunofluorescence analyses fail to detect any abnormal 
differentiation dynamics or a lack of differentiation potential in MECP2-null, human 
neuronal precursors. 
In order to assess in a more quantitative manner the ability of MeCP2 KO neuronal 
progenitors to differentiate into mature neurons, I performed RT-qPCR analysis on 22 
different loci at days 0, 2 and 9 of differentiation (Figure 33 + Figure 34). Overall there are 
no differences between WT and KO progenitors or neurons in the expression level of these 
mRNAs. Markers of proliferating progenitor cells decrease in all cell lines as differentiation 
progresses (Figure 33A) and markers of mature neurons (Figure 33B+C), synaptic proteins 
(Figure 34A) and dopaminergic neurons (Figure 34B) increase. There are some instances 
where KO2 has an alternative expression level of an mRNA compared to the other three cell 
lines, for example SOX2 on day 0, TUBB3 on day 2 and NEUROD1 on day 2. As KO1 has 
the same expression level as the two control cell lines, these dissimilarities are probably due 
to clonal differences rather than due to the KO of MeCP2. Nevertheless the decrease in 
TUBB3 mRNA might be worth analysing in further detail using more KO cell lines, due to 
the published report that the protein this mRNA produces (TuJ/βIII-tubulin) is reduced in 
RTT iPSC-derived neurons containing T158M and R306C MeCP2 (Kim et al., 2011). While 
there are no strong differences between WT and KO cell lines, there are some differences in 
mRNA expression level between the cloned cell lines (E10, KO1 and KO2) and the uncloned 
WT cells, suggesting that single cell isolation strategies alter the expression profile of 
LUHMES cells. Examples include NDNF, SEMA4D and SYN at day 9. Even though the 
LUHMES cell line is itself a sub-clone, perhaps the process of further cloning affects the 
expression level of certain genes in a subtle manner or perhaps there is heterogeneity in the 
population. These alterations, however, do not appear to affect the ability of the cells to 
differentiate into mature neurons. Overall, there are no striking differences between the 
expression level or expression dynamics of 22 mRNAs between WT and MeCP2 KO cells. 
 











Decreases in nuclear volume have been observed in a number of MeCP2 mutant model 
systems including RTT patient iPSCs differentiated into neurons and hippocampal slices 
from Mecp2-/y brain (Ananiev et al., 2011; Yazdani et al., 2012). Supplementary Table 3 
details these observations, which cover a range of nuclear size decreases from 5% to 33%. 
Most studies have measured nuclear size (µm2) using DAPI staining and conventional 
microscopy, but a recent array tomography approach used DAPI staining of ultra-thin brain 
slices to measure nuclear volume (µm3). This study found a 5% decrease in the average 
nuclear volume of hippocampal CA1, MeCP2 null neurons in female heterozygous Mecp2+/- 
mice (Linhoff et al., 2015). While this result was statistically significant, there was 
considerable spread in both the WT and null datasets, suggesting a trend towards smaller 
nuclear volumes in null neurons, rather than an absolute, defined decrease. 
 
In order to assess the nuclear volume of MeCP2 KO LUHMES-derived neurons I 
differentiated WT, E10, KO1 and KO2 cell lines to day 9 and fixed and stained the neurons 
with an antibody against laminB1 in order to label the periphery of live nuclei (Figure 35A). 
The use of laminB1, as opposed to DAPI, removes fragmented DAPI foci from the analysis 
and therefore removes the confounding effect of dead cells. Furthermore, laminB1 staining 
gives a sharper and more defined nuclear outline compared to DAPI staining (Figure 35A). 
Z-stack images were taken on a confocal microscope and stacks were analysed in ImagePro 
Premier for measurement of nuclear volume. This experiment was performed in triplicate 
and the cumulative data is shown in Figure 35B. The analysis shows that there is no nuclear 
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Perhaps the decrease in nuclear size that has been observed in other systems is a 
downstream, secondary effect of MeCP2 KO and therefore analysis of older LUHMES-
derived neurons may be worthwhile. Alternatively, assessment of neurons using the 
ChromATin technique might be sensitive enough to detect small alterations in nuclear 
volume (Linhoff et al., 2015). 
 
In addition to nuclear volume, there have been a number of studies that suggest altered 
morphology of neurites in MeCP2 mutant samples. Supplementary Table 4 details these 
observations, which include shorter neurites, decreased dendritic branching and decreased 
spine densities (Du et al., 2016; Li et al., 2013c). It is important to note, however, that not all 
studies have found defects in neuronal morphology. Pyramidal neurons from mice that 
contain a truncated MeCP2 do not display any altered apical or basal dendritic arborisation 
(Moretti et al., 2006). These mice do display motor abnormalities, social behaviour defects, 
and memory and learning deficits, suggesting that perhaps some of the phenotypes in RTT 
model mice are not caused by an underlying neuronal morphology defect (Moretti et al., 
2006; Shahbazian et al., 2002b). 
 
As LUHMES-derived neurons do not exhibit a complex neuronal architecture that can be 
assessed by Scholl analysis (Scholz et al., 2011), neurite length was examined. Neurons were 
differentiated in 96-well and 6-well TPP plates (Inherent scratches in Nunclon plates 
affected neurite analysis) and imaged every three hours in an IncuCyte machine in order to 
observe the growth of neurites during differentiation. The IncuCyte ZOOM software was 
then trained to distinguish neurites from cell bodies and debris using the NeuroTrack 
analysis software (Supplementary Figure 11), thus creating a processing definition called 
“All Older.” This processing definition was then assessed for the ability to distinguish 
neurites in two cell lines during four stages of differentiation (Supplementary Figure 12). 
While the software accurately determined neurites in the early stages of differentiation, as 
neurons matured and neurites clumped together, the software was unable to identify these 
clumps of neurites. Therefore, all analysis performed here was done during the first few days 
of differentiation. 
 
Assessment of neurite length in two MeCP2 KO and three control cell lines that were 
differentiated in 6-well plates revealed no difference in neurite length for any KO cell line 




for neurites grown in 96-well plates (Figure 37A+B+C). The morphology of MeCP2 KO 
neurons, and their matched control cell lines, is to be rather more densely packed such that 
cell body clumps and neurite aggregates form. This phenotype makes it difficult for the 
IncuCyte software to correctly distinguish a neurite from a cell body (Supplementary Figure 
12) and thus could contribute to the observed lack of neurite length phenotype in these cells. 
Perhaps, co-culture with astrocytes or glial cells will prevent neurite clumping, as has been 
previously reported (Kuijlaars et al., 2016), and thus re-analysis of MeCP2 KO cell lines 
under these conditions may be useful. 
 
While a neurite length phenotype is well reported for MeCP2 KO neurons (Supp Table 9.4), 
neurite defects in neurons that overexpress MeCP2, and thus are a model for MeCP2 
duplication syndrome, are less clear cut. A reduction in dendritic complexity has been 
observed in mouse hippocampal cultures transfected with Flag-tagged MeCP2 (Zhou et al., 
2006), and decreased dendrite length and dendritic arbour complexity has been observed 
upon hMeCP2 overexpression in the developing Xenopus (Marshak et al., 2012). On the 
other hand, overexpression of MeCP2 in transfected mouse cortical cultures resulted in 
increased length and complexity of both axonal and dendritic processes (Jugloff et al., 2005), 
and in vivo analysis in transgenic mice overexpressing hMeCP2 revealed an increased 
length, increased number of branch points and increased complexity of dendritic arbours 
(Jiang et al., 2013a). LUHMES-derived neurons that overexpress MeCP2 have been created 
by Dr Justyna Cholewa-Waclaw and thus I assessed the neurite length of these using the 
same protocol as for MeCP2 KO neurons. Overexpression of MeCP2 by ~4-fold and ~12-
fold were created by lentivirus infections of Synapsin promoter driven MECP2 and CMV 
promoter driven MECP2 constructs respectively. Details of the individual cell lines are 
described in Supplementary Figure 10. Analysis of these cell lines identified a consistent 
decrease in neurite length for all OE cell lines, compared to all control cell lines (Figure 
36C,D,E). A decrease in neurite length was observed at all stages of differentiation, and for 
three independent differentiations in 6-well plates (Figure 36C,D,E). These results were 
confirmed by analysis of differentiations in 96-well plates (Figure 37). 
 
To conclude, MeCP2 KO LUHMES-derived neurons do not have a neurite length 
phenotype, while MeCP2 OE LUHMES-derived neurons exhibit a consistent decrease in 
neurite length. 











Due to the ability of MeCP2 to bind to sites of methylated DNA both in vitro (Meehan et al., 
1992; Nan et al., 1993) and in vivo (Klose et al., 2005; Lewis et al., 1992)(Skene et al., 
2010), and to repress transcription in in vitro repression assays (Nan et al., 1997), it is 
thought that MeCP2 functions to repress transcription. Evidence in support of this view 
includes the list of transcriptional corepressors that MeCP2 has been shown to interact with, 
including Sin3a (Nan et al., 1998), ATRX (Nan et al., 2007) and NCoR/SMRT (Lyst et al., 
2013), and recent in vivo RNA-sequencing studies (Chen et al., 2015; Gabel et al., 2015; 
Lagger et al., 2017). As a result, there has been much emphasis to define the transcriptional 
profiles in MeCP2 mutant models in order to explain disease pathology. Initial experiments 
focussed on the identification of MeCP2 target loci, whose promoters MeCP2 binds to, and 
whose expression was altered in MeCP2 null samples. BDNF has been identified as a 
potential MeCP2-regulated gene; MeCP2 was shown to bind to the BDNF promoter, and 
BDNF expression was increased in MeCP2-/y cortical neurons (Chen et al., 2003; 
Martinowich et al., 2003). The observation, however, that BDNF and indeed other MeCP2-
regulated genes were not consistently misregulated in different transcriptome datasets led the 
field to move from a target gene-centric view of MeCP2 function, to a global view. Recent 
genome-wide RNA-sequencing experiments have found large numbers of misregulated 
genes in MeCP2 KO datasets, but the observation that genes are increased and decreased 
upon MeCP2 mutation or KO complicates the picture (Chen et al., 2015; Gabel et al., 2015; 
Lagger et al., 2017; Rube et al., 2016). Despite these common global transcriptional profiles 
there is still much debate as to whether MeCP2 activates or represses genes, and how it 
brings about these changes; binding to mCG + mCAC, binding to long genes, binding to 
regions of GC-rich unmethylated DNA. All of these studies have thus far focused on 
different regions of the mouse brain, thus analysis of a homogeneous population of human 
neurons might reveal a clearer mechanism for how MeCP2 regulates transcription. 
 
By measuring the amount of incorporated radiolabelled [32P]-UTP in isolated nuclei from 
MeCP2-/y mESCs differentiated into neurons, Yazdani and colleagues discovered that mutant 
neurons had approximately 40% of the transcriptional output of WT neurons (Yazdani et al., 
2012). This was the first assessment of total RNA levels in MeCP2 mutant neurons as all 
previous transcriptional analysis had focussed on steady-state measurements of mRNA by 




differentiated into neurons, where MeCP2 KO neurons had 27% and 47% less total RNA 
compared to isogenic controls at 2 weeks and 4 weeks of differentiation (Li et al., 2013c), 
and in olfactory neuroepithelium cells that had 25% less RNA (Rube et al., 2016). I therefore 
measured the total RNA in LUHMES-derived neurons using a highly accurate methodology. 
 
HPLC (high-performance liquid chromatography) has been used to measure the total amount 
of RNA in regions of the mouse brain by comparing the ratio of ribonucleosides to 
deoxyribonucleosides in WT and KO samples. Using this approach a ~13% decrease in total 
RNA in 6-week old Mecp2-/y hypothalamus, cortex and cerebellum compared to Mecp2+/y 
controls was found (Lagger et al., 2017) (also shown in Table 13). This technique involves 
the direct lysis of material in lysis buffer, a proteinase K treatment, and ethanol precipitation 
of total nucleic acid content from cells. The lack of column purifications during nucleic acid 
extraction reduces the chance of losing material. Furthermore, the simultaneous 
deoxyribonucleoside measurement provides an internal control for cell number and thus 
avoids the use of cell counting machines which have a margin of error. 
 
Using this technique, the total RNA content in MeCP2 KO, OE and R306C LUHMES cells 
was measured. The total RNA amount was found to be reduced in undifferentiated neuronal 
progenitors from KO and R306C samples (Figure 38A); a novel finding as RNA amounts 
have not been assessed in neuronal progenitors before. This defect remained throughout 
differentiation resulting in a decrease of approximately 9% in 9-day old LUHMES-derived 
neurons (Figure 38B, Table 13). On the other hand, there is no consistent defect in MeCP2 
OE cell lines, in the undifferentiated state or as neurons (Figure 38 C+D). Although in the 
undifferentiated state, the 12X OE cell lines have a statistically significant decrease in total 
RNA amount when compared to both controls, the 4X OE does not. This difference could be 
accounted for by the fact that the CMV promoter that drives the 12X OE is active in 
LUHMES progenitors, whereas the Synapsin promoter that drives the 4X OE is not. Analysis 
of MeCP2 protein level in the undifferentiated cells would be necessary to confirm whether 
overexpression of MeCP2 in neuronal progenitors causes the decrease of total RNA in the 
12X OE cell lines observed here. While overexpression of MeCP2 causes a small but 
statistically significant decrease in total RNA at day 9 when compared to clonal WT cell 
lines, there is no change when compared to the lentivirus infected control cell line (Figure 38 
XD). The variability in total RNA amount between the controls, in the undifferentiated state 
and in 9-day old neurons, affects the ability to draw a firm conclusion about the effect of 
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MeCP2 overexpression in LUHMES-derived neurons on total RNA levels and suggests that 
any effect of MeCP2 overexpression is small. 
 
As the LUHMES MeCP2 KO data was in agreement with the data from MeCP2 KO mouse 
brain regions (Table 13), I assessed if a decrease in total RNA could also be observed in 
R306C KI mice. Previous analysis of KO and OE mice was performed at 6-weeks of age 
(Lagger et al., 2017). R306C mice, however, are not particularly symptomatic at this age and 
thus analysis was performed at 11-weeks when they have a similar phenotype as the MeCP2-
null mice do at 6 weeks (Brown et al., 2016). Similar to previous HPLC analysis of mouse 
brain regions, WT cerebellum has a dramatically reduced level of RNA compared to the 
other WT brain regions (Figure 38E) (Lagger et al., 2017). Figure 38 shows that the R306C 
point mutation causes a decrease in total RNA in the hypothalamus and cortex of 11-week 
old mice, but no significant difference was observed in the cerebellum (Table 13). 
 
 
LUHMES d0 LUHMES d9 Hypothalamus Cortex Cerebellum 
KO 3.6% 8.8% 14.9% 12.0% 10.3% 
OE 9.3% 0.8% ↑ 3.7% 3.2% 3.5% 
R306C 4.7% 8.7% 12.6% 9.3% 12.0% 
 
The lack of a strong phenotype in MeCP2 OE mice and LUHMES-derived neurons could be 
due to the young age of analysis. Mice that overexpress MeCP2 have a mild phenotype at 6-
weeks of age, which progresses as the mice age (Collins et al., 2004). Thus analysis of OE 
samples at later stages of development might reveal more striking differences in total RNA 
levels. In addition, it may be interesting to analyse pre-symptomatic KO and R306C mice in 
order to assess whether decreases in RNA amount are a cause or consequence of the RTT-
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To conclude, the total level of RNA is decreased in MeCP2 null and MeCP2-R306C 
proliferating LUHMES progenitors and LUHMES-derived neurons, as well as in brain 
regions form 11-week old MeCP2-R306C mice. MeCP2 overexpression in LUHMES 
progenitors may also result in a decrease in total RNA; a decrease that does not remain in 
LUHMES-derived neurons. 
 
Most evidence points towards MeCP2 playing a role in the negative regulation of gene 
expression. There have been a large number of studies using RNA-sequencing or microarray 
techniques to assess the transcriptional changes that occur with MeCP2 mutation or deletion. 
As MeCP2 is known to bind to methylated cytosines, these gene expression changes are 
often related to the level of methylation within the gene, i.e. the number of MeCP2 binding 
sites within the gene. 
 
Dr Justyna Cholewa-Waclaw has produced bisulphite-sequencing, TAB-sequencing (Tet-
assisted bisulphite) and oxBS-sequencing datasets from WT LUHMES-derived neurons, 
allowing the entire methylome to be mapped. This analysis revealed that LUMHES-derived 
neurons contain very low amounts of mCA, and hydroxymethylation. All transcriptome data 
in this project was compared to densities of mCG as this modified dinucleotide sequence 
comprises ~93% of the total methylation in LUHMES-derived neurons. Methylation 
density/kb was analysed for each gene rather than methylation amount or methylation 
density, in order to normalise for the length of the gene. This method of analysis stems from 
the hypothesis that it is the density of methylated cytosines within a gene (i.e. the density of 
MeCP2 binding sites), rather than the number of methylated cytosines (i.e. the absolute 
number of MeCP2 binding sites) per gene that is important for MeCP2-mediated regulation 
of transcription (Figure 39). 
 
RNA-sequencing was performed in quadruplet for two KO cell lines (KO1 and KO2) and 
two wild-type cell lines (E10 and F6). Venn diagram analysis revealed 5629 significantly 
changing genes in the KO1 to control comparison, with 5068 significantly changing genes in 
the KO2 to control comparison (Figure 40A+B). Previous microarray analysis of Mecp2-null 
mouse cerebellum revealed 30% fewer misregulated genes when low levels of a truncated 
MeCP2 protein was expressed compared to complete KO of all protein (Jordan et al., 2007). 
This result led to the hypothesis that low levels of a truncated MeCP2 protein results in 





truncated protein (which lacks coding from exon 3) may retain partial MeCP2 functionality 
despite having lost half of its MBD (Jordan et al., 2007). The LUMHES data here 
contradicts this previous hypothesis as comparable numbers of genes are misregulated in 
KO1 (low levels of a truncated protein due to loss of coding from exon 3) and KO2 
(complete MeCP2 KO). The differences in the number of misregulated genes observed in the 
previous study could be due to differences in the strain background of the mice rather than a 
reflection of the functional relevance of a truncated MeCP2 protein (Jordan et al., 2007). 
 
Averaging the datasets for E10 and F6 control cell lines, and comparing this aggregate 
control dataset to each KO cell line reveals a total number of 3850 significantly misregulated 
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genes, a third of which are consistent between the two KO datasets (Figure 40C). In order to 
assess how these genes are changing and what properties might account for the 
misregulation, the log2fold-change between KO and WT was plotted against various 
parameters. First, genes were grouped into eight bins of equal size according to their 
promoter mCG density (Figure 40D). This analysis revealed no correlation between the 
direction or scale of a genes misregulation, and the methylation density of its promoter. 
Plotting instead against gene body mCG density revealed a strong correlation, with genes 
that contain more gene body methylation being more upregulated in the KO cell lines 
(Figure 40E). While there is a large spread of data in each of the bins, there is a shift of gene 
density from below the zero line to above it as mCG density increases, with the average 
log2FC for each bin (denoted by white dots) increasing in value with more gene body mCG 
density. Previous analysis of RNA-sequencing data from mouse identified a gene-length 
dependent effect on transcription in multiple brain regions whereby longer genes were more 
upregulated in KO tissues (Gabel et al., 2015). No gene-length dependent upregulation of 
genes was observed in the LUHMES dataset, and in fact it seemed that longer genes were 
actually downregulated in KO neurons (Figure 40F). Assessment of the methylation 
complement of these genes revealed that longer genes tend contain lower amounts of gene 
body mCG density/kb, and thus the apparent downregulation of genes is likely to be due to 
the effect of less methylation, rather than due to an intrinsic property of gene length (Figure 
40F). The discrepancy between the Gabel dataset and this studies dataset could be explained 
by the lack of mCA in LUHMES-derived neurons, as the long-gene effect is attributed more 
strongly to mCA than to mCG (Gabel et al., 2015). Another difference between the two 
studies is how the methylation analysis is performed. Here, the methylation density of a gene 
is plotted relative to its total length (mCpG density/kb in Figure 39), while in the Gabel study 
the methylation density was calculated by summing all methylated cytosine’s in the gene and 
dividing it by the total number of cytosine residues, with no scaling for gene length (mCpG 
density in Figure 39). This LUHMES project concludes that the denser the gene body 
methylation, the more upregulated a genes expression will be in the MeCP2 KO neurons. 
Recent re-analysis of the Gabel data, also came to the same conclusion when gene length 
was normalised for (Kinde et al., 2016).  Finally, analysis of all 13, 154 protein coding genes 
also revealed a correlation between the fold-change in expression of a gene and the level of 
gene body mCG density (Figure 40G). The presence of a gene-body methylation- dependent 
correlation with gene expression changes in the entire transcriptome dataset, that is 
strengthened when significantly changing genes are selected for, suggests a role for MeCP2 
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The precise mechanism that occurs downstream of MeCP2 binding to methylated DNA that 
contributes to gene repression is unknown. Recruitment of the HDAC-containing 
NCoR/SMRT corepressor complex throughout the gene body might alter the chromatin 
status of the gene in order to contribute to its repression. The deacetylation of histones by 
HDAC3 may then inhibit the progression of RNA polymerase (RNAP) through the gene. In 
addition, the occupation of methylated sites by direct binding of MeCP2 to mCG throughout 
the gene could itself hinder the progression of RNAP. Most likely, MeCP2 is exerting its 
effect on gene expression via a combination of these mechanisms. Patients with an R306C 
point mutation and Mecp2R306C/y mice have a less severe phenotype compared to other point 
mutations (Bebbington et al., 2008; Brown et al., 2016; Cuddapah et al., 2014). MeCP2-
R306C protein retains the ability to bind to sites of methylation within a gene body, but 
cannot recruit the NCoR/SMRT complex to these sites, perhaps resulting in an intermediate 
level of gene repression and a less severe Rett syndrome phenotype. 
 
In order to test this hypothesis I performed RNA-sequencing analysis of the MeCP2-R306C 
LUHMES cell line in quadruplicate, again using E10 and F6 cell lines as controls. Analysis 
revealed, only 27 genes to be significantly misregulated in R306C neurons when compared 
to both control cell lines (Figure 41A). This measure of significance (p-adj, p-adjusted value) 
takes into account the variability between the individual replicates when calculating 
significance and was used for the KO RNA-seq data analysis. When the less stringent p-
value measure of significance is used the number of significantly misregulated genes 
increases to 124 (Figure 41B). Assessment of the extent of gene misregulation for both sets 
of genes showed no gene-body mCG density-dependent effects (Figure 41C+D, purple 









As it is difficult to draw conclusions from such a small number of genes, the line plots were 
repeated to include all misregulated genes from each R306C vs control comparison (i.e the 
117 genes in R306C vs E10 and the 94 genes in R306C vs F6 comparisons when the p-adj 
value of significance is used). This analysis failed to reveal any gene-body mCG dependent 
misregulation (Figure 41E), even when the larger p-value dataset was used that contains 425 
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and 914 genes (Figure 41F). In order to understand whether the small numbers of 
misregulated genes in the R306C dataset are also misregulated in the KO datasets, Venn 
diagrams comparing the significantly changing genes were drawn. This analysis revealed 
some overlap, but the majority of genes in the R306C dataset were not altered in the KO 
dataset (Figure 41G + Supplementary Figure 13). Finally, the 1276 significantly changing 
genes that were identified in the KO dataset (Figure 40C) were plotted using the R306C 
log2FC values. Even though the vast majority of these genes are not significantly changing in 
the R306C dataset, perhaps they exhibit small shifts in expression which do not pass the test 
for statistical significance, but do demonstrate a mCpG-dependent effect. This analysis also 
revealed no correlation between gene expression change and gene body methylation (Figure 
41H). Overall, it would appear that R306C LUHMES-derived neurons have extremely minor 
gene expression changes upon mutation of MeCP2, which do not correlate with the gene-
body methylation density of the gene. The ability of R306C MeCP2 to still bind to sites of 
methylation throughout the genome suggests that perhaps MeCP2 exerts its repressive effect 
via physical binding and obstruction of RNA polymerase alone. 
 
While a strong and consistent decrease in RNA level is observed in both MeCP2 KO and 
R306C LUHMES-derived neurons, gene expression defects are observed only in the MeCP2 
KO cell lines. The extent of this gene misregulation appears to agree with a model whereby 
MeCP2 binds to methylated cytosines within the body of genes to contribute to their 
repression. Removal of MeCP2 from the gene body removes a block on the progression of 
RNA polymerase and thus causes an increase in the expression level of those genes. While 
the NCoR/SMRT complex is not implicated in this obstruction model of gene expression, the 
corepressor complex clearly has a role in the maintenance of RNA levels in neurons as 
R306C LUHMES-derived neurons and mouse brain regions have a loss of total RNA. Since 
the R306C point mutation causes Rett syndrome, this suggests that reduction of total RNA is 
a) independent of increased gene expression and b) extremely deleterious for brain function. 
It is unknown how the R306C point mutation can cause a decrease in total RNA but not have 
an effect on the transcriptome of protein coding genes. Perhaps, the loss of total RNA is 
predominantly due to a loss of rRNA, and the NCoR/SMRT complex can regulate the level 
of rRNA, but cannot affect the expression of MeCP2-bound protein-coding genes. Further 






The R306C mutation causes little to no transcriptional defects when introduced into 
endogenous MeCP2 in LUHMES-derived neurons. This is in contrast to previous analysis of 
Mecp2R306C/y mouse cerebellum where small changes in gene misregulation were observed 
(Gabel et al., 2015). In order to examine this in more detail, LUHMES cell lines were 
generated that overexpress mutant R306C MeCP2 on top of WT MeCP2. Based on the 
LUHMES R306C KI data, it would be expected that overexpression of R306C will result in 
a similar transcriptional profile to the overexpression of WT MeCP2. Alternatively, if 
R306C protein is truly non-functional its overexpression in LUHMES cells would result in a 
similar transcriptome to WT LUHMES cells. 
 
The positive control for this experiment is overexpression of WT MeCP2. The two negative 
controls are WT cells infected with a lentivirus containing no MeCP2 (OEC) and cells 
overexpressing of R111G, a protein that has reduced stability (this study, Figure 26), and 
reduced binding to methylated DNA (Heckman et al., 2014)and thus should not cause any 
methylation-dependent gene misregulation compared to WT cells. 
 
I made two batches of lentiviruses: virus 49 contained R306C-MECP2 and virus 50 
contained R111G-MECP2. After LUHMES cell infection and single-cell sorting, individual 
LUHMES clones were differentiated in 24-well plates, and probed for increased MeCP2 
expression compared to a WT cell line. All clones had increased expression of MeCP2 
compared to WT cells (Figure 42A), and two clones per virus infection were chosen for 
downstream analysis based on high and uniform MeCP2 expression. The mutant transgene 














RNA-sequencing of four cell lines was performed in triplicate: OEC and OE CMV C10 as 
described in Supplementary Figure 10B, and R111G OE B8 and R306C OE C8 as described 
in Chapter 6.5.1. Western blotting of all samples that were sent for RNA-sequencing is 
shown in Figure 43A. Quantification of this shows that the overexpression of R111G-
MeCP2 produces a total MeCP2 level of 6-fold WT level and is equivalent to the OE CMV 
C10 control (overexpression of WT MeCP2), while the overexpression of R306C reaches a 
total level of 9-fold (Figure 43B). 
 
Using Venn diagrams to visualise the number of genes that are misregulated in both R111G 
OE and R306C OE cell lines reveals large numbers of genes that are misexpressed in all 
comparisons (Figure 43C). When comparing R111G OE to OEC, 3930 genes are 
misexpressed, suggesting that the presence of 6-fold R111G MeCP2 protein on top of WT 
protein affects gene expression (Figure 43Ci). This misregulation, however, does not mean 
that the overexpressed R111G protein is functioning as WT protein. Indeed, comparison of 
R111G OE to WT OE (which contain the same amount of total MeCP2 protein, Figure 43B) 
reveals that 5607 genes are misregulated (Figure 43Cii). There are fewer misregulated genes 
in the R306C OE cell line than the R111G OE cell line, but the pattern is the same in that 
neither mutant OE cell line has a transcriptome similar to WT cells or to WT OE cells. This 
indicates that both R111G and R306C, when overexpressed, retain some functionality to 
induce transcriptional changes, but both have lost complete WT function. 
 
These large numbers of misregulated genes tell us that the overexpression of R111G and 
R306C affects the global transcriptional profile of neurons; but it does not tell us if this is 
mCpG-dependent and therefore whether the overexpressed protein is behaving in a manner 
that recapitulates WT MeCP2. In order to explore this, the log2FC between the mutant OE 
cell lines and the OEC control cell line were plotted in relation to gene body mCpG density 
(Figure 43D). This analysis revealed a minor relationship between gene-body mCpG density 
and log2FC for R111G OE, indicating that although 3930 genes are misexpressed, these are 
not misexpressed in a gene-body mCpG-dependent manner. The overexpression of R306C, 
on the other hand, has a relationship whereby the more gene-body mCpG density a gene has, 
the more repressed it is in the overexpression cell line. This suggests that the R306C protein, 
despite the mutation, retains some capabilities to act like WT protein and bring about gene 
repression in a methylation-dependent manner. This repression, however, is not as 
pronounced as when WT MeCP2 is overexpressed; which leads to 5448 misregulated genes  








(as opposed to 2237 for R306C OE) and displays a strong relationship with gene-body 
mCpG density (Figure 43D: compare y-axis scales in Figure 43D+E). Thus, despite being 
expressed to a higher level, R306C cannot repress genes to the same degree as WT protein. 
This can be shown by plotting the gene-body mCpG densities against log2 fold-changes 
between WT OE and R306C OE cell lines (Figure 43F). This graph demonstrates that the 
higher the gene-body mCpG density of a gene, the more expressed it will be in the R306C 
OE sample compared to the WT OE sample, i.e. genes with higher gene-body mCpG 
densities are more strongly repressed when WT protein is overexpressed than when R306C 
protein is overexpressed. The same is true for the overexpression of R111G protein (Figure 
43F). This suggests that neither mutant protein can function as WT and that both are 
impaired in their ability to repress gene expression in a gene-body mCpG dependent fashion. 
 
Thus the data supports a model where R306C protein is non-functional, and its 
overexpression in LUHMES-derived neurons does not induce significant methylation-
dependent gene expression changes. This is in line with published data demonstrating 
transcriptional defects in mice that express R306C as an endogenous locus KI (Gabel et al., 
2015), and the lack of a phenotype in mice that overexpress R306C protein (Heckman et al., 
2014). The data here, however, demonstrates that neither R111G or R306C are completely 
inert, non-functional proteins as their overexpression does cause large numbers of genes to 
be misexpressed compared to WT cells. Further analysis of these RNA-sequencing datasets 
will be required to determine if there are any common gene properties to these misexpressed 
genes. 
 
This chapter analysed the morphological and transcriptional phenotypes in MeCP2 KO and 
R306C LUMHES-derived neurons. The finding that LUHMES neuronal progenitors can 
differentiate into neurons as determined by immunocytochemistry and extensive RT-qPCR 
analysis confirms, in combination with published datasets, that RTT is not a 
neurodevelopmental disorder. Despite observations that neurons differentiated from RTT 
patient iPSCs display reduced TuJ staining (Kim et al., 2011), and that olfactory epithelium 
neurons have an apparent neuronal maturation defect (Gabriele V. Ronnett et al., 2003), girls 
who are born with RTT mutations can survive well into adulthood and despite significant 
neuronal malfunction, mature neurons do develop (Dawna Armstrong, 2005). A reduction in 
TuJ staining has not been observed in other systems (Ananiev et al., 2011; Caballero et al., 
2009; Yazdani et al., 2012), and the maturation defect in olfactory epithelial neurons was 
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observed in samples from RTT patients who had no detectable MeCP2 mutation, suggesting 
that this effect is a pathological outcome in patients, but not necessarily a primary 
consequence of MeCP2 mutation. This study found no decrease in the expression level of 
TuJ nor of MAP2, a microtubule-associated protein. This is in contrast to published reports 
of decreased mRNA (Colantuoni et al., 2001) and protein levels (Kaufmann et al., 2000) of 
this microtubule-stabilising protein in post-mortem brain samples from RTT patients. Mining 
of the LUHMES KO vs control RNA-sequencing dataset reveals a small but statistically 
significant reduction in MAP2 mRNA levels in one of the two KO cell lines (KO1 vs E10: 
log2FC 0.12, p-value 0.26, KO1 vs F6: log2FC 0.052, p-value 0.62, KO2 vs E10: log2FC -
0.25, p-value 0.016,  KO2 vs F6: log2FC -0.32, p-value 0.002). Nonetheless other tissue-
culture models report normal levels of MAP2 (Li et al., 2013c; Marchetto et al., 2010), thus 
reduced MAP2 levels are not a consistent defect observed in RTT models. Historically RTT 
has been considered a neurodevelopmental disorder, but the observation that symptoms can 
be reversed in a mouse model (Guy et al., 2007) and recent evidence from a variety of model 
systems that mature neurons can be differentiated from precursors suggests that RTT is not a 
disorder of neuronal development. The analysis performed in LUHMES cells in this study 
further confirms the lack of a differentiation defect and establishes normal developmental 
dynamics by analysis of 22 markers by RT-qPCR. 
 
While MeCP2 mutant cells are reported to differentiate into mature neurons, the neurons 
seem to exhibit a vast array of morphological defects including reduced nuclear size and 
decreased neurite length (Supplementary Table 3 and  
Supplementary Table 4). Smaller neurons, shorter neurites and reduced dendritic complexity 
have also been observed in post-mortem brain samples from patients with Rett syndrome 
(Dawna Armstrong, 2005; Dawna Armstrong et al., 1995). The finding here that MeCP2 KO 
neurons do not have shorter neurons or smaller nuclei could reflect the young age of neurons 
that were assessed. Analysis of older neurons may reveal a deficit in neurite length; however 
the technique should be altered so that the Incucyte software is able to detect individual 
neurites within the thick mesh of neuronal projections. To do this, LUHMES cells could be 
infected at a very low multiplicity of infection (MOI) with a lentivirus expressing GFP, such 
that only a few neurons in a single field of view are GFP-positive (Scholz et al., 2011). This 
would enable the Incucyte software to detect individual neurons and calculate the neurite 
length of GFP-positive neurons in an accurate manner. Similarly, analysis of the nuclear 
volume of older LUHMES-derived neurons using a more sophisticated approach such as 




The finding here, that gross morphological changes are not apparent, whereas strong and 
robust transcriptional changes can be detected suggests that the morphological changes that 
are frequently observed in mutant neurons are a downstream effect of global transcriptional 
changes. Assessment of young neurons (only 9 days after differentiation was initiated) has 
enabled the primary transcriptional consequences of MeCP2 mutation in human neurons to 
be analysed. RNA-sequencing analysis at this stage has not revealed the presence of a small 
number of MeCP2 target genes, but rather that large numbers of genes are mis-expressed 
upon MeCP2 deletion. While it may seem obvious to state that transcriptional changes when 
we delete a methylated DNA-binding protein are upstream of morphological changes, this 
data has implications for therapeutic strategies for RTT. While nonselective drugs such as 
ketamine that affect a wide variety of neurological pathways are being trialled for 
amelioration of RTT symptoms (Katz et al., 2016), the fact that many tested drugs so far 
have fallen below the expected efficacy standard (for example mecasermin/IGF-1 (Khwaja et 
al., 2014)) suggests that the broad transcriptional changes (and resulting neurological 
phenotypes) are too varied for a single drug that targets an individual pathway to provide 
significant levels of benefit (Kaufmann et al., 2016). 
 
The analysis here found that gene body methylation, rather than promoter methylation, is the 
primary modification through which MeCP2 exerts its repressive effect on transcription, in 
agreement with previous reports in mice (Kinde et al., 2016). While the role of promoter 
methylation is well established, the role of gene body methylation is not so clear (Jones, 
2012; Moore et al., 2013). Gene body methylation has been associated with H3K36me3 and 
actively transcribed genes (Baubec et al., 2015), suppression of alternative tissue-specific 
intragenic promoters (Maunakea et al., 2010), and with gene repression during neuronal 
development (Lister et al., 2013). Precisely how MeCP2 is exerting its effect on transcription 
via binding throughout gene bodies is unknown, but may occur via modulation of the 
initiation and/or elongation of RNA polymerase (RNAP). 
 
There have been few analyses of the dynamics of RNAP progression in MeCP2 mutant 
samples. A recent study found the total level of Pol II Serine5-phosphorylation to be 
decreased Mecp2-null neurons in brain slices of MeCP2+/- heterozygous female mice, which 
could indicate decreased rates of Pol II initiation and therefore explain the global decrease in 
RNA amount observed in this study (Linhoff et al., 2015). However the total amount of Pol 
II in the WT and mutant samples were not measured using the same sensitive technique, and 
thus it cannot be ruled out that total RNAP levels are decreased in mutant samples and 
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therefore all RNAP modifications are reduced (Linhoff et al., 2015). An alternative study 
found increased Pol II binding by ChIP-qPCR at promoters of immediate-early genes that 
display increased in expression in Mecp2T308 mice (Su et al., 2012). This study saw an 
increased level of Ser2-phos and Ser5-phos to the same degree thus suggesting, at least at 
these two immediate-early response genes, MeCP2 modulates the ability of Pol II to bind to 
promoters, not just the elongation rate of bound Pol II. Analysis of Pol II modification status 
in LUHMES cells combined with histone modification analysis may elucidate the 
mechanism through which MeCP2 affects transcription. In particular, H3K36me3 and RNAP 
II Ser2-phos levels would assess the efficiency of polymerase progression through the gene 
body, while RNAP II Thr4-phos levels will determine if transcripts are efficiently terminated 
in the absence of MeCP2 (Schlackow et al., 2017). Combining Pol II and histone 
modification levels with studies assessing the rate of nascent transcription will be critical to 
deciphering the mechanism of gene-body, MeCP2-mediated transcriptional repression. 
 
In addition to such endogenous studies of the transcriptional and chromatin landscape in 
LUHMES-derived neurons, more artificial studies could help to elucidate the importance of 
gene-body MeCP2 binding on transcription. For example, MeCP2 could be tethered to sites 
throughout the body of endogenous genes in WT cells (perhaps by Cas9-recruitment), and 
the transcriptional output of this locus measured by RT-qPCR analysis. By performing this 
experiment on loci that have different endogenous transcriptional outputs (e.g. highly 
expressed vs lowly expressed genes), different endogenous methylation profiles, and that are 
located within alternative chromatin environments, the ability of MeCP2 to repress 
transcription and how the local chromatin environment affects this repression can be 
assessed in the endogenous environment of human neuronal cells. In addition, the 
combination of MeCP2 tethering assays with HDAC inhibitor application (such as 
trichostatin A) would determine the importance of histone deacetylation activity for the 
repression of endogenous genes in their endogenous chromatin environments. This analysis 
could be performed in LUHMES-derived neurons or even in LUHMES neuronal precursors 
as MeCP2 is expressed and total RNA defects have been observed at this early stage. If such 
experiments were successful, the contribution of RTT mutations (such as R306C) to this 
repression could then be assessed. 
 
The finding that in LUHMES cells, deletion of MeCP2, insertion of the R306C point 
mutation, or overexpression of MeCP2 by 12-fold results in a decrease of RNA in 




during hESC differentiation found no change in RNA amount at the neural precursor stage, 
and only saw a decrease in neurons that were 2-weeks and 4-weeks old (Li et al., 2013c). 
Most transcriptional studies are performed on mature neurons, either from mouse brain or 
tissue culture differentiation systems, but the finding that RNA levels are affected even at the 
precursor stage suggests that transcriptional studies should be assessed at this early stage as 
well. If transcriptional misregulation is not observed in LUHMES precursors then the 
decrease in RNA amount cannot be explained by secondary effects of MeCP2 loss of 
function and experiments to determine the mechanism leading to the loss of RNA will be 
vital. 
 
The observation that total RNA is reduced in both MeCP2 KO and R306C LUMHES-
derived neurons is somewhat contradictory for a protein that is hypothesised to repress 
transcription. Nevertheless this observation agrees with data from MeCP2-null human (Li et 
al., 2013c) and mouse (Yazdani et al., 2012) ESC-derived neurons as well as in vivo in 
olfactory neuroepithelium (Rube et al., 2016), suggesting it may play an important role in 
RTT pathology. The majority of RNA is composed of ribosomal RNA (rRNA), and thus 
perhaps the discordance between the apparent repressive effect of MeCP2 by RNA-seq 
analysis and the apparent activation effect as judged by HPLC could explained by effects on 
different RNA populations. In order to assess the contribution of rRNA and mRNA to the 
decrease in total RNA levels, rRNA and pre-rRNA levels could be assessed by Northern blot 
or qPCR analysis. Levels of the 5.8S and 5S rRNAs were found to be decreased in neurons 
differentiated from hESCs indicating a strong reduction in rRNA, but not ruling out a similar 
reduction in mRNA (Li et al., 2013c). In line with this data, significantly smaller nucleoli 
(the sites of rRNA transcription) have been observed in tissue cores from MeCP2-/y brain and 
in cultured cortical neurons suggesting reduced transcription of rRNA (Singleton et al., 
2011). Analysis of the number and size of nucleoli in LUHMES-derived mutant neurons, for 
example by staining for Ki67, nucleolin or using the CytoPainter Nucleolar/Nuclear staining 
kit from Abcam, may contribute towards a greater understanding. 
 
A potential hypothesis for how MeCP2 loss results in decreased RNA levels could involve 
MeCP2 playing a role in the repression of spurious transcription throughout gene bodies. 
MeCP2 bound to gene body methylation could inhibit RNA polymerase initiation at these 
sites, but allow the elongation of existing polymerase molecules through the gene, a 
proposed mechanism for the purpose for gene body methylation (Jones, 2012). The removal 
of MeCP2 would result in increased spurious transcription throughout the gene body, which 
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could result in inefficient transcription of the full-length transcript and thus decreased levels 
of the intended transcript ( 
Figure 44). Experiments to test this hypothesis would involve analysis of RNAP II by ChIP-
seq and assessments of its modification status by mNET-seq, in particular paying attention to 
the Ser5-phos, Ser2-phos and Thr4-phos modifications which mark the transcription 
initiation, elongation and termination sites of genes (Heidemann et al., 2013; Nojima et al., 
2015; Schlackow et al., 2017). Techniques to analyse nascent RNA transcription, such as 
4sU-seq (Cleary et al., 2005), Gro-seq (Core et al., 2008) and TT-seq (Schwalb et al., 2016) 
will be useful for analysing RNAP progression through genes and directly assessing sites of 
spurious transcription. This could be combined with inhibition of the exosome complex to 
increase the chance of observing spurious transcription and transient RNA molecules. 
Alternatively, the total RNA decrease could simply be a secondary effect, caused by more 
fundamental transcriptional changes that lead to smaller cells and subsequent decreased 
transcriptional outputs (Padovan-Merhar et al., 2015). While it is incongruous to associate a 
transcriptional repressor protein with maintenance of high RNA levels, further experiments 
to determine the mechanistic cause of this phenotype will be necessary to determine primary 






This study found that 9-fold overexpression of R306C-MeCP2 resulted in 4204 genes that 
were misexpressed when compared to the overexpression of WT MeCP2, suggesting that 
R306C-MeCP2 does not function like the WT protein. Closer analysis of these genes 
revealed that genes with higher mCpG gene-body densities were more highly expressed in 
R306C OE than WT OE, suggesting impairment in the ability of MeCP2 R306C to repress 
gene expression in a gene-body methylation dependent manner. On-the-other-hand, 
comparison of R306C OE to WT cells, revealed a weak ability of R306C MeCP2 to repress 
genes in a gene-body methylation dependent manner. Overexpression of R306C MeCP2 to 9 
times the level of the WT protein results in this extra protein binding to and occupying 
methylated sites in the genome that are not already covered by WT MeCP2. MeCP2 binding 
is not a static event, and the residency time of WT MeCP2 is approximately 15 seconds as 
measured by fluorescence recovery after photobleaching (FRAP) (Schmiedeberg et al., 
2009). Thus, the law of mass action applies, where extremely high levels of MeCP2 protein 
in the nucleus forces greater and more frequent binding to DNA. This binding is enough to 
bring about gene repression in a methylation-dependent manner, but the inability of R306C-
MeCP2 to recruit NCoR/SMRT may reflect the inability of overexpressed R306C-MeCP2 to 
repress transcription to the same degree as overexpressed WT MeCP2. The recent 
observations that R306C protein binds to methylated DNA with a reduced affinity, despite 
retaining a completely intact MBD (Brown et al., 2016; Heckman et al., 2014) would 
suggest that R306C in LUHMES cells not only affects transcription by a lack of recruitment 
of NCoR/SMRT, but also by reduced binding to DNA. Indeed, recent ChIP-qPCR data from 
Dr Justyna Cholewa-Waclaw has demonstrated that R306C has an approximately 50% 
reduction in DNA binding in LUHMES-derived neurons (personal communication). This 
data suggests that the LUHMES R306C KI RNA-sequencing data here should be more 
pronounced. Perhaps performing the experiment using more R306C clones will reveal a 
more pronounced defect, or perhaps analysis of nascent transcription using the techniques 
described above will be more fruitful. 
 
To conclude, MeCP2 null and R306C LUHMES-derived neurons have been phenotypically 
assessed by a number of parameters. Thus far, no defect in neuronal morphology has been 
observed. Re-analysis of neuronal volume and neurite length using more sophisticated 
techniques might reveal morphological abnormalities. Analysis of neuronal function using 
the calcium imaging and electrophysiological techniques described in Chapter 3.6 will be 
useful to assess the ability of LUHMES-derived neurons to function in the presence of gross 
transcriptional defects. RNA-sequencing of MeCP2 KO neurons has revealed large numbers 
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of misregulated genes that are modulated in a gene-body methylation-dependent manner. 
Analysis of MeCP2 knock-down and overexpression LUHMES cell lines show similar and 
reciprocal gene expression effects respectively thus highlighting the functional significance 
of this mode of action for MeCP2 (J Cholewa-Waclaw + RR Shah et al., unpublished data). 
Future experiments to assess the interplay of MeCP2, nascent transcription and RNA 
polymerase will be critical to understanding the precise molecular mechanism that underlies 
this repression. The observation that total RNA is dramatically reduced in neuronal 
precursors and neurons from MeCP2 null and R306C LUHMES cell lines is exciting, but 
also surprising. Further experiments need to be performed to assess if this is a consequence 
of sub-standard, smaller neurons, or if in combination with the RNA-sequencing defects, it 










For therapeutic intervention in disease, the direct application of protein or nucleic acid 
molecules to cells or tissues is generally not possible due to the impermeable nature of the 
plasma membrane. Viruses, however, such as AAV or lentiviruses readily infect a wide 
variety of cell types and can be manipulated to package a gene of interest such that 
application of the recombinant virus to cells will result in delivery and expression of that 
gene as required. The field of gene therapy has focussed primarily on rAAV vectors and has 
demonstrated delivery and long-term transgene expression, in a variety of cell types in vivo 
including muscle, liver, the eye, lungs and the brain (Samulski & Muzyczka, 2014). There 
are, however, some drawbacks to the in vivo use of AAV. The small packaging size restricts 
the use of gene therapy to small genes and limits the ability to control gene expression 
through the use of endogenous promoters and regulatory elements. Furthermore, a number of 
clinical trials have observed immune responses to the AAV vector or the transgene itself, in 
some cases resulting in clearance of the virus from the system (Halbert et al., 1998; Manno 
et al., 2006; Murphy et al., 2008; Vandenberghe et al., 2006). This affects the ability of 
rAAV to be delivered in multiple doses for long-term transgene expression and life-long 
therapeutic intervention, although is perhaps not so problematic for immune-privileged 
tissues such as the brain and eye (Bennett et al., 2012; Daya & Berns, 2008). 
 
The delivery of protein into cells (protein transduction) as an alternative to virus-mediated 
gene delivery is attractive for multiple reasons. Firstly, the dosage of protein can be more 
tightly controlled. Second, the insertional mutagenesis risk that viral vectors pose is not a 
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problem. Third, protein persistence has been observed for at least 2 months after topical 
application to mice (Wang et al., 2013b). Fourth, initial studies in patients have 
demonstrated a lack of immune clearance of the protein in the blood, thus allowing for 
multiple dose regimes to be implemented without a loss of efficacy (J. Edmond Wraith et al., 
2008). But there have been fewer clinical trials using protein therapy compared to rAAV, 
thus more evidence is needed to rigorously test the latter point. 
 
There are two alternative approaches to protein transduction; mixing the protein of interest 
with a substance that aids transduction, or tagging it with a peptide that can mediate plasma 
membrane translocation. Examples of the former include 10% carboxymethylcellulose 
(Wang et al., 2013b), NaCl (Jr. et al., 1978), sucrose and PEG (Okada & Rechsteiner, 1982), 
chloroquine (Luthman & Magnusson, 1983), and NaCl with propanebetain (D'Astolfo et al., 
2015). The observation that some proteins have natural cell-penetrating abilities, conferred 
by small regions within the protein paved the way for cell penetrating peptides (CPPs) to be 
identified, for example the homeodomain from the Drosophila Antennapedia protein 
(Derossi et al., 1994), and a portion of the TAT protein from HIV-1 (Vives et al., 1997). 
Fusion of these CPPs to heterologous proteins, such as cre recombinase and β-galactosidase, 
allows the translocation of the protein into cells and tissues and has been demonstrated to 
work in vivo (Kim et al., 2009; Peitz et al., 2002; Schwarze et al., 1999). 
 
While the sequence of CPPs varies, a common feature between all CPPs is that they are basic 
proteins. Although the exact mechanisms for transduction are unknown, the observation that 
polycationic peptides can also function as CPPs suggests that proteins that are naturally rich 
in lysine and arginine residues might have intrinsic protein transduction ability (Kabouridis, 
2003). In line with this, cre protein on its own is able to transduce cultured cells and this 
activity is enhanced if cre is tagged with 6xhistidine or NLS signals (Lin et al., 2004; Will et 
al., 2002). MeCP2 is a very basic protein and has an intrinsic histidine run (Nan et al., 1996), 
thus the hypothesis is that MeCP2 itself will be able to transduce cells without the need for a 
CPP. 
 
This chapter aimed to determine if MeCP2 is able to cross the plasma membrane of MeCP2-
null LUHMES-derived neurons. Such studies would lay the groundwork for future work 





Previous experiments performed by Dr Matthew Lyst have suggested that WT human 
MeCP2_e1 protein prepared from E. coli is able to transduce mouse embryonic fibroblasts 
(MEFs) in the presence of chloroquine. In his experiments, 4 hours after MeCP2 and 
chloroquine were added to cell culture media, Western blotting detected the presence of 
MeCP2 in nuclear extracts prepared from MEF cells, which do not express MeCP2. 
Furthermore, MeCP2 protein was only detected if the nuclear extracts were treated with 
benzonase, indicating that MeCP2 was only released into solution upon nucleic acid 
digestion, implying that it was bound to DNA. 
 
Using MeCP2 prepared by Dr Matthew Lyst (Figure 45A) I added protein with or without 
chloroquine to 6-day old, MeCP2 KO, LUHMES-derived neurons. Nuclear extracts were 
prepared using benzonase, and probed for the presence of MeCP2 by Western blot analysis. 
Figure 45B shows that, similar to MEFs, MeCP2 protein was able to enter the nuclei of 
LUHMES-derived neurons within 4 hours. Yet, in contrast to MEFs, this transduction was 
not dependent on chloroquine. Figure 45C shows that MeCP2 protein was still present in 
nuclei 24 hours after initial protein addition to cell media. While this experiment suggests 
that MeCP2 protein is able to cross the cellular membrane and enter nuclei, the protein could 
be entering during the cell lysis and nuclei preparation steps. In order to assess this 
possibility, I performed immunofluorescence analysis using LUHMES-derived neurons. 
Figure 46A shows nuclear localisation of MeCP2 protein in WT neurons, and the absence of 
any signal in the KO or KO + chloroquine samples. While there is substantial MeCP2 
immunoreactivity in the KO samples that were incubated with MeCP2 protein, the signal is 
not exclusively nuclear localised and a large majority of it appears to be extra-cellular.  
Further assessment of these images demonstrates that localised circles of MeCP2 protein are 
co-localising with foci of small, condensed or fragmented DAPI (Figure 46B, open arrows). 
These DAPI foci are often devoid of any MAP2 or NF staining, suggesting that these 
neurons are dead. On the other hand, intact DAPI foci that retain MAP2 and NF staining 
have very little co-localised MeCP2 (Figure 46Bii, box). In fact these neurons appear to have 
foci of MeCP2 protein that are sequestering on the outer surface of the cell body (Figure 
46Bi, closed arrow), perhaps reflecting MeCP2 protein that is transiting into the cell, or an 
inability of protein to enter the neurons. Similar foci can be observed along the length of 
multiple neurites (Figure 46Bi, rectangles). 












This data suggests that neurons which are transduced by MeCP2 protein are subsequently 
dying. Alternatively, it could be that only dying neurons are capable of being transduced. 
While intact nuclei were harvested for Western blot analysis, and full-length MeCP2 was 
observed in these samples, the ladder of MeCP2 immunoreactivity suggests that these 
neurons were successfully transduced by MeCP2 and then subsequently enter an apoptotic 
pathway (Figure 45B+C). In this experiment, there could be two stimuli for an apoptotic 
pathway. Perhaps there are contaminants in the MeCP2 protein preparation that affects the 
cells. Alternatively, the large quantities of protein that are being added to the neurons could 
be a trigger. In this experiment, 12.5pg of MeCP2 was added per neuron (Table 8, Chapter 
2.26), which is approximately 10-fold higher than the amount of MeCP2 protein that exists 
in the nuclei of NeuN+ nuclei from mouse brain (Skene et al., 2010) and 50-fold higher than 
the amount calculated for LUHMES-derived neurons (Table 9, Chapter 3.4.1). 
 
In an attempt to avoid excessive amounts of cell death as observed by immunofluorescence, 
a new protein preparation was made by Dr Matthew Lyst. The first protein prep (Figure 
45A) was purified with a Ni-NTA column using the endogenous Histidine run in MeCP2 
(amino acids 366-372) while the second protein prep (Figure 45D) was made using 
shallower gradients of ionic strength/imidazole in order to better separate MeCP2 from 
contaminants. As can be seen in Figure 45E, 1.25pg/cell of this new protein was able to 
transduce LUMHES-derived neurons within 4 hours, and in the absence of chloroquine. 
Furthermore, the extra step in the protein purification strategy produced a purer preparation 
of MeCP2 (Figure 45, compare A to D), and this resulted in less cellular degradation 
products after protein transduction (Figure 45, compare C to E). A time course analysis 
established that MeCP2 could be detected in nuclear extracts 30 minutes after the addition of 
protein to the cell culture media (Figure 45F). Immunofluorescence analysis of neurons 4 
hours after protein addition confirmed that less protein was applied (Figure 47). While large 
foci of MeCP2 protein that stained negative for NF were still apparent, they were fewer and 
there were a number of MeCP2 foci that co-stained for NF and appeared to be localised to 
intact neurons (arrows, Figure 47). This data suggests that a cleaner preparation of MeCP2 
protein, applied in smaller amounts is able to transduce LUHMES-derived neurons while 






Further analysis of neurons transduced with lower amounts of the new MeCP2 protein 
preparation will be necessary. In particular, high magnification images of neurons that are 
co-stained with DAPI will help to assess the fraction of neurons that have condensed or 
fragmented DAPI foci. Furthermore, Western blot analysis of neurons 24 hours after protein 
addition (Figure 45F) suggests that, as with the initial protein preparation, apoptotic 
pathways are being initiated. Thus immunofluorescence comparisons between 4 hours and 
24 hours will be necessary to assess this. Overall, these experiments have demonstrated that 
MeCP2 protein, on its own or in combination with chloroquine, can transduce LUHMES-
derived neurons to a certain degree. 
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The ability to deliver proteins and other macromolecules directly to cells without the need 
for transfection techniques is challenging but extremely desired for therapeutic purposes. 
There has been a lot of work surrounding the use of so-called cell penetrating peptides 
(CPPs), as the ability to transduce cells simply by adding a small tag onto your protein of 
interest would make such an approach applicable to a wide variety of cells, tissues and 
protein molecules. 
 
The discovery that Cre protein on its own is able to transduce eukaryotic cells, and that this 
activity is enhanced with a 6xhistidine-tag suggests that basic proteins might have an 
intrinsic ability to transduce cells without the need for CPPs (Lin et al., 2004; Will et al., 
2002). Indeed, basic, polycationic peptides have been reported to be effective at crossing the 
plasma membrane, with polyarginine runs being the most efficient (Futaki et al., 2001; Mi et 
al., 2000; Mitchell et al., 2000; Wender et al., 2000). MeCP2 is another basic protein (Lewis 
et al., 1992), which suggested that it may be able to transduce cells without the need for a 
CPP. 
 
The experiments here have demonstrated that MeCP2 protein on its own can enter human, 
LUHMES-derived neurons and is highly suggestive that this protein subsequently enters the 
nuclei of these neurons. MeCP2 has an endogenous NLS which combined with its MBD aid 
the translocation of MeCP2 into nuclei (Lyst et al., 2016; Nan et al., 1996). Thus any 
MeCP2 protein that successfully crosses the plasma membrane would be expected to enter 
nuclei and bind to methylated DNA. While MeCP2 protein does enter LUHMES-derived 
neurons, the efficiency appears to be quite low, and the process itself appears to induce 
apoptosis. Performing immunofluorescence analysis and co-staining for apoptotic markers 
would help to confirm this, for example using the Annexin V-FITC/PI Apoptosis Detection 
Kit (BD Pharmingen) or TUNEL staining (Orii et al., 2006). 
 
The previous observation that chloroquine was necessary for MeCP2 transduction in MEFs 
was not true for LUHMES-derived neurons. Immunofluorescence analysis of MEFs 
(transduced with the new protein preparation at 1.25pg/cell) suggests that actually 
chloroquine has little effect on the ability of MeCP2 protein to enter MEFs (Supplementary 
Figure 14). Whether chloroquine was included or not, MeCP2 protein was observed attached 
to the plasma membrane, in the cytoplasm, and, on occasion, in the nuclei of MEFs (white 




useful for observing the cytoplasm, was a surprise. The positive staining could reflect non-
specific antibody binding. 
 
In order to understand the dynamics of protein translocation and subsequent neuronal death, 
live cell imaging studies would be extremely useful. A preparation of fluorescently tagged 
MeCP2 could be applied to neurons imaged in real-time to understand if dying neurons are 
transduced by the protein, or if neurons that take up the protein subsequently die. There is 
the possibility that tagging of MeCP2 with a large fluorescent molecule will affect its ability 
to transduce cells, particularly if the overall positive charge of the molecule is lost, so this 
would need to be assessed. 
 
While the experiments here suggest that decreasing the amount of protein applied to cells 
results in decreased cell death, Western blots after 24 hours were suggestive of apoptotic 
pathways. It would be interesting to decrease the amount of MeCP2 protein further in an 
attempt to avoid cell death pathways. Live cell imaging may even help to observe two 
neurons side by side that take up different amounts of protein, and thus perhaps survive for 
different lengths of time. Such studies could be combined with tools that fluoresce upon 
apoptotic triggers, such as acridine orange (Galluzzi et al., 2009). In addition to this, small 
amounts of MeCP2 could be added by multiple applications over a prolonged period of time 
in order to avoid cell death. Such an experiment would be reminiscent of the procedure used 
for the MeCP2 reversal experiments in mice where instant reactivation of the inactive 
MeCP2 allele often resulted in toxicity (Guy et al., 2007). 
 
Immunofluorescence analysis indicated that MeCP2 loading is uneven among all neurons in 
the population. Some neurons take up extremely high quantities of protein while others 
remain MeCP2 null. Perhaps mixing MeCP2 with a CPP will encourage a more even loading 
that would ultimately reduce the population cell death levels. Mixing a sgRNA molecule 
with a polyarginine CPP successfully transduced the negatively charged sgRNA into cells, 
and while the purpose of the CPP was to alter the electrostatic properties of the sgRNA, 
perhaps interactions between MeCP2 and the CPP will aid protein delivery (Ramakrishna et 
al., 2014). Alternatively MeCP2 could be tagged with a CPP, or the iTOP method which 
uses NaCl and a propanebetaine to encourage pinocytic uptake of protein (D'Astolfo et al., 
2015) could be used to encourage more even loading and reduced levels of cell death. 
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While these experiments begin exploration of protein transduction therapy for Rett 
syndrome, adapting the process for in vivo work will not be trivial. Direct injection into sites 
in the brain, as is used for AAV delivery in mouse models (Gadalla et al., 2017) and in 
clinical trials of stem cell injections (Steinberg et al., 2016), or intrathecal injections (Calias 
et al., 2014) would give the best chance of efficient delivery. The isoelectric point (pI) of 
MeCP2 is very high (~10) (Lombardi et al., 2015) suggesting that systemic injections of 
MeCP2 protein would likely result in clearance of the protein resulting in low therapeutic 
efficacies, as has been observed in the minipig with monoclonal antibodies (Zheng et al., 
2012). Recently, pre-assembled, CPP-tagged Cas9 RNPs have been stereotaxically injected 
into four brain regions in the mouse brain and in vivo CRISPR-induced DNA editing was 
observed (Staahl et al., 2017). This suggests that protein delivery to the brain and subsequent 
cellular protein transduction is possible in vivo. The authors observed a larger spread of 
protein transduction throughout the injected brain region when a higher concentration of 
protein was injected, however the transduction was still localised around the injection site, 
thus the therapeutic potential of such a delivery method is still questionable (Staahl et al., 
2017). 
 
More experiments are needed to determine if a lower dosage of protein will circumvent the 
cell death that has been observed in this study. Future assessment of other parameters, such 
as mixing with CPPs or iTOP, may also prove to be beneficial for elucidating an efficient 
and reproducible protein delivery method. LUHMES KO cells can be expanded to large 
quantities as precursors and differentiated in a high throughput manner in 24-well plates, 












Overall, the data presented in this study suggests that the LUHMES cell line and its derived 
neurons will be a useful model system for future studies into MeCP2 and Rett syndrome. 
The cells are easy to handle, can be genetically manipulated and rapidly differentiate into a 
homogeneous population of mature neurons. In addition, experiments using MeCP2 mutant 
neurons reveal robust changes to the transcriptome and future studies using these cells will 
help to elucidate the molecular mechanisms behind these alterations. In particular, studies 
such as 4sU-sequencing will be easier and cheaper to perform in tissue culture model 
systems compared to rodent models due to the ability to produce large quantities of starting 
material allowing for numerous biological and technical replicates to generate reliable data. 
 
One negative to LUHMES-derived neurons in terms of studying the function of MeCP2 is 
the low abundance of mCA that exists in the genome. While LUHMES-derived neurons 
have 14% mCH/mC, the amount in vivo increases during development reaching ~53% of all 
methylated cytosine residues in the adult human brain (Lister et al., 2013). Recent analysis 
comparing neurons derived from young and old fibroblasts demonstrates an inherent 
difference in the age of the resulting neurons as judged by epigenetic signatures, miRNA 
profiles and telomere length, among other assays (Huh et al., 2016). This suggests that 
global mCH levels could be another age-related signature that is inherent to the cell, and as 
LUHMES cells were derived from 8-week old fetal tissue their derived neurons may never 
be able to generate high levels of mCH on par with the adult brain. Artificially increasing 
mCH levels by overexpression of DNMT3A could be used to boost mCA amounts in order 
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to see if MeCP2 dynamics are altered and transcriptional outputs differ. Nevertheless, the 
MeCP2-regulated transcriptional changes observed in this study, where only mCG was 
studied, revealed similar mechanisms as mice studies that assess mCA and mCG (Kinde et 
al., 2016; Lagger et al., 2017). This suggests that boosting mCA levels in LUHMES cells 
will not be necessary for understanding the mechanism of MeCP2 function in human 
neurons. 
 
A second disadvantage of LUHMES-derived neurons is the inability to differentiate the 
precursors into alternative neuronal lineages. LUHMES precursor cells appear to be 
committed to a dopaminergic lineage (this study and (Scholz et al., 2011)). Removal of 
GDNF and cAMP from the differentiation media results in decreased levels of TH, RET and 
DRD2 in LUHMES-derived neurons as well as reduced dopamine levels. But the unaltered 
expression level of six other dopaminergic markers and four other neurotransmitter markers 
suggests that a change in neurotransmitter type does not occur under these culture conditions 
(Scholz et al., 2011). While MeCP2 likely has the same function in different neuronal 
subtypes (to bind to methylated DNA and repress transcription), the output of this 
mechanism of action is likely to be different in different neurons and thus the phenotype 
when MeCP2 function is perturbed will vary. Evidence for this is already apparent with 
chromatin compaction only being observed in hippocampal CA1 pyramidal neurons and 
hippocampal dentate granule cells but not in cerebellar granule cells upon MeCP2 deletion 
(Linhoff et al., 2015). Likewise the effect of MeCP2 overexpression on neurite complexity is 
the opposite in hippocampal cultures to that in cortical cultures (Jugloff et al., 2005; Zhou et 
al., 2006). Thus, for detailed phenotypic analysis of specific neuronal populations, hiPSC-
derived neurons and in vivo studies in rodents would be a more appropriate model than 
LUHMES-derived neurons.  
 
The transcriptome map produced in this study of WT LUHMES-derived neurons could be 
complemented with similar analysis of LUHMES neuronal precursors and the two datasets 
then compared to published datasets of human brain development using the CoNTeXT 
framework. This would be useful for assessing the human developmental time point that 
LUHMES-derived neurons correspond to, and to observe which neuronal gene expression 
networks are preserved in the tissue-culture differentiation system (Stein et al., 2014). This 
framework was built by comparing the transcriptome of multiple tissue-culture 
differentiation systems, including hiPSCs and primary neural progenitors (phNPCs), to in 




found that hiPSCs produce neurons that have a more immature transcriptome compared to 
phNPCs and that neither phNPCs nor hiPSCs could be encouraged to differentiate past fetal-
stage neurons even if left in culture for months (Stein et al., 2014). In addition to CoNTeXT, 
the LUHMES transcriptome could be compared to that from human dopaminergic iPSC-
derived neurons and laser-captured human dopaminergic neurons, which have already been 
compared transcriptionally to one another (Sandor et al., 2017). Thus, one could use such 
analyses to more accurately determine the stage of development (“maturity”) that LUHMES-
derived neurons correspond to and compare their transcriptional profile to in vivo 
dopaminergic neurons from an adult human brain. Furthermore, comparison of the active 
gene networks in LUHMES-derived neurons to in vivo brain development may help to 
determine the expected phenotypic outputs in tissue culture. 
 
Future avenues of research using LUHMES-derived neurons could also explore co-culture 
with astrocytes or the development of organoids (Ardhanareeswaran et al., 2017). Such 
systems are known to produce neurons that are more mature, and perhaps more responsive to 
external cues thus analysis of MeCP2-induced phenotypes in such a culture system might 
better represent the in vivo situation in RTT patients (Johnson et al., 2007; Kuijlaars et al., 
2016; Odawara et al., 2014; Tang et al., 2013). 
 
In summary, I believe that LUHMES-derived neurons will be a valuable tool for assessing 
the molecular defects that occur upon MeCP2 mutation. In addition, the demonstration in 
this study that neurons can be differentiated in a high-throughput manner in 96-well plates 
highlights the potential utility of these neurons for drug screening purposes. The ease of 
differentiation, efficient genetic manipulation and appearance of strong phenotypes suggests 




One particular area of research that the LUHMES cell line will likely contribute to is 
transcriptome analysis in MeCP2 mutant neurons. There have now been numerous studies 
assessing the transcriptome of MeCP2 mutant neuronal samples, both in tissue culture (Li et 
al., 2013c), in mouse brain regions (Ben-Shachar et al., 2009; Chahrour et al., 2008; Chen et 
al., 2015; Gabel et al., 2015; Jordan et al., 2007; Kinde et al., 2016; Rube et al., 2016) and in 
patient cortex (Colantuoni et al., 2001). While early microarray studies hypothesised a role 
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for MeCP2 in transcriptional activation (Ben-Shachar et al., 2009; Chahrour et al., 2008; Li 
et al., 2013c), recent RNA-sequencing analysis combined with high coverage ChIP-
sequencing and methylation mapping have confirmed the association of MeCP2 with gene 
repression that was discovered in early repressor assays (Gabel et al., 2015; Lagger et al., 
2017; Nan et al., 1997). The RNA-sequencing analysis in LUHMES-derived neurons from 
this study further confirms the role of MeCP2 in gene repression and additionally suggests 
that MeCP2 functions via gene-body methylation. While gene-body methylation has been 
suggested as being important for MeCP2-mediated gene repression in a prior mouse study 
(Gabel et al., 2015), large domains of methylation have also been implicated as the mode of 
MeCP2 repression (Lagger et al., 2017). In the LUHMES dataset, gene body methylation 
levels and surrounding methylation levels are very highly correlated, thus distinguishing the 
contributions of each to gene repression will be difficult (J Cholewa + RR Shah et al, 
unpublished results). By analysis of short genes within large methylation domains, Kinde 
and colleagues determined an individual genes methylation as being more critical for 
repression than being situated in a methylated domain (Kinde et al., 2016). Similar 
bioinformatics approaches should be applied to the LUHMES datasets in order to assess the 
importance of gene body and flanking region methylation on MeCP2-mediated gene 
regulation. 
 
While steady-state RNA-sequencing datasets have been vital in determining the role of 
MeCP2 in gene expression, future studies should look at dynamically changing and nascent 
gene transcription. In its native environment a neuron is rarely in a steady-state, but is in 
constant communication with surrounding neurons as part of an active network. Assessment 
of the transcriptional profile of WT and mutant neurons before and after KCl-induced 
depolarisation might reveal stark defects in the ability of MeCP2 mutant neurons to respond 
to depolarisation signals. In particular qPCR experiments assessing the activation of early 
response genes such as JUN and FOS immediately after depolarisation and the late response 
genes such as BDNF and GPR22 at later time points might be insightful. Indeed, excessive 
induction of Junb, and Arc (but not Fos) has been observed in Mecp2T308 striatum after 
cocaine administration (Su et al., 2012), and activity-dependent phosphorylation of MeCP2 
has been reported to allow for increased BDNF transcription (Chen et al., 2003; Zhou et al., 
2006) and increased Npas4 transcription (Ebert et al., 2013). These studies suggest that 
MeCP2 functions to repress activity-regulated genes, and that loss of MeCP2 binding to 
genes (by genetic mutation or by phosphorylation) results in increased expression of these 




found reduced expression of immediate-early response genes ARC, FOS, NPAS4 and BDNF 
in a basal state, and a lack of induction of these genes after KCl-induced depolarisation (Li et 
al., 2013c). Similar RNA-sequencing and qPCR experiments in the mutant LUHMES-
derived neurons generated in this study may reveal differences in the expression of 
immediate-early genes, as well as global transcriptional profiles after KCl-induced 
depolarisation. 
 
In order to fully understand the effect MeCP2 binding has on gene expression, nascent RNA-
sequencing technologies should be employed such as 4sU-sequencing (Cleary et al., 2005). 
In particular treatment of neurons with DRB to first inhibit all transcription, combined with 
DRB wash-out and 4sU treatment will provide accurate datasets of nascent transcription and 
elongation rates in WT and MeCP2 mutant samples (Fuchs et al., 2016). Integration of 
elongation rates and MeCP2 ChIP-seq data will help to determine the effect of MeCP2 
binding (perhaps throughout gene bodies) on the Pol II elongation rate in genes. Combined 
with genome-wide mapping of RNAP II initiation, elongation and termination (as judged by 
its various phosphorylation states) these datasets will help towards an understanding of the 
mechanism of MeCP2-mediated gene repression. 
 
While RNA is an essential intermediate in gene expression, the proximal cause of 
phenotypic variation is likely to be at the level of protein. Therefore, in addition to more 
detailed assessments of the transcriptome, future studies could focus on the proteome in 
mutant neurons. The finding in this study that total RNA is reduced in both MeCP2 KO and 
R306C neurons suggests that total protein levels will be decreased as well. This will be 
especially pertinent if, as hypothesised, rRNAs are reduced in mutant LUHMES-derived 
neurons. Among the RNA species that Li and colleagues found reduced in MECP2-null 
hESC-derived neurons, were a number of mRNAs coding for ribosomal proteins as well as 
rRNAs (Li et al., 2013c). This suggested that mutant neurons might have an inability to 
efficiently translate proteins and in line with this, incorporation of radiolabelled cysteine and 
methionine amino acids was found to be reduced by 25% (Li et al., 2013c). Apart from 
assessing the importance of the proteome for RTT pathologies and for identifying potential 
therapeutic avenues, proteome analysis may reveal biomarkers that can be used when testing 
compounds in drug screens. 
 
 




This project set out to assess the utility of the LUHMES cell line as a new model system for 
studying MeCP2 and Rett syndrome. The project begun with some basic characterisations of 
the cell line and its derived neurons and found that LUHMES cells differentiate quickly and 
efficiently into a homogeneous population of neurons. As to the maturity of these neurons, 
markers such as NeuN, MAP2, Neurofilament, TH, DAT and PSD-95 were all found to be 
expressed suggesting that mature neurons were produced within 9 days. As to how this level 
of maturity compares to neurons in an in vivo context is unknown and direct transcriptome 
comparisons between LUHMES-derived neurons and brain-derived neurons during 
development should be performed to assess this further. 
 
The demonstration that efficient and reproducible transfection, single cell cloning and 
genetic engineering techniques can be performed in LUHMES cells demonstrates the ease of 
use of this cell line. The ability to manipulate LUHMES cells will be useful for modelling 
disease-causing Rett syndrome mutations, for cellular perturbation to probe MeCP2-related 
molecular pathways, and will be applicable for uses outside the MeCP2/Rett syndrome field. 
 
Assessment of MeCP2-null LUHMES-derived neurons found no decreases in neurite length 
or nuclear volume. This is in contrast to published reports of similar studies using alternative 
model systems and is perhaps indicative of a limitation of LUHMES cells with respect to 
mirroring disease pathology. Being a population of neurons alone, as opposed to the mixed 
cellular environment in brain slices and iPSC systems, perhaps limits the ability of 
LUHMES-derived neurons to phenocopy neurons in an in vivo context. This would suggest 
that the environment a neuron is situated in can affect the phenotypic outcome. As such, 
LUHMES-derived neurons are useful for studying the inherent phenotypes within 
dopaminergic neurons, but will not be useful for recapitulating the endogenous disease state. 
 
Molecular analyses, on the other hand, can readily be probed in LUHMES-derived neurons. 
The ability to generate large quantities of neurons in a short space of time using a simple 
differentiation procedure means that LUHMES cells are a great candidate for a plethora of 
molecular and biochemical studies. This is illustrated by the number of biochemical 
perturbations that were found in mutant LUHMES-derived neurons in this study. The 
approximate 10% decrease in total RNA, and the gene-body methylation dependent gene 




mutant samples. The strong relationship between transcription and gene-body methylation, 
which shows a reciprocal effect between MeCP2 null and MeCP2 overexpression cell lines, 
suggests that the primary role of MeCP2 in human neurons is to repress transcription, and 
that MeCP2 achieves this goal by binding to sites of methylation within the transcriptional 
unit of a gene. 
 
While this is a significant step forward, a full understanding of how MeCP2 achieves this 
gene repression is still unknown. Is the recruitment of the entire NCoR/SMRT complex 
critical for this constraint on gene expression or is TBL1/TBLR1 recruitment alone 
sufficient? Does MeCP2 hinder RNA polymerase II elongation through the gene body? Is the 
chromatin environment altered in MeCP2 mutant samples, and if so, is this a primary or 
secondary or even compensatory effect? Is the total RNA decrease a primary effect from 
MeCP2 mutation or secondary, due to “sub-optimal” neurons? Future directions to assess the 
mechanism of MeCP2-mediated gene repression will require genome-wide analysis of 
nascent transcription, for example by 4sU-sequencing. Complementary to this will be ChIP-
sequencing of total and phosphorylated RNA polymerase II to assess the ability of RNA 
polymerase II to initiate and elongate in mutant samples. The decrease in total RNA 
observed in MeCP2-mutant samples is perplexing for a protein that is proposed to repress 
transcription, not activate it. Further studies to evaluate the importance of this finding will 
involve analysing mice before the onset of symptoms. If young mice have decreased total 
RNA before symptoms have emerged, this might suggest a causal role of reduced RNA 
levels in Rett-like symptoms. Other experiments will involve assessing rRNA transcription 
by Northen blot analysis, measurement of nucleolar volumes (the sites of rRNA 
transcription, processing and ribosome assembly), and measurements of the number and 
volume of UBF compartments (the sites of rRNA transcription). 
 
Since the discovery of MeCP2 25 years ago and its link to Rett syndrome 18 years ago huge 
progress has been made in multiple areas; investigating the function of MeCP2, identifying 
that Rett syndrome is a reversible disorder, and working towards trials of therapeutic 
strategies. There is still a long way to go, however, for a full molecular understanding of how 
MeCP2 functions and precisely how this is perturbed in Rett syndrome. LUHMES-derived 
neurons will be extremely useful for probing these molecular questions and may even prove 
to be valuable in the search for therapeutics for Rett syndrome. As the field moves forward 
the use of multiple model systems, and in particular studies in human neurons, will help to 












System Gender Mutation Reference 
Mouse ESCs 
 
Male Exon 3 + 4 deletion (Yazdani et al., 2012) 
Human ECSs 
 
Male + Female 
 






















































































KO 517bp deletion 
V247fs 
(Bu et al., 2017) 





* No change in TuJ or PAX6 as determined by immunofluorescence in R294X-iPSC derived 
neurons (Ananiev et al., 2011). 
* No change in MAP2 in male mice that express MeCP2 that is truncated at residue 308 










System Difference Technique Reference 
T158M-iPSC derived 
neurons 
50% decrease in number of 
cells that are TuJ positive* 
Immunofluorescence of 
TuJ in neurons. 
(Kim et al., 2011) 




injected with tamoxifen 
at 15 or 34 weeks to 
ablate MeCP2, age of 
mice at experiment is 
“within days” of 
tamoxifen treatment. 
Syn1 to 25%. VGLUT1 to 
40%. NMDAR2A to 40%. 
SHANK1 + SHANK2 to 
50%. No change in SHANK3, 
CAMKIIa or b, GABABR2, 
GluR2/3, PSD93, SYT1. 
Western blot. 3 mice per 
group. No replicates of 
Western blots? Β-actin 
used as loading control. 
Odyssey scanner used to 
scan membranes and 
measure band intensities. 
(Du et al., 2016) 
Brain slices of 11 
patients with classical 
RTT + 12 age-matched 
controls 
Tendency for MAP2 staining 
to be decreased* but only 
significantly different in 1/3 
of brain regions. Tendency 
for NF staining to be 
increased and decreased, but 
only significantly different in 
1/3 of brain regions. 
Brain slices, fixed and 
stained for MAP2 and 
NF. Layers II-III and V-
VI in somatosensory / 
motor cortex assessed. 
Both somatic and 
dendritic staining 
assessed. 
(Kaufmann et al., 
2000) 
Nasal biopsies from 29 
RTT patients (8 of 
which had no MeCP2 
mutation) 
Increased staining of NST 
(immature olfactory neuron 
marker and increased staining 
of OMP (mature olfactory 
neuron marker) 
Nasal biopsies, fixed and 
stained for NST and 
OMP. Control was 31 
normal male and females. 
(Gabriele V. Ronnett 





* No change in nuclear size in olfactory neuroepithelium neurons from MeCP2-/y mouse (Rube et 
al., 2016) 
System Difference Technique Reference 
R294X-iPSC derived 
neurons 
9% and 17% 
2493 ± 24 AU  2061 ± 18 
or 2273 ±23 or 2267 ±50 
AU. 
DAPI staining circled in 
Photoshop and measured in 
Photoshop. 1 WT cell line, 3 
iPSC clones from the same 
patient. N=378, 490, 279, 90 
Ananiev et 
al. 2011 
Mecp2-/y mESC derived 
neurons 
25-30% 
27 µm2  20 µm2 (DIV8) 
32 µm2  24 µm2 (DIV26) 
No difference at 3 DIV 
Hoescht staining of nuclei, 
ImageJ calculates size. 
N=131+184 for DIV8. N=49+61 
for DIV26. Yazdani et 
al. 2012 Mecp2-/y mouse brain 
slices, 1-month old 
CA3 region of the 
hippocampus 
138.2 ± 2.1 µm2  98.7 ± 
1.6 µm2 
No change in size of 
astrocytes 
Hoescht staining of nuclei, 
ImageJ calculates size. N = 56 
WT and 92 KO. 
KO hESC-derived neurons 
(deletion of exon 3) 
25% 
100 µm2  75 µm2 
DAPI staining of nuclei. No 
methods given. No details about 
replicates or numbers. 
Li et al., 
2013 
MeCP2-/+ mouse brain 
slices, 5 month old, 
hippocampal CA1 neurons 
5% 
155 ± 19 µm3  
147 ± 18 µm3 
ChromATin. N=51 for WT and 
55 for null. From 3 mice. 
Linhoff et 
al., 2015 
MeCP2-/y mouse brain 
slices 
33% DAPI staining. No cut-off for 






with tamoxifen at 15 
weeks to ablate MeCP2, 
age of mice at experiment 
probably 17 weeks. 
15% 
175 µm2 to 150 µm2 
Hippocampus CA1, DAPI 
colocalised with NeuN, ImageJ 
calculates. Three mice per group, 
20 neurons per animal. 
Du et al., 
2016 




System Difference Technique Reference 
KO hESCs- derived 
neurons (de 
 
letion of exon 3) 
Number of intersections 
decreased by about 1/3 at all 
distances along the neurite. 
Scholl analysis using 
synapsin-GFP. Measured 
using ImageJ. No details 
about replicates or numbers. 
(Li et al., 2013c) 
MeCP-/y mice: Bird 
and Jaenisch alleles 
Dendrites: Decreased spine 
density, decreased spine area, 
increased number of 2.5 µm 
that have no spines, increased 
frequency spine swelling, trend 
for decreased spine widths, 
trend for increased spine neck 
length 
Axons: Increased density of 
axons, decreased alignment of 
axons 
Brain slices. Injected with 
Lucifer yellow to observe 
dendrites or with 
carbocyanine to image axons. 
Motor cortex, CA1 region of 
hippocampus and fascia 
dentate were examined. For 
all measurements, n = 3 mice.  




tamoxifen at 15 or 
20 weeks to ablate 
MeCP2, age of mice 
at experiment 
“within days”. 
Dendritic length: 350150 µm 
(50%). Number of nodes: 
125. Spine density: 11060 
spines/100 µm. Number of 
crossings (scholl) decreased by 
½ at peak and reduced at all 
distances. 
Golgi impregnation, 3D 
neuronal reconstruction using 
camera lucida device, 
analysed by neurolucida 
explorer software for spine 
density, branches and Sholl 
analysis. CA1 pyramidal 
neurons. 
(Du et al., 2016) 
MeCP2lox/y/CreER 
injected with 
tamoxifen at 10 
weeks to ablate 
MeCP2, age of mice 
at experiment 14 
weeks. 
Dendritic length: 25% 
reduction. No change in spine 
density (small change at 18 
weeks). 
Brain sections of 
RTT patients, ages 
2.9 – 35 years old. 
Decreased branches in some, 
but not all brain regions tested. 
Golgi impregnation, camera 
lucida drawings of pyramidal 
neurons in the cortex, subiculum 
and CA1 of the hippocampus. 
Sholl analysis. N = 10 neurons 
per sample, 16 patients. 
(Dawna Armstrong 
et al., 1995) 
 
* No defect in neuronal morphology was observed in the cortex of male mice expressing 
MeCP2 that is truncated at residue 308 as judged by Golgi staining, camera lucida drawings 
and Scholl analysis. They did, however, by transmission electron microscopy of the CA1 
region observe a reduction in the number of larger post-synaptic density neurons but no 
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